TRADE SECRET

Study Title H-28548: COMBINED CHRONIC TOXICITY/ONCOGENICITY STUDY 2-YEAR ORAL GAVAGE STUDY IN RATS

Laboratory Project ID: DuPont-18405-1238

Volume 12 of 13

Number of pages in volume: 351

TEST GUIDELINES: • U.S. EPA Health Effects Test Guidelines OPPTS 870.4300

Combined Chronic Toxicity/Carcinogenicity (1998)

• OECD Guidelines for the Testing of Chemicals Section 4

(No. 453) Health Effects (2009)

• JMAFF Japan Agricultural Chemicals Regulation Law

12 Nousan No. 8147 (2000)

• EEC Methods for the Determination of Toxicity Method B.33

Combined Chronic/Carcinogenicity test, Directive 88/302/EC

(1988)

AUTHOR: Lisa Craig, B.S.

STUDY COMPLETED ON: March 28, 2013

APPLICANT/SPONSOR: E.I. du Pont de Nemours and Company

Wilmington, Delaware 19898

U.S.A.

PERFORMING LABORATORY: MPI Research, Inc.

54943 North Main Street

Mattawan, Michigan 49071-8353

U.S.A.

WORK REQUEST NUMBER: 18405

SERVICE CODE NUMBER: 1238

MPI RESEARCH STUDY NUMBER: 125-141

Unpublished Work

Copyright ©2013 E.I. du Pont de Nemours and Company

DuPont-18405-1238

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1519	E	Microscopic thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits pituitary tumor
1520	S	Macroscopic mammary gland	 swollen/thickened, tan, generalized, mild corresponds to antemortem observation (swelling)
1520	S	Microscopic adrenal glands kidneys	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal hyperplasia, transitional cell, unilateral, minimal mineralization, pelvic, bilateral, minimal

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1520	S	Microscopic	
		liver	- focus of cellular alteration, basophilic, mild
			- focus of cellular alteration, eosinophilic, mild
			- hematopoiesis, extramedullary, minimal
			- hyperplasia, bile duct, minimal
		lung	- histiocytosis, alveolar, minimal
		mammary gland	- hyperplasia, lobular, mild
			corresponds to macroscopic observation (mammary gland - swollen/thickened)
		pancreas	 adenoma, islet cell, benign, primary, incidental, not cause of death
		stomach, nonglandular	- within normal limits
		tongue	- within normal limits
		uterus with cervix	- within normal limits
1521	Е	Macroscopic	
		lymph node, axillary	- within normal limits
		•	draining node for mass a, right.

S - Scheduled necropsy E - Euthanized *in extremis*

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1521	E	Macroscopic	
		lymph node, inguinal	- within normal limits
			draining node for mass b, right.
		skin, subcutis	- mass, tan, mass a, right axillary area, present
			corresponds to antemortem observation (mass 1)
			approximately 7.0 cm in diameter.
			- mass, tan, mass b, right inguinal area, present
			corresponds to antemortem observation (mass 2)
			approximately 11.0 x 6.0 x 4.0 cm.
1521	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, mild
			 hematopoiesis, extramedullary, bilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1521	E	Microscopic	
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- within normal limits
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, eosinophilic, mild
			- hematopoiesis, extramedullary, minimal
			- hyperplasia, bile duct, minimal
			- necrosis, focal, minimal
			- vacuolation, periportal, minimal
		lung	- histiocytosis, alveolar, minimal
		-	•

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1521	Е	Microscopic	
		lymph node, axillary	- within normal limits
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- fibroadenoma, benign, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b)
			- hyperplasia, lobular, minimal
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits

DuPont-18405-1238

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1521	E	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, mild
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
			- hyperplasia, epithelial cell, minimal
		thyroid gland	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1521	Е	Microscopic	
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- metaplasia, squamous, minimal
		vagina	- within normal limits
		Cause of Death	- mammary tumor
1522	E	Macroscopic	
		animal/whole body	- body fat depleted, moderate
		·	corresponds to antemortem observation (thin)
		lymph node, inguinal	- within normal limits
			draining node for mass a, left.
		pituitary gland	- enlarged, red, severe
		skin, subcutis	- mass, tan, mass a, left anogenital region, present
			corresponds to antemortem observation (mass 1)
			approximately 3.0 cm in diameter.
			·· · · · ·

DuPont-18405-1238

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1522	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1522	Е	Microscopic	
		kidneys	- dilatation, tubular, bilateral, mild
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- within normal limits
		lung	- within normal limits
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenocarcinoma, malignant, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a) hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1522	E	Microscopic	
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- cyst, unilateral, mild
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1522	E	Microscopic small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits depletion, lymphoid, generalized, severe hyperplasia, c-cell, focal, unilateral, minimal within normal limits pituitary tumor

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

			Terminal
Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1523	E	Macroscopic	
		lymph node, axillary	- within normal limits
			draining node for mass a, right, and mass c, right.
		lymph node, inguinal	- within normal limits
			draining node for mass b, right.
		pituitary gland	- enlarged, red, mild
		skin, subcutis	 mass, black, mass a, right axillary area, present
			corresponds to antemortem observation (mass 1)
			approximately 4.5 x 4.0 x 2.0 cm.
			 mass, black, mass b, right anogenital region, present
			corresponds to antemortem observation (mass 2)
			approximately 4.5 x 4.5 x 3.0 cm.
			- mass, tan, mass c, right axillary area, present
			corresponds to antemortem observation (nodule)
			approximately 0.8 x 0.5 x 0.5 cm.
1523	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
			 hyperplasia, focal medullary, unilateral, moderate
			 hypertrophy, focal cortical, unilateral, minimal

E - Euthanized in extremis

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

50 mg/kg/day 1523 E Microscopic aorta - within normal limits bone marrow, femur - within normal limits bone, femur - within normal limits bone, sternum - within normal limits brain - within normal limits brain - within normal limits esophagus - within normal limits esophagus - within normal limits eyes, optic nerves - within normal limits eyes, retina galt - within normal limits harderian glands - within normal limits harderian glands - within normal limits heart - cardiomyopathy, minimal joint, tibiofemoral - within normal limits kidneys - mineralization, pelvic, bilateral, minimal nephropathy, chronic progressive, bilateral, minimal nephropathy, chronic progressive, bilateral, minimal	Group, Animal Number	Fate	Tissue	Observations
1523 B Microscopic aorta	50 mg/kg/day			
bone marrow, femur bone marrow, sternum bone, femur bone, sternum bone, sternum bone, sternum bone, sternum brain esophagus eyes eyes, optic nerves eyes, retina galt harderian glands heart joint, tibiofemoral kidneys kidneys bone, sternum brain ewithin normal limits ewithin normal lim		Е	Microscopic	
bone marrow, sternum			aorta	- within normal limits
bone, femur bone, sternum brain esophagus eyes eyes, optic nerves eyes, retina galt harderian glands heart joint, tibiofemoral kidneys lacrimal glands, exorbital exithin normal limits - within normal limits			bone marrow, femur	- within normal limits
bone, sternum brain esophagus eyes eyes, optic nerves eyes, retina galt harderian glands heart joint, tibiofemoral kidneys kidneys kidneys lacrimal glands, exorbital exitin normal limits within normal limits cardiomyopathy, minimal within normal limits			bone marrow, sternum	- within normal limits
brain - within normal limits esophagus - within normal limits eyes - within normal limits eyes, optic nerves - within normal limits eyes, retina - within normal limits galt - within normal limits harderian glands - within normal limits heart - cardiomyopathy, minimal joint, tibiofemoral - within normal limits kidneys - mineralization, pelvic, bilateral, minimal mineralization, tubular, unilateral, minimal nephropathy, chronic progressive, bilateral, minimal enephropathy, chronic progressive, bilateral, minimal			bone, femur	- within normal limits
esophagus eyes eyes, optic nerves eyes, retina galt harderian glands heart joint, tibiofemoral kidneys esophic nerves within normal limits within normal limits within normal limits eyes, retina within normal limits within normal limits cardiomyopathy, minimal within normal limits exists within normal limits			bone, sternum	- within normal limits
eyes, optic nerves eyes, retina eyes, retina galt harderian glands heart joint, tibiofemoral kidneys eyes - within normal limits - within normal limits - within normal limits - cardiomyopathy, minimal - within normal limits - within normal limits - within normal limits - within normal limits - mineralization, pelvic, bilateral, minimal - mineralization, tubular, unilateral, minimal - nephropathy, chronic progressive, bilateral, minimal - nephropathy, chronic progressive, bilateral, minimal - within normal limits			brain	- within normal limits
eyes, optic nerves eyes, retina eyes, retina eyes, retina galt within normal limits harderian glands heart joint, tibiofemoral kidneys kidneys heart emineralization, pelvic, bilateral, minimal mineralization, tubular, unilateral, minimal nephropathy, chronic progressive, bilateral, minimal within normal limits			esophagus	- within normal limits
eyes, retina galt - within normal limits harderian glands heart - cardiomyopathy, minimal joint, tibiofemoral kidneys - mineralization, pelvic, bilateral, minimal - mineralization, tubular, unilateral, minimal - nephropathy, chronic progressive, bilateral, minimal - nephropathy, chronic progressive, bilateral, minimal - within normal limits			eyes	- within normal limits
galt - within normal limits harderian glands - within normal limits heart - cardiomyopathy, minimal joint, tibiofemoral - within normal limits kidneys - mineralization, pelvic, bilateral, minimal mineralization, tubular, unilateral, minimal nephropathy, chronic progressive, bilateral, minimal lacrimal glands, exorbital - within normal limits			eyes, optic nerves	- within normal limits
harderian glands heart cardiomyopathy, minimal joint, tibiofemoral kidneys kidneys mineralization, pelvic, bilateral, minimal mineralization, tubular, unilateral, minimal nephropathy, chronic progressive, bilateral, minimal lacrimal glands, exorbital within normal limits within normal limits within normal limits			eyes, retina	- within normal limits
heart - cardiomyopathy, minimal joint, tibiofemoral - within normal limits kidneys - mineralization, pelvic, bilateral, minimal mineralization, tubular, unilateral, minimal nephropathy, chronic progressive, bilateral, minimal lacrimal glands, exorbital - within normal limits			galt	- within normal limits
joint, tibiofemoral - within normal limits kidneys - mineralization, pelvic, bilateral, minimal mineralization, tubular, unilateral, minimal nephropathy, chronic progressive, bilateral, minimal lacrimal glands, exorbital - within normal limits			harderian glands	- within normal limits
kidneys - mineralization, pelvic, bilateral, minimal - mineralization, tubular, unilateral, minimal - nephropathy, chronic progressive, bilateral, minimal lacrimal glands, exorbital - within normal limits			heart	- cardiomyopathy, minimal
- mineralization, tubular, unilateral, minimal - nephropathy, chronic progressive, bilateral, minimal lacrimal glands, exorbital - within normal limits			joint, tibiofemoral	- within normal limits
- nephropathy, chronic progressive, bilateral, minimal lacrimal glands, exorbital - within normal limits			kidneys	- mineralization, pelvic, bilateral, minimal
lacrimal glands, exorbital - within normal limits				- mineralization, tubular, unilateral, minimal
· · · · · · · · · · · · · · · · · · ·				- nephropathy, chronic progressive, bilateral, minimal
			lacrimal glands, exorbital	- within normal limits
large intestine, cecum - within normal limits			large intestine, cecum	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1523	E	Microscopic large intestine, colon large intestine, rectum larynx liver	 within normal limits within normal limits within normal limits focus of cellular alteration, basophilic, minimal hematopoiesis, extramedullary, minimal hyperplasia, bile duct, minimal within normal limits
		lymph node, axillary lymph node, inguinal lymph node, mandibular lymph node, mesenteric	 within normal limits within normal limits erythrocytosis/erythrophagocytosis, sinus, minimal within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1523	E	Microscopic	
1923	E	nerve, sciatic nose, level a nose, level b nose, level c nose, level d ovaries	 adenocarcinoma, malignant, multiple, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass b; skin, subcutis - mass c) galactocele, moderate corresponds to macroscopic observation (skin, subcutis - mass a) hyperplasia, lobular, minimal degeneration, axonal/myelin, minimal within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	 within normal limits one of pair present
		pharynx	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1523	E	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, mild
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits

DuPont-18405-1238

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1523	E	Microscopic	
		thymus	 depletion, lymphoid, generalized, moderate hyperplasia, epithelial cell, mild
		thyroid gland	 adenoma, c-cell, benign, bilateral, primary, incidental, not cause of death
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- dilatation, gland/lumen, minimal
		vagina	- within normal limits
		Cause of Death	- mammary tumor
1524	E	Macroscopic	
		lymph node, axillary	- within normal limits
			draining node for mass a, left.
		lymph node, inguinal	- within normal limits
			draining node for mass b, right.

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1524	E	Macroscopic	
		mammary gland	- swollen/thickened, tan, generalized, moderate
			corresponds to antemortem observation (hair sparse swelling)
		pituitary gland	- enlarged, moderate
		skin, subcutis	- mass, tan, mass b, right inguinal area, present
			approximately 1.0 cm in diameter.
			 mass, ulcerated, left axillary area, mass a, present
			corresponds to antemortem observation (mass 1)
			approximately 2.0 x 1.0 x 1.0, tan.
		uterus with cervix	- enlarged, horn, moderate
1524	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	 compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1524	E	Microscopic	
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, unilateral, minimal
			- pyelitis, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, basophilic, minimal
			- hyperplasia, bile duct, minimal
		lung	- within normal limits
		lymph node, axillary	- within normal limits
		lymph node, inguinal	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1524	E	Microscopic	
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenocarcinoma, malignant, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b)
			- hyperplasia, lobular, mild
			corresponds to macroscopic observation (mammary gland - swollen/thickened)
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- cyst, unilateral, minimal
		oviducts	- within normal limits
		pancreas	- atrophy, acinar, minimal
		parathyroid glands	- not examined
		pharynx	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1524	Е	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats Individual Animal Listing - FEMALE

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Terminal Group, Observations Animal Number Fate Tissue 50 mg/kg/day 1524 Ε **Microscopic** thyroid gland - within normal limits - within normal limits tongue trachea - within normal limits - within normal limits ureters urinary bladder - within normal limits uterus with cervix - dilatation, gland/lumen, mild corresponds to macroscopic observation (uterus with cervix enlarged) vagina - within normal limits Cause of Death - mammary tumor Ε 1525 Macroscopic lymph node, axillary - within normal limits left, draining node for mass a. pituitary gland - enlarged, red, severe - mass, tan, mass a, left axillary area, present skin, subcutis corresponds to antemortem observation (nodule swelling) approximately 1.0 x 1.0 x 0.5 cm.

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1525	Е	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
			- pyelitis, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1525	Е	Microscopic	
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, basophilic, minimal
		lung	- within normal limits
		lymph node, axillary	- within normal limits
		lymph node, mandibular	- erythrocytosis/erythrophagocytosis, sinus, moderate
		lymph node, mesenteric	- within normal limits
		mammary gland	- adenocarcinoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1525	Е	Microscopic	
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
50 mg/kg/day 1525	E	Microscopic stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea	 within normal limits within normal limits depletion, lymphoid, generalized, moderate hyperplasia, epithelial cell, minimal hyperplasia, c-cell, focal, bilateral, minimal within normal limits within normal limits
		ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits within normal limits dilatation, gland/lumen, mild within normal limits pituitary tumor
1526	E	Macroscopic lymph node, inguinal pituitary gland	 not identified, bilateral, no grade draining node for mass a, left and mass b, right. enlarged, moderate

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1526	E	Macroscopic	
		skin, subcutis	- mass, tan, mass a, left inguinal area, present
			corresponds to antemortem observation (mass 1)
			approximately 5.0 cm in diameter
			- mass, tan, mass b, right inguinal area, present
			approximately 2.0 cm in diameter.
1526	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal
			 hyperplasia, focal cortical, unilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits

DuPont-18405-1238

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1526	E	Microscopic	
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	 mineralization, pelvic, unilateral, minimal
			 mineralization, tubular, unilateral, minimal
			- pyelitis, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 focus of cellular alteration, basophilic, minimal
			 hematopoiesis, extramedullary, minimal
			- hyperplasia, bile duct, minimal
			 vacuolation, periportal, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- within normal limits
		, ,	

DuPont-18405-1238

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1526	Е	Microscopic	
		lymph node, mesenteric	- within normal limits
		mammary gland	- fibroadenoma, benign, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b)
			- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	 exudate, nasal passage, moderate
			- inflammation, mild
		nose, level b	 exudate, nasal passage, moderate
			- inflammation, minimal
		nose, level c	- exudate, nasal passage, minimal
		nose, level d	- exudate, nasal passage, minimal
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1526	E	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1526	E	Microscopic	
		thymus	- depletion, lymphoid, generalized, moderate
			- hyperplasia, epithelial cell, minimal
		thyroid gland	 adenoma, c-cell, benign, unilateral, primary, incidental, not cause of death
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- pituitary tumor
1527	E	Macroscopic	
		ears	- nodule, tan, left, present
			corresponds to antemortem observation (nodule)
			approximately 0.4 cm in diameter.
		lymph node, axillary	- within normal limits
			draining node for mass b, right.

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1527	Е	Macroscopic	
		lymph node, inguinal	- within normal limits
			draining node for mass a, right.
		pituitary gland	- enlarged, red, moderate
		skin, subcutis	 mass, tan, mass a, right anogenital region, present
			corresponds to antemortem observation (mass 1)
			approximately 2.5 cm in diameter.
			 mass, tan, mass b, right axillary area, present
			corresponds to antemortem observation (mass 2)
			approximately 8.5 x 9.0 x 3.5 cm.
1527	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	 compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
<u>50 mg/кg/day</u> 1527	E	Microscopic eyes eyes, optic nerves eyes, retina galt harderian glands heart joint, tibiofemoral kidneys lacrimal glands, exorbital large intestine, cecum large intestine, rectum larynx	 within normal limits within normal limits degeneration/atrophy, retina, unilateral, mild within normal limits within normal limits within normal limits within normal limits mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal nephropathy, chronic progressive, bilateral, minimal within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1527	E	Microscopic	
		liver	- focus of cellular alteration, basophilic, minimal
			- focus of cellular alteration, eosinophilic, minimal
			- hyperplasia, bile duct, minimal
			 hypertrophy, hepatocyte, centrilobular, minimal
			 vacuolation, periportal, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, axillary	- within normal limits
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	 erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits
		mammary gland	- fibroadenoma, benign, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a;
			skin, subcutis - mass b)
			- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1527	Е	Microscopic	
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- hyperplasia, acinar cell, focal, moderate
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		skin, subcutis	- fibrosarcoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (ears - nodule)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1527	E	Microscopic spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder	 within normal limits within normal limits within normal limits hematopoiesis, extramedullary, increased, mild within normal limits within normal limits depletion, lymphoid, generalized, severe within normal limits
1528	S	uterus with cervix vagina Cause of Death Macroscopic lymph node, inguinal	 within normal limits within normal limits mammary tumor not identified, right, no grade draining node for mass a.

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1528	S	Macroscopic	
		skin, subcutis	- mass, tan, mass a, right inguinal area, present
			corresponds to antemortem observation (mass 1)
			approximately 8.0 x 7.0 x 4.5 cm.
		spleen	- enlarged, mild
		uterus with cervix	- enlarged, cervix, mild
1528	S	Microscopic	
		adrenal glands	 hyperplasia, focal medullary, bilateral, mild
		kidneys	- dilatation, tubular, bilateral, mild
			 edema, papilla, unilateral, minimal
			 hyperplasia, transitional cell, bilateral, minimal
			 mineralization, pelvic, bilateral, minimal
			 nephropathy, chronic progressive, bilateral, mild
		liver	 hematopoiesis, extramedullary, minimal
			 hyperplasia, bile duct, minimal
		lung	- within normal limits
		mammary gland	- adenocarcinoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
		pancreas	 hyperplasia, acinar cell, focal, mild

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Microscopic spleen stomach, nonglandular	- hematopoiesis, extramedullary, increased, mild corresponds to macroscopic observation (spleen - enlarged) within pormal limits.
spleen stomach, nonglandular	corresponds to macroscopic observation (spleen - enlarged)
stomach, nonglandular	corresponds to macroscopic observation (spleen - enlarged)
· •	
· •	within normal limits
	- within normal limits
ongue	- within normal limits
uterus with cervix	- dilatation, gland/lumen, moderate
	corresponds to macroscopic observation (uterus with cervix - enlarged)
	- hyperplasia, cervical fibromuscular, mild
	corresponds to macroscopic observation (uterus with cervix - enlarged)
	- hyperplasia, squamous cell, minimal
Macroscopic	
•	- enlarged, moderate
* *	• ,
adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal
١	Macroscopic oituitary gland Microscopic adrenal glands

S - Scheduled necropsy E - Euthanized *in extremis*

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1529	E	Microscopic	
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
		•	- mineralization, tubular, unilateral, minimal
			- nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		- J	

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

			Terminal
Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1529	E	Microscopic	
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- degeneration, cystic, focal, minimal
			- focus of cellular alteration, clear, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, minimal
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1529	Е	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	 depletion, lymphoid, generalized, severe

Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Fate Tissue	Observations
E Microscopic thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina	 within normal limits
Cause of Death	- pituitary tumor
E Macroscopic pituitary gland	- enlarged, red, moderate
E Microscopic adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal hyperplasia, focal cortical, unilateral, minimal within normal limits within normal limits
aorta bone marrow,	femur

Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1530	Е	Microscopic	
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- hyperplasia, focal, unilateral, minimal
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- hydronephrosis, unilateral, mild
			- hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, unilateral, minimal
			- nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1530	Е	Microscopic	
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 vacuolation, periportal, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- atrophy, acinar, mild
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		b	

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1530	E	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1530	Е	Microscopic	
		thymus	- depletion, lymphoid, generalized, moderate
			- hyperplasia, epithelial cell, minimal
		thyroid gland	- hyperplasia, c-cell, focal, unilateral, mild
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- pituitary tumor
1531	Е	Macroscopic	
		mammary gland	- swollen/thickened, tan, left axillary area, mild
		, ,	corresponds to antemortem observation (swelling)
		pituitary gland	- enlarged, red, severe
		stomach, nonglandular	- irregular surface, tan, mild

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1531	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal
			 vacuolation, focal, unilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
		•	- nephropathy, chronic progressive, unilateral, minimal

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1531	E	Microscopic	
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 vacuolation, periportal, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (mammary gland - swollen/thickened)
			- hyperplasia, lobular, minimal
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1531	E	Microscopic	
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1531	Е	Microscopic	
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	 hyperplasia, epithelial, nonglandular, moderate
			corresponds to macroscopic observation (stomach, nonglandular - irregular surface)
			- inflammation, mild
		thymus	 depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- pituitary tumor
1532	S	Macroscopic	
		lymph node, axillary	- within normal limits
		- · ·	draining node for mass b, right.

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1532	S	Macroscopic	
		lymph node, inguinal	- not identified, left, no grade
			draining node for mass c and mass d.
		lymph node, mandibular	- within normal limits
			draining node for mass a, right.
		pituitary gland	- enlarged, red, mild
		skin, subcutis	- mass, tan, mass a, right lateral neck, present
			corresponds to antemortem observation (mass 1)
			approximately 6.0 x 5.0 x 2.5 cm.
			- mass, tan, mass b, right axillary area, present
			corresponds to antemortem observation (swelling)
			approximately 2.5 cm in diameter.
			- mass, tan, mass c, left inguinal area, present
			approximately 3.0 x 3.0 x 1.0 cm.
			- mass, tan, mass d, left anogenital region, present
			approximately 2.5 cm in diameter.
1532	S	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild

S - Scheduled necropsy

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1532	S	Microscopic	
		kidneys	- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			 nephropathy, chronic progressive, unilateral, minimal
		liver	- hematopoiesis, extramedullary, minimal
			 hyperplasia, bile duct, minimal
		lung	- within normal limits
		lymph node, axillary	- within normal limits
		lymph node, mandibular	- within normal limits
		mammary gland	- fibroadenoma, benign, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b; skin, subcutis - mass c; skin, subcutis - mass d)
		pancreas	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		stomach, nonglandular	- within normal limits
		tongue	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1532	S	Microscopic uterus with cervix	- within normal limits
1533	Е	Macroscopic lymph node, axillary	 within normal limits draining node for mass a, left.
		skin, subcutis	 mass, ulcerated, mass a, left axillary area, present corresponds to antemortem observation (mass 1) approximately 7.0 x 7.0 x 3.0 cm, tan.
1533	E	Microscopic adrenal glands aorta bone marrow, femur bone marrow, sternum bone, femur bone, sternum brain esophagus	 angiectasis/cystic degeneration, focal cortical, bilateral, mild within normal limits

S - Scheduled necropsy E - Euthanized *in extremis*

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1533	E	Microscopic	
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- nephropathy, chronic progressive, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, basophilic, minimal
		lung	- within normal limits
		lymph node, axillary	- within normal limits
		lymph node, mandibular	- erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1533	E	Microscopic	
		mammary gland	- fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, minimal
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- exudate, nasal passage, mild
			- foreign material, minimal
			plant.
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- atrophy, acinar, minimal
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	- within normal limits
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1533	E	Microscopic	
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	- hyperplasia, c-cell, focal, unilateral, minimal
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1533	E	Microscopic	
		vagina	- within normal limits
		Cause of Death	- mammary tumor
1534	D	Macroscopic	
		pituitary gland	- enlarged, moderate
1534	D	Microscopic	-
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), severe
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits

E - Euthanized in extremis

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

50 mg/kg/day 1534	oup, mal Number	Fate	Tissue	Observations
1534 D Microscopic galt harderian glands heart joint, tibiofemoral kidneys lacrimal glands, exorbital large intestine, rectum large intestine, rectum largynx larynx within normal limits	mg/kg/day			
harderian glands heart joint, tibiofemoral kidneys lacrimal glands, exorbital large intestine, colon large intestine, rectum larynx larynx liver lung liver lung lung lymph node, mandibular - within normal limits - cardiomyopathy, minimal - within normal limits		D	Microscopic	
heart - cardiomyopathy, minimal joint, tibiofemoral - within normal limits kidneys - nephropathy, chronic progressive, bilateral, minimal lacrimal glands, exorbital - within normal limits large intestine, cecum - within normal limits large intestine, colon - within normal limits large intestine, rectum - within normal limits larynx - exudate, luminal, minimal liver - hyperplasia, bile duct, minimal infiltration, mononuclear cell, minimal - vacuolation, periportal, mild lung - within normal limits lymph node, mandibular - within normal limits			galt	- within normal limits
joint, tibiofemoral kidneys - nephropathy, chronic progressive, bilateral, minimal lacrimal glands, exorbital large intestine, cecum large intestine, colon large intestine, rectum larynx - within normal limits - inflammation, minimal - inflammation, minimal - infiltration, mononuclear cell, minimal - infiltration, periportal, mild - within normal limits			harderian glands	- within normal limits
kidneys			heart	- cardiomyopathy, minimal
lacrimal glands, exorbital large intestine, cecum large intestine, colon large intestine, rectum large intestine, rectum large intestine, rectum large intestine, rectum larynx larynx liver liv			joint, tibiofemoral	- within normal limits
lacrimal glands, exorbital large intestine, cecum large intestine, colon large intestine, rectum large intestine, rectum large intestine, rectum larynx larynx liver liver liver liver lung lung lung lymph node, mandibular within normal limits within normal limits within normal limits - within normal limits			kidneys	- nephropathy, chronic progressive, bilateral, minimal
large intestine, colon large intestine, rectum large intestine, colon large intestine, colon large intestine, colon large intestine, rectum limits limits lymph node, mandibular limits lymph node, within normal limits lymph node, mandibular limits lymph node, within normal limits			lacrimal glands, exorbital	
large intestine, colon large intestine, rectum large intestine, colon large intestine, colon large intestine, colon large intestine, rectum limits limits lymph node, mandibular limits lymph normal limits lymph normal limits lymph normal limits lymph normal limits			large intestine, cecum	- within normal limits
large intestine, rectum larynx exudate, luminal, minimal inflammation, minimal liver hyperplasia, bile duct, minimal infiltration, mononuclear cell, minimal vacuolation, periportal, mild lung lung lymph node, mandibular within normal limits within normal limits			large intestine, colon	- within normal limits
- inflammation, minimal liver - hyperplasia, bile duct, minimal - infiltration, mononuclear cell, minimal - vacuolation, periportal, mild lung - within normal limits lymph node, mandibular - within normal limits			_	- within normal limits
- inflammation, minimal liver - hyperplasia, bile duct, minimal - infiltration, mononuclear cell, minimal - vacuolation, periportal, mild lung - within normal limits lymph node, mandibular - within normal limits			larynx	- exudate, luminal, minimal
 infiltration, mononuclear cell, minimal vacuolation, periportal, mild lung within normal limits lymph node, mandibular within normal limits 			·	
 infiltration, mononuclear cell, minimal vacuolation, periportal, mild lung within normal limits lymph node, mandibular within normal limits 			liver	- hyperplasia, bile duct, minimal
lung - within normal limits lymph node, mandibular - within normal limits				- infiltration, mononuclear cell, minimal
lung - within normal limits lymph node, mandibular - within normal limits				
, , , , , , , , , , , , , , , , , , , ,			lung	
			lymph node, mandibular	- within normal limits
				- within normal limits
mammary gland - hyperplasia, lobular, mild			- ·	- hyperplasia, lobular, mild
nerve, sciatic - within normal limits				

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1534	D	Microscopic	
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- mucus increased, mild
		nose, level d	- mucus increased, mild
		ovaries	- cyst, unilateral, mild
			- hyperplasia, sex-cord/stromal, bilateral, mild
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1534	D	Microscopic	
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- inflammation, acute, minimal
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- pituitary tumor
		Cause of Death	- pitultary turnor

Individual Animal Listing - FEMALE Terminal

So mg/kg/day 1535 E Macroscopic Iymph node, axillary - within normal limits draining node for mass a, left. - mass, ulcerated, mass a, left lateral neck, present corresponds to antemortem observation (mass 1) approximately 8.0 x 7.0 x 5.0 cm, tan. 1535 E Microscopic adrenal glands - angiectasis/cystic degeneration, focal cortical, bilateral, moderate one medulla present aorta within normal limits bone marrow, femur within normal limits bone, femur within normal limits bone, sternum within normal limits within normal limits bone, sternum within normal limits within normal limits esophagus eyes within normal limits eyes eyes, optic nerves within normal limits within normal limits eyes within normal limits eyes within normal limits eyes within normal limits eyes within normal limits within normal limits eyes	Group, Animal Number	Fate	Tissue	Observations
1535 Because I skin, subcutis Skin, subcutis E Microscopic Skin, subcutis E Microscopic adrenal glands aorta bone marrow, femur bone marrow, sternum bone, sternum bona, sternum borain borain esophagus eyes within normal limits	50 mg/kg/day			
lymph node, axillary - within normal limits draining node for mass a, left.		E	Macroscopic	
skin, subcutis - mass, ulcerated, mass a, left lateral neck, present corresponds to antemortem observation (mass 1) approximately 8.0 x 7.0 x 5.0 cm, tan. E Microscopic adrenal glands - angiectasis/cystic degeneration, focal cortical, bilateral, moderate one medulla present aorta - within normal limits bone marrow, femur - within normal limits bone, femur - within normal limits bone, sternum - within normal limits brain - within normal limits brain - within normal limits esophagus - within normal limits esophagus - within normal limits				- within normal limits
corresponds to antemortem observation (mass 1) approximately 8.0 x 7.0 x 5.0 cm, tan. E Microscopic adrenal glands adrenal glands - angiectasis/cystic degeneration, focal cortical, bilateral, moderate one medulla present aorta - within normal limits bone marrow, femur bone, femur bone, femur bone, sternum bo				draining node for mass a, left.
approximately 8.0 x 7.0 x 5.0 cm, tan. High Microscopic adrenal glands adrenal glands and a aorta aorta bone marrow, femur bone marrow, sternum bone, femur bone, femur bone, sternum borain esophagus within normal limits esophagus within normal limits eyes within normal limits - within normal limits - within normal limits - within normal limits - within normal limits - within normal limits - within normal limits			skin, subcutis	- mass, ulcerated, mass a, left lateral neck, present
E Microscopic adrenal glands - angiectasis/cystic degeneration, focal cortical, bilateral, moderate one medulla present aorta - within normal limits bone marrow, femur bone marrow, sternum bone, femur bone, femur bone, sternum				corresponds to antemortem observation (mass 1)
adrenal glands - angiectasis/cystic degeneration, focal cortical, bilateral, moderate one medulla present aorta - within normal limits bone marrow, femur - within normal limits bone, femur - within normal limits bone, sternum - within normal limits bone, sternum - within normal limits bone, sternum - within normal limits brain - within normal limits esophagus - within normal limits eyes - within normal limits				approximately 8.0 x 7.0 x 5.0 cm, tan.
moderate one medulla present aorta bone marrow, femur bone marrow, sternum bone, femur bone, sternum bone, sternum brain brain esophagus eyes moderate one medulla present within normal limits	1535	E	Microscopic	
aorta - within normal limits bone marrow, femur - within normal limits bone marrow, sternum - within normal limits bone, femur - within normal limits bone, sternum - within normal limits brain - within normal limits esophagus - within normal limits eyes - within normal limits			adrenal glands	
bone marrow, femur - within normal limits bone, femur - within normal limits bone, sternum - within normal limits bone, sternum - within normal limits brain - within normal limits esophagus - within normal limits eyes - within normal limits				one medulla present
bone marrow, sternum - within normal limits bone, femur - within normal limits bone, sternum - within normal limits brain - within normal limits esophagus - within normal limits eyes - within normal limits			aorta	- within normal limits
bone, femur - within normal limits bone, sternum - within normal limits brain - within normal limits esophagus - within normal limits eyes - within normal limits			bone marrow, femur	- within normal limits
bone, sternum - within normal limits brain - within normal limits esophagus - within normal limits eyes - within normal limits			bone marrow, sternum	- within normal limits
brain - within normal limits esophagus - within normal limits eyes - within normal limits			bone, femur	- within normal limits
esophagus - within normal limits eyes - within normal limits			bone, sternum	- within normal limits
eyes - within normal limits			brain	- within normal limits
.,			esophagus	- within normal limits
eyes, optic nerves - within normal limits			eyes	- within normal limits
			eyes, optic nerves	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats Individual Animal Listing - FEMALE Terminal

MPI Research Study Number 125-141

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1535	Е	Microscopic	
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, mild
			- edema, papilla, bilateral, minimal
			- nephropathy, chronic progressive, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, basophilic, minimal
			- hematopoiesis, extramedullary, minimal
			 necrosis, hepatocytes, centrilobular, moderate
		lung	- histiocytosis, alveolar, minimal
		lymph node, axillary	 hyperplasia, lymphocyte/plasmacyte, medulla, mild
		lymph node, mandibular	- within normal limits
		rymph node, mandibulai	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Microscopic Iymph node, mesenteric within normal limits fibroadenoma, benign, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis hyperplasia, lobular, mild nerve, sciatic within normal limits nose, level a within normal limits nose, level b within normal limits nose, level c within normal limits nose, level d within normal limits ovaries cyst, unilateral, mild oviducts within normal limits pancreas within normal limits one of pair present pharynx pharynx within normal limits within normal limits salivary gland within normal limits within norm	
Microscopic Iymph node, mesenteric Iymph node, mesenteric Fibroadenoma, benign, primary, mortality-independent Corresponds to macroscopic observation (skin, subcutis hyperplasia, lobular, mild nerve, sciatic within normal limits nose, level a within normal limits within normal limits nose, level c within normal limits nose, level d within normal limits ovaries ovaries cyst, unilateral, mild oviducts within normal limits pancreas parathyroid glands within normal limits one of pair present pharynx pituitary gland within normal limits within normal limits over the pituitary gland within normal limits within normal limits one of pair present within normal limits within normal limits within normal limits within normal limits one of pair present within normal limits w	
mammary gland - fibroadenoma, benign, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis hyperplasia, lobular, mild nerve, sciatic within normal limits nose, level a within normal limits nose, level b within normal limits nose, level c within normal limits nose, level d within normal limits ovaries cyst, unilateral, mild oviducts within normal limits pancreas within normal limits parathyroid glands within normal limits one of pair present pharynx within normal limits pituitary gland within normal limits within normal limits	
corresponds to macroscopic observation (skin, subcutis hyperplasia, lobular, mild nerve, sciatic nose, level a nose, level b nose, level c nose, level d ovaries ovaries oviducts pancreas parathyroid glands corresponds to macroscopic observation (skin, subcutis hyperplasia, lobular, mild within normal limits within normal limits within normal limits cyst, unilateral, mild within normal limits within normal limits one of pair present pharynx pituitary gland corresponds to macroscopic observation (skin, subcutis hyperplasia, lobular, mild within normal limits within normal limits within normal limits within normal limits	
- hyperplasia, lobular, mild nerve, sciatic - within normal limits nose, level a - within normal limits nose, level b - within normal limits nose, level c - within normal limits nose, level d - within normal limits ovaries - cyst, unilateral, mild oviducts - within normal limits pancreas - within normal limits parathyroid glands - within normal limits one of pair present pharynx - within normal limits pituitary gland - within normal limits	nt
nerve, sciatic	utis - mass a)
nose, level a - within normal limits nose, level b - within normal limits nose, level c - within normal limits nose, level d - within normal limits ovaries - cyst, unilateral, mild oviducts - within normal limits pancreas - within normal limits parathyroid glands - within normal limits one of pair present pharynx - within normal limits pituitary gland - within normal limits	
nose, level b nose, level c nose, level d ovaries oviducts pancreas parathyroid glands pharynx pituitary gland - within normal limits	
nose, level c nose, level d ovaries oviducts pancreas parathyroid glands pharynx pituitary gland - within normal limits	
nose, level d - within normal limits ovaries - cyst, unilateral, mild oviducts - within normal limits pancreas - within normal limits parathyroid glands - within normal limits one of pair present pharynx - within normal limits pituitary gland - within normal limits	
ovaries - cyst, unilateral, mild oviducts - within normal limits pancreas - within normal limits parathyroid glands - within normal limits one of pair present pharynx - within normal limits pituitary gland - within normal limits	
oviducts	
pancreas - within normal limits parathyroid glands - within normal limits one of pair present pharynx - within normal limits pituitary gland - within normal limits	
parathyroid glands - within normal limits one of pair present pharynx - within normal limits pituitary gland - within normal limits	
one of pair present pharynx - within normal limits pituitary gland - within normal limits	
pharynx - within normal limits pituitary gland - within normal limits	
pituitary gland - within normal limits	
adjuary gland, mandibular, within normal limits	
Salivary glariu, mandibular - within normal limits	
salivary gland, parotid - within normal limits	
salivary gland, sublingual - within normal limits	

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1535	Е	Microscopic	
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		-	

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1535	E	Microscopic Cause of Death	- mammary tumor
1536	Е	Macroscopic pituitary gland skin	 enlarged, moderate hair sparse, generalized, mild corresponds to antemortem observation (hair sparse) most affected areas dorsal cervical, forelimbs bilateral and shoulders bilateral.
1536	E	Microscopic adrenal glands aorta bone marrow, femur bone marrow, sternum bone, femur bone, sternum brain	 angiectasis/cystic degeneration, focal cortical, unilateral, moderate within normal limits compression, ventral (pituitary tumor), moderate

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1536	Е	Microscopic	
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- hydronephrosis, unilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- angiectasis, mild
			- hyperplasia, bile duct, minimal
		lung	- histiocytosis, alveolar, minimal

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

 within normal limits within normal limits hyperplasia, lobular, minimal within normal limits within normal limits within normal limits within normal limits
 within normal limits hyperplasia, lobular, minimal within normal limits within normal limits within normal limits
 within normal limits hyperplasia, lobular, minimal within normal limits within normal limits within normal limits
 hyperplasia, lobular, minimal within normal limits within normal limits within normal limits
within normal limitswithin normal limitswithin normal limits
within normal limitswithin normal limits
- within normal limits
- within normal limits
- within normal limits
 adenoma, pars distalis, benign, primary, fatal, positive cause of death
corresponds to macroscopic observation (pituitary gland - enlarged)
- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1536	E	Microscopic	
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- alopecia/hypotrichosis, mild
			corresponds to macroscopic observation (skin - hair sparse)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1536	E	Microscopic	
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- pituitary tumor
1537	E	Macroscopic	
		pituitary gland	- enlarged, severe
1537	E	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1537	Е	Microscopic	
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- nephropathy, chronic progressive, bilateral, minimal
			- pyelitis, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, basophilic, minimal
			- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
			- vacuolation, periportal, minimal
		lung	- within normal limits
		lymph node, mandibular	- erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits
		•	

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1537	Е	Microscopic	
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- cyst, unilateral, minimal
		oviducts	- within normal limits
			one of pair present
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1537	Е	Microscopic	
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
			- hyperplasia, epithelial cell, minimal
		thyroid gland	 adenoma, c-cell, benign, unilateral, primary, incidental, not cause of death
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1537	E	Microscopic uterus with cervix vagina Cause of Death	within normal limitswithin normal limitspituitary tumor
1538	S	Macroscopic adrenal glands mammary gland ovaries pancreas spleen	 enlarged, left, moderate swollen/thickened, mild right and left inguinal and axillary region mostly affected. cyst, clear, left, mild cyst, red, multiple, mild focus/foci, white, mild
1538	S	Microscopic adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, severe corresponds to macroscopic observation (adrenal glands - enlarged) atrophy, cortical, unilateral, moderate

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1538	S	Microscopic	
		kidneys	- mineralization, pelvic, bilateral, minimal
			 nephropathy, chronic progressive, bilateral, mild
			- polyarteritis, bilateral, moderate
			renal artery.
			- pyelitis, unilateral, minimal
		liver	 focus of cellular alteration, basophilic, minimal
			 hematopoiesis, extramedullary, minimal
			- hyperplasia, bile duct, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mesenteric	- dilatation, sinus, mild
			corresponds to macroscopic observation (pancreas - cyst)
		mammary gland	- fibroadenoma, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (mammary gland - swollen/thickened)
			- hyperplasia, lobular, moderate
			corresponds to macroscopic observation (mammary gland - swollen/thickened)
		ovaries	- cyst, unilateral, mild
			corresponds to macroscopic observation (ovaries - cyst)
			- hyperplasia, sex-cord/stromal, unilateral, minimal

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1538	S	Microscopic	
		pancreas	- atrophy, acinar, minimal
			- polyarteritis, moderate
			corresponds to macroscopic observation (pancreas - cyst)
		spleen	- fibrosis, capsular, mild
			corresponds to macroscopic observation (spleen - focus/foci, white)
			- hematopoiesis, extramedullary, increased, minimal
		stomach, nonglandular	- within normal limits
		tongue	- within normal limits
		uterus with cervix	- dilatation, gland/lumen, minimal
1539	E	Macroscopic	
		lung with bronchi	- discoloration, pink, azygous lobe, moderate
		lymph node, axillary	- within normal limits
			draining node for mass a, right and mass c, left.
		lymph node, mandibular	- within normal limits
			draining node for mass b, left.
		pituitary gland	- enlarged, mild

S - Scheduled necropsy E - Euthanized *in extremis*

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1539	Е	Macroscopic	
		skin .	- abrasion/scab, right lateral head, moderate
			corresponds to antemortem observation (abrasion(s) swelling)
		skin, subcutis	- mass, tan, mass a, right axillary area, present
			corresponds to antemortem observation (mass 1)
			approximately 6.0 x 4.0 x 3.0 cm.
			- mass, tan, mass b, left lateral neck, present
			approximately 1.5 x 1.5 x 0.5 cm.
			- mass, tan, mass c, left axillary area, present
			corresponds to antemortem observation (swelling)
			approximately 1.0 cm in diameter.
1539	E	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	 hyperplasia, granulocytic, mild
		bone marrow, sternum	 hyperplasia, granulocytic, minimal
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits

E - Euthanized in extremis

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1539	Е	Microscopic	
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, unilateral, minimal
		•	- nephropathy, chronic progressive, bilateral, minimal
			- pyelitis, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hyperplasia, bile duct, minimal
			- vacuolation, periportal, mild
		lung	- histiocytosis, alveolar, minimal
		Č	

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
539	E	Microscopic	
		lymph node, axillary	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenocarcinoma, malignant, primary, incidental, not cause of death
			corresponds to macroscopic observation (skin, subcutis - mass b)
			 fibroadenoma, benign, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass c)
			- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1539	E	Microscopic	
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death corresponds to macroscopic observation (pituitary gland -
		salivary gland, mandibular	enlarged) - within normal limits
		salivary gland, mandibular salivary gland, parotid	- within normal limits
		salivary gland, parotid salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	 carcinoma, squamous cell, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin - abrasion/scab)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1539	E	Microscopic	
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
			- hyperplasia, epithelial cell, minimal
		thyroid gland	- within normal limits
		tongue	- hyperplasia, squamous cell, moderate
			- inflammation, subacute/chronic, mild
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		non-correlated macro observation	- lung with bronchi - discoloration, pink
		Cause of Death	- skin tumor
1540	E	Macroscopic	
		lymph node, axillary	- within normal limits
			right is draining node for mass c.

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats Individual Animal Listing - FEMALE

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

			Terminal
Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1540	E	Macroscopic lymph node, inguinal pituitary gland skin, subcutis	 within normal limits right is draining node for mass a, left is draining node for mass b. enlarged, red, severe mass, tan, mass b, left inguinal area, present corresponds to antemortem observation (mass 2) approximately 4.5 x 3.0 x 3.0 cm. mass, tan, mass c, right axillary area, present corresponds to antemortem observation (mass 3) approximately 2.0 cm in diameter.
1540	E	Microscopic adrenal glands aorta bone marrow, femur	 mass, ulcerated, mass a, right inguinal area, present corresponds to antemortem observation (mass 1) approximately 2.5 x 2.0 x 1.5 cm and tan in color. angiectasis/cystic degeneration, focal cortical, bilateral, moderate within normal limits within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1540	E	Microscopic	
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1540	E	Microscopic	
		liver	- focus of cellular alteration, basophilic, mild
			- hematopoiesis, extramedullary, minimal
			- hyperplasia, bile duct, minimal
			- vacuolation, periportal, minimal
		lung	- within normal limits
		lymph node, axillary	- not examined
			not found at the time of trimming
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	- erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenocarcinoma, malignant, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a)
			- fibroadenoma, benign, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass b; skin, subcutis - mass c)
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1540	Е	Microscopic	
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
50 mg/kg/day 1540	E	Microscopic spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters	 within normal limits within normal limits hematopoiesis, extramedullary, increased, mild within normal limits within normal limits depletion, lymphoid, generalized, moderate hyperplasia, epithelial cell, minimal within normal limits hyperplasia, squamous cell, moderate inflammation, subacute/chronic, mild within normal limits within normal limits
		urinary bladder uterus with cervix vagina Cause of Death	 within normal limits dilatation, gland/lumen, mild within normal limits mammary tumor
1541	S	Macroscopic adrenal glands	- enlarged, red, right, mild

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1541	S	Macroscopic	
		lymph node, mandibular	- within normal limits
			draining node for mass a, right. draining node for mass b, left.
		mammary gland	 swollen/thickened, tan, generalized, moderate
		pituitary gland	- enlarged, red, mild
		skin, subcutis	- mass, tan, mass a, right lateral neck, present
			corresponds to antemortem observation (swelling)
			approximately 2.3 cm in diameter.
			- mass, tan, mass b, left lateral neck, present
			approximately 2.0 cm in diameter.
1541	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, severe
			corresponds to macroscopic observation (adrenal glands - enlarged)
			- atrophy, cortical, unilateral, moderate
		kidneys	- hyperplasia, transitional cell, unilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			 nephropathy, chronic progressive, unilateral, minimal

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1541	S	Microscopic	
		liver	- focus of cellular alteration, basophilic, mild
			- focus of cellular alteration, clear, minimal
			- hematopoiesis, extramedullary, minimal
			- hyperplasia, bile duct, minimal
			 vacuolation, periportal, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		mammary gland	 adenocarcinoma, malignant, primary, incidental, not cause of death
			corresponds to macroscopic observation (mammary gland - swollen/thickened)
			- fibroadenoma, benign, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b)
			- hyperplasia, lobular, mild
			corresponds to macroscopic observation (mammary gland - swollen/thickened)
		pancreas	- atrophy, acinar, minimal
			- hyperplasia, acinar cell, focal, minimal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1541	S	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death corresponds to macroscopic observation (pituitary gland - enlarged)
		stomach, nonglandular	- within normal limits
		tongue	- within normal limits
		uterus with cervix	- within normal limits
1542	D	Macroscopic mammary gland pituitary gland	swollen/thickened, generalized, mildenlarged, red, severe
		skin	- abrasion/scab, dorsal thoracic region, mild
			 hair sparse, neck, shoulder, right, mild corresponds to antemortem observation (hair sparse)
1542	D	Microscopic	corresponds to different about fallon (name spaces)
	_	adrenal glands	- within normal limits
		aorta	- within normal limits

S - Scheduled necropsy D - Died on Study

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1542	D	Microscopic	
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, unilateral, minimal
			- nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		-	

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1542	D	Microscopic	
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- within normal limits
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
			corresponds to macroscopic observation (mammary gland - swollen/thickened)
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1542	D	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- alopecia/hypotrichosis, mild
			corresponds to macroscopic observation (skin - hair sparse)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1542	D	Microscopic	
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		non-correlated macro observation	- skin - abrasion/scab
		Cause of Death	- pituitary tumor
1543	S	Macroscopic	
		adrenal glands	- enlarged, left, mild
		pituitary gland	- cyst, clear, mild
1543	S	Microscopic	•
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
			corresponds to macroscopic observation (adrenal glands - enlarged)

S - Scheduled necropsy D - Died on Study

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1543	S	Microscopic	
		kidneys	- mineralization, pelvic, bilateral, minimal
		liver	- hyperplasia, bile duct, minimal
		lung	- within normal limits
		pancreas	- atrophy, acinar, minimal
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - cyst)
		stomach, nonglandular	- within normal limits
		tongue	- within normal limits
		uterus with cervix	- within normal limits
1544	Е	Macroscopic	
		pituitary gland	- enlarged, severe
		skin	- nodule, tan, nose/muzzle, present
			corresponds to antemortem observation (nodule)
			approximately 0.2 cm in diameter.
1544	Е	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, moderate

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1544	E	Microscopic	
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- degeneration/atrophy, retina, unilateral, mild
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, unilateral, minimal
		•	- pyelitis, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1544	Е	Microscopic	
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, basophilic, minimal
			- hyperplasia, bile duct, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1544	E	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- hyperplasia, epidermal, moderate
			corresponds to macroscopic observation (skin - nodule)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1544	E	Microscopic thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 depletion, lymphoid, generalized, moderate within normal limits pituitary tumor
1545	D	Macroscopic eyes eyes, optic nerves eyes, retina	 absent/cannibalized, right, no grade corresponds to antemortem observation (cannibalized/partially cannibalized) absent/cannibalized, right, no grade corresponds to antemortem observation (cannibalized/partially cannibalized) absent/cannibalized, right, no grade corresponds to antemortem observation (cannibalized/partially cannibalized)

E - Euthanized in extremis

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1545	D	Macroscopic	
		lacrimal glands, exorbital	 absent/cannibalized, right, no grade
			corresponds to antemortem observation (cannibalized/partially cannibalized)
		salivary gland, mandibular	- absent/cannibalized, bilateral, no grade
		salivary gland, parotid	- absent/cannibalized, bilateral, no grade
			corresponds to antemortem observation (cannibalized/partially cannibalized)
		salivary gland, sublingual	 absent/cannibalized, bilateral, no grade
			corresponds to antemortem observation (cannibalized/partially cannibalized)
1545	D	Microscopic	
		adrenal glands	- within normal limits
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1545	D	Microscopic	
		esophagus	- within normal limits
		eyes	- within normal limits
			one of pair present
		eyes, optic nerves	- within normal limits
			one of pair present
		eyes, retina	- not examined
			autolysis too severe for diagnosis
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- within normal limits
		lacrimal glands, exorbital	- within normal limits
		-	one of pair present
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

50 mg/kg/day 1545	D	Microscopic lung	
	D		
		luna	
		9	- bacterial colonies, minimal
			areas with lysis of red blood cells indicative of dosing injury.
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, minimal
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	- within normal limits
		salivary gland, mandibular	- not examined
			cannibalized

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

545 D Microscopic salivary gland, parotid - not examined cannibalized skeletal muscle, biceps femoris skin - within normal limits small intestine, duodenum - within normal limits small intestine, jejunum - within normal limits small intestine, jejunum - within normal limits spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spinal cord, thoracic - within normal limits spinal cord, plandular - within normal limits stomach, nonglandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate thyroid gland - within normal limits tongue - within normal limits	Group, Animal Number	Fate	Tissue	Observations
545 Microscopic Salivary gland, parotid Salivary gland, sublingual Sakeletal muscle, biceps femoris Sakin Sali intestine, duodenum Small intestine, duodenum Small intestine, ileum Small intestine, ileum Small intestine, jejunum Swithin normal limits Spinal cord, lumbar Spinal cord, suthin normal limits Spinal cord, suthin normal limits Spinal cord, suthin normal limits Spinal cord,	50 mg/kg/day			
salivary gland, parotid salivary gland, sublingual salivary gland, sublingual skeletal muscle, biceps femoris skin small intestine, duodenum small intestine, ileum small intestine, jejunum small inites spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus depletion, lymphoid, generalized, moderate thyroid gland tongue within normal limits swithin normal limits	1545	D	Microscopic	
cannibalized salivary gland, sublingual skeletal muscle, biceps femoris skin small intestine, duodenum small intestine, ileum small intestine, jejunum spinal cord, cervical spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue skeletal muscle, biceps femoris within normal limits spinal cord, thoracic within normal limits stomach, glandular within normal limits within normal limits within normal limits within normal limits				- not examined
skeletal muscle, biceps femoris skin small intestine, duodenum small intestine, ileum small intestine, jejunum small intestine, jejunum spinal cord, cervical spinal cord, thoracic spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus tongue cannibalized within normal limits stomach, glandular within normal limits depletion, lymphoid, generalized, moderate within normal limits within normal limits within normal limits within normal limits				cannibalized
skeletal muscle, biceps femoris skin small intestine, duodenum small intestine, ileum small intestine, jejunum small intestine, jejunum spinal cord, cervical spinal cord, thoracic spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus tongue cannibalized within normal limits stomach, glandular within normal limits depletion, lymphoid, generalized, moderate within normal limits within normal limits within normal limits within normal limits			salivary gland, sublingual	- not examined
skin - within normal limits small intestine, duodenum - within normal limits small intestine, ileum - within normal limits small intestine, jejunum - within normal limits spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate thyroid gland - within normal limits tongue - within normal limits				cannibalized
small intestine, duodenum small intestine, ileum small intestine, jejunum small intestine, jejunum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spinal cord, thoracic spleen spleen stomach, glandular stomach, nonglandular thymus thymus tongue - within normal limits			skeletal muscle, biceps femoris	- within normal limits
small intestine, ileum - within normal limits small intestine, jejunum - within normal limits spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate thyroid gland - within normal limits tongue - within normal limits			skin	- within normal limits
small intestine, jejunum - within normal limits spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate thyroid gland - within normal limits tongue - within normal limits			small intestine, duodenum	- within normal limits
spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate thyroid gland - within normal limits tongue - within normal limits			small intestine, ileum	- within normal limits
spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate thyroid gland - within normal limits tongue - within normal limits			small intestine, jejunum	- within normal limits
spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate thyroid gland - within normal limits tongue - within normal limits			spinal cord, cervical	- within normal limits
spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate thyroid gland - within normal limits tongue - within normal limits			spinal cord, lumbar	- within normal limits
stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate thyroid gland - within normal limits tongue - within normal limits			spinal cord, thoracic	- within normal limits
stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate thyroid gland - within normal limits tongue - within normal limits			spleen	- within normal limits
thymus - depletion, lymphoid, generalized, moderate thyroid gland - within normal limits tongue - within normal limits			stomach, glandular	- within normal limits
thyroid gland - within normal limits tongue - within normal limits			stomach, nonglandular	- within normal limits
tongue - within normal limits			thymus	- depletion, lymphoid, generalized, moderate
			thyroid gland	- within normal limits
trachea - within normal limits			tongue	- within normal limits
			trachea	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1545	D	Microscopic ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits within normal limits within normal limits within normal limits dosing injury
1546	S	Macroscopic pituitary gland uterus with cervix	enlarged, red, mildenlarged, horn, mild
1546	S	Microscopic adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate hyperplasia, focal cortical, unilateral, minimal pheochromocytoma, benign, unilateral, primary, incidental, not cause of death

S - Scheduled necropsy D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1546	S	Microscopic	
		kidneys	- hyperplasia, transitional cell, unilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, minimal
		liver	- fibrosis, minimal
			- focus of cellular alteration, eosinophilic, minimal
			- hematopoiesis, extramedullary, minimal
			- hyperplasia, bile duct, minimal
			- necrosis, focal, minimal
		lung	- within normal limits
		pancreas	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		stomach, nonglandular	- within normal limits
		tongue	- within normal limits
		uterus with cervix	- dilatation, gland/lumen, mild
			corresponds to macroscopic observation (uterus with cervix - enlarged)

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1547	S	Macroscopic	
		adrenal glands	- enlarged, left, mild
		pituitary gland	- enlarged, severe
1547	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
			corresponds to macroscopic observation (adrenal glands - enlarged)
		kidneys	- cyst, unilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, unilateral, minimal
			- nephropathy, chronic progressive, unilateral, minimal
		liver	- focus of cellular alteration, basophilic, minimal
			- hematopoiesis, extramedullary, minimal
			- hyperplasia, bile duct, minimal
		lung	- within normal limits
		pancreas	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats **Individual Animal Listing - FEMALE**

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

_			
- 1	err	nır	nai

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1547	S	Microscopic pituitary gland stomach, nonglandular tongue	 adenoma, pars distalis, benign, primary, incidental, not cause of death corresponds to macroscopic observation (pituitary gland - enlarged) within normal limits within normal limits
1548	E	uterus with cervix Macroscopic lymph node, inguinal	 within normal limits not identified, right, no grade draining node for mass a and mass c. draining node for mass b, left.

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1548	E	Macroscopic	
		skin, subcutis	- mass, tan, mass a, right anogenital region, present
			corresponds to antemortem observation (mass 1)
			approximately 9.0 x 5.0 x 3.0 cm.
			- mass, tan, mass b, left anogenital region, present
			approximately 3.0 cm in diameter.
			- mass, tan, mass c, right inguinal area, present
			approximately 2.0 x 1.5 x 1.0 cm.
		spleen	- enlarged, minimal
		uterus with cervix	- enlarged, horn, mild
1548	E	Microscopic	•
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal
			- hyperplasia, focal cortical, bilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- hyperplasia, granulocytic, mild
		bone marrow, sternum	- hyperplasia, granulocytic, minimal
		bone, femur	- within normal limits
		bone, sternum	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1548	Е	Microscopic	
		brain .	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- hyperplasia, transitional cell, unilateral, minimal
		•	- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hematopoiesis, extramedullary, minimal
			- vacuolation, periportal, minimal

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1548	E	Microscopic	
		lung	- within normal limits
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenocarcinoma, malignant, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b; skin, subcutis - mass c)
			- hyperplasia, lobular, mild
		nerve, sciatic	 degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Solivary Solivary	Group, Animal Number	Fate	Tissue	Observations
1548 E pituitary gland - adenoma, pars distalis, benign, primary, incidental, not cause of death salivary gland, mandibular salivary gland, parotid within normal limits salivary gland, sublingual within normal limits skeletal muscle, biceps femoris skin within normal limits small intestine, duodenum within normal limits small intestine, jejunum within normal limits spinal cord, cervical within normal limits spinal cord, dumbar spinal cord, thoracic spleen within normal limits stomach, glandular stomach, nonglandular thymus P within normal limits within normal limits within normal limits stomach, nonglandular within normal limits	50 mg/kg/day			
pituitary gland - adenoma, pars distalis, benign, primary, incidental, not cause of death salivary gland, mandibular - within normal limits salivary gland, sublingual - within normal limits skeletal muscle, biceps femoris skin - within normal limits small intestine, duodenum - within normal limits small intestine, ileum - within normal limits small intestine, jejunum - within normal limits small ord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits		Е	Microscopic	
salivary gland, parotid salivary gland, sublingual skeletal muscle, biceps femoris skin small intestine, duodenum small intestine, ileum small intestine, jejunum spinal cord, cervical spinal cord, thoracic spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus salivary gland, parotid within normal limits spinal cord, thoracic within normal limits				
salivary gland, sublingual skeletal muscle, biceps femoris skin within normal limits small intestine, duodenum small intestine, ileum small intestine, jejunum spinal cord, cervical spinal cord, thoracic spleen spleen stomach, glandular stomach, nonglandular thymus salivary gland, sublingual within normal limits depletion, lymphoid, generalized, moderate			salivary gland, mandibular	- within normal limits
skeletal muscle, biceps femoris skin - within normal limits small intestine, duodenum small intestine, ileum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, lumbar spinal cord, thoracic spleen - within normal limits spleen - within normal limits spleen - hematopoiesis, extramedullary, increased, mild corresponds to macroscopic observation (spleen - enlarged) stomach, glandular stomach, nonglandular stomach, nonglandular thymus - depletion, lymphoid, generalized, moderate			salivary gland, parotid	- within normal limits
skin - within normal limits small intestine, duodenum - within normal limits small intestine, ileum - within normal limits small intestine, jejunum - within normal limits spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - hematopoiesis, extramedullary, increased, mild corresponds to macroscopic observation (spleen - enlarged) stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate			salivary gland, sublingual	- within normal limits
small intestine, duodenum small intestine, ileum small intestine, jejunum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spieen spieen stomach, glandular stomach, nonglandular thymus - within normal limits - depletion, lymphoid, generalized, moderate			skeletal muscle, biceps femoris	- within normal limits
small intestine, ileum small intestine, jejunum small intestine, jejunum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spinal cord, thoracic spleen - hematopoiesis, extramedullary, increased, mild corresponds to macroscopic observation (spleen - enlarged) stomach, glandular stomach, nonglandular stomach, nonglandular thymus - within normal limits - within normal limits - depletion, lymphoid, generalized, moderate			skin	- within normal limits
small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus - within normal limits - depletion, lymphoid, generalized, moderate			small intestine, duodenum	- within normal limits
spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - hematopoiesis, extramedullary, increased, mild corresponds to macroscopic observation (spleen - enlarged) stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate			small intestine, ileum	- within normal limits
spinal cord, lumbar spinal cord, thoracic spleen - within normal limits - within normal limits - within normal limits - hematopoiesis, extramedullary, increased, mild - corresponds to macroscopic observation (spleen - enlarged) - within normal limits			small intestine, jejunum	- within normal limits
spinal cord, thoracic - within normal limits spleen - hematopoiesis, extramedullary, increased, mild corresponds to macroscopic observation (spleen - enlarged) stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate			spinal cord, cervical	- within normal limits
spleen - hematopoiesis, extramedullary, increased, mild corresponds to macroscopic observation (spleen - enlarged) stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate			spinal cord, lumbar	- within normal limits
corresponds to macroscopic observation (spleen - enlarged) stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate			spinal cord, thoracic	- within normal limits
stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate			spleen	- hematopoiesis, extramedullary, increased, mild
stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, moderate				corresponds to macroscopic observation (spleen - enlarged)
thymus - depletion, lymphoid, generalized, moderate			stomach, glandular	- within normal limits
· · · · · · · · · · · · · · · · · · ·			stomach, nonglandular	- within normal limits
- hyperplasia, epithelial cell, minimal			thymus	- depletion, lymphoid, generalized, moderate
				- hyperplasia, epithelial cell, minimal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1548	E	Microscopic	
		thyroid gland	 adenoma, c-cell, benign, unilateral, primary, incidental, not cause of death
			- hyperplasia, c-cell, focal, unilateral, mild
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- dilatation, gland/lumen, mild
			corresponds to macroscopic observation (uterus with cervix - enlarged)
		vagina	 granular cell tumor, benign, primary, incidental, not cause of death
		Cause of Death	- mammary tumor
1549	s	Macroscopic	
		adrenal glands	- focus/foci, red, left, mild
		lymph node, inguinal	- not identified, bilateral, no grade
		y we was a superior	draining node for mass a, left and mass b, right.

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1549	S	Macroscopic	
		pituitary gland	- enlarged, mild
		skin, subcutis	- mass, tan, mass a, left anogenital region, present
			corresponds to antemortem observation (mass 1)
			approximately 5.0 x 4.0 x 3.0 cm.
			- mass, tan, mass b, right anogenital region, present
			approximately 1.5 cm in diameter.
1549	S	Microscopic	
1040		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
			corresponds to macroscopic observation (adrenal glands - focus/foci, red)
			- hyperplasia, focal medullary, unilateral, minimal
		kidneys	- mineralization, pelvic, unilateral, minimal
			- mineralization, tubular, unilateral, minimal
			 nephropathy, chronic progressive, bilateral, minimal
		liver	- focus of cellular alteration, basophilic, mild
		lung	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1549	S	Microscopic	
		mammary gland	- fibroadenoma, benign, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b)
		pancreas	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		stomach, nonglandular	- within normal limits
		tongue	- within normal limits
		uterus with cervix	- within normal limits
1550	D	Macroscopic	
		lymph node, axillary	- within normal limits
			draining node for mass b, left.
		lymph node, inguinal	- not identified, left, no grade
			draining node for mass a.
		pituitary gland	- enlarged, red, severe

S - Scheduled necropsy D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1550	D	Macroscopic	
		skin, subcutis	- mass, tan, mass a, left inguinal area, present
			corresponds to antemortem observation (mass 1)
			approximately 4.0 x 3.0 x 2.0 cm.
			- mass, tan, mass b, left axillary area, present
			corresponds to antemortem observation (nodule)
			approximately 1.0 cm in diameter.
1550	D	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	 compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

50 mg/kg/day 1550 D Microscopic galt - within normal limi harderian glands - within normal limi heart - within normal limi joint, tibiofemoral - within normal limi kidneys - mineralization, pe lacrimal glands, exorbital - within normal limi large intestine, cecum - within normal limi large intestine, colon - within normal limi large intestine, rectum - within normal limi large intestine, rectum - within normal limi larynx - within normal limi	
D Microscopic galt - within normal limi harderian glands - within normal limi heart - within normal limi joint, tibiofemoral - within normal limi kidneys - mineralization, pe lacrimal glands, exorbital - within normal limi large intestine, cecum - within normal limi large intestine, colon - within normal limi large intestine, rectum - within normal limi	
harderian glands - within normal limi heart - within normal limi joint, tibiofemoral - within normal limi kidneys - mineralization, pe lacrimal glands, exorbital - within normal limi large intestine, cecum - within normal limi large intestine, colon - within normal limi large intestine, rectum - within normal limi	
heart - within normal limi joint, tibiofemoral - within normal limi kidneys - mineralization, pe lacrimal glands, exorbital - within normal limi large intestine, cecum - within normal limi large intestine, colon - within normal limi large intestine, rectum - within normal limi	s
joint, tibiofemoral - within normal limi kidneys - mineralization, pe lacrimal glands, exorbital - within normal limi large intestine, cecum - within normal limi large intestine, colon - within normal limi large intestine, rectum - within normal limi	s
kidneys - mineralization, per lacrimal glands, exorbital - within normal limit large intestine, colon - within normal limit large intestine, rectum - within nor	s
lacrimal glands, exorbital- within normal limilarge intestine, cecum- within normal limilarge intestine, colon- within normal limilarge intestine, rectum- within normal limi	s
large intestine, cecum- within normal limilarge intestine, colon- within normal limilarge intestine, rectum- within normal limi	vic, bilateral, minimal
large intestine, colon - within normal limi large intestine, rectum - within normal limi	s
large intestine, rectum - within normal limi	s
	s
larynx - within normal limi	s
	s
liver - hyperplasia, bile	uct, minimal
lung - within normal limi	s
lymph node, axillary - within normal limi	s
lymph node, mandibular - within normal limi	s
lymph node, mesenteric - within normal limi	s

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1550	D	Microscopic	
		mammary gland	- adenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass b)
			- fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, mild
		nerve, sciatic	 degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- cyst, unilateral, mild
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits

D - Died on Study

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1550	D	Microscopic	
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
			- hyperplasia, epithelial cell, minimal
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1550	D	Microscopic urinary bladder uterus with cervix vagina Cause of Death	 within normal limits metaplasia, squamous, minimal within normal limits pituitary tumor
1551	E	Macroscopic lung with bronchi lymph node, iliac ovaries	 focus/foci, red, multiple lobes, mild within normal limits draining node for mass a, left. mass, red, mass a, left, present
1551	E	stomach, nonglandular Microscopic	approximately 2.0 cm in diameter focus/foci, tan, mild
.00	_	adrenal glands aorta bone marrow, femur	 angiectasis/cystic degeneration, focal cortical, unilateral, minimal within normal limits within normal limits

E - Euthanized in extremis

D - Died on Study

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1551	E	Microscopic	
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- lymphoma, malignant, multicentric, fatal, positive cause of death
		joint, tibiofemoral	- within normal limits
		kidneys	- hyaline, droplets, increased, bilateral, mild
			 lymphoma, malignant, bilateral, multicentric, fatal, positive cause of death
			- mineralization, pelvic, bilateral, minimal
			- nephropathy, chronic progressive, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1551	E	Microscopic	
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- inflammation, minimal
		liver	- focus of cellular alteration, basophilic, minimal
			- lymphoma, malignant, multicentric, fatal, positive cause of death
		lung	- congestion, chronic passive, severe
			- lymphoma, malignant, multicentric, fatal, positive cause of death
			corresponds to macroscopic observation (lung with bronchi - focus/foci, red)
		lymph node, iliac	- within normal limits
		lymph node, mandibular	- lymphoma, malignant, multicentric, fatal, positive cause of death
		lymph node, mediastinal	 lymphoma, malignant, multicentric, fatal, positive cause of death slide 14.
		lymph node, mesenteric	- erythrocytosis/erythrophagocytosis, sinus, mild
			- lymphoma, malignant, multicentric, fatal, positive cause of death
		mammary gland	- hyperplasia, lobular, mild
		multicentric neoplasm	- lymphoma, malignant, multicentric, fatal, positive cause of death
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

		16	ennina
Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1551	E	Microscopic	
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	 sex-cord/stromal tumor, malignant, unilateral, primary, incidental, not cause of death
			corresponds to macroscopic observation (ovaries - mass a) slide 15 and 26-1.
		oviducts	- within normal limits
		pancreas	- atrophy, acinar, minimal
		·	- fibrosis, minimal
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits

E - Euthanized in extremis

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
<u>55 115</u>	E	Microscopic small intestine, duodenum small intestine, ileum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular	 within normal limits considered to macroscopic observation (stomach, nonglandular focus/foci, tan)
		thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix	 erosion/ulcer, limiting ridge, minimal within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1551	E	Microscopic	
		vagina	- within normal limits
		Cause of Death	- lymphoid tumor
1552	E	Macroscopic	
		pituitary gland	- enlarged, severe
1552	E	Microscopic	-
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	 compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1552	E	Microscopic	
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, mild
		•	- nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, basophilic, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1552	E	Microscopic	
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

16	rmد	inal
- 1 (,,,,,	HIGH

50 mg/kg/day 1552	E	Microscopic spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular	- within normal limits - within normal limits - within normal limits - within normal limits
	Е	spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen	within normal limitswithin normal limitswithin normal limits
		stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits within normal limits depletion, lymphoid, generalized, severe within normal limits within normal limits within normal limits not examined within normal limits within normal limits within normal limits within normal limits pituitary tumor
1553	S	Macroscopic adrenal glands	- enlarged, left, mild

S - Scheduled necropsy E - Euthanized *in extremis*

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1553	S	Macroscopic	
		lymph node, axillary	- within normal limits
			draining node for mass b, right. draining node for mass c, left.
		lymph node, inguinal	- within normal limits
			draining node for mass a, right.
		pituitary gland	- enlarged, red, moderate
		skin, subcutis	- mass, tan, mass a, right inguinal area, present
			corresponds to antemortem observation (mass 1)
			approximately 2.0 cm in diameter.
			 mass, tan, mass b, right axillary area, present
			approximately 1.2 cm in diameter.
			 mass, tan, mass c, left axillary area, present
			approximately 1.8 cm in diameter.
1553	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, severe
			corresponds to macroscopic observation (adrenal glands - enlarged)
		kidneys	- mineralization, pelvic, bilateral, minimal
			 nephropathy, chronic progressive, bilateral, mild

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
0 mg/kg/day			
553	S	Microscopic	
		liver	- infiltration, mononuclear cell, minimal
			 vacuolation, periportal, minimal
		lung	- within normal limits
		lymph node, axillary	- within normal limits
		lymph node, inguinal	- within normal limits
		mammary gland	 adenocarcinoma, malignant, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass c)
			- fibroadenoma, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (skin, subcutis - mass b)
		pancreas	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		stomach, nonglandular	- within normal limits
		tongue	- within normal limits
		uterus with cervix	- dilatation, gland/lumen, minimal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1554	E	Macroscopic	
		lymph node, inguinal	- within normal limits
			draining node for mass a, right.
		pituitary gland	- enlarged, red, severe
		skin, subcutis	- mass, tan, mass a, right anogenital region, present
			approximately 3.5 cm in diameter.
1554	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	 compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

<u>50 mg/kg/day</u>			
1554	E	Microscopic	
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, unilateral, minimal
			- mineralization, tubular, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, eosinophilic, mild
			- hematopoiesis, extramedullary, minimal
			- hyperplasia, bile duct, minimal
		lung	- within normal limits
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1554	Е	Microscopic	
		mammary gland	- fibroadenoma, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, minimal
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1554	Е	Microscopic	
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1554	Е	Microscopic	
		vagina	- within normal limits
		Cause of Death	- pituitary tumor
1555	D	Macroscopic	
		pituitary gland	- enlarged, red, moderate
		skin	- hair sparse, dorsal cervical region, dorsal head, mild
			corresponds to antemortem observation (hair sparse)
		thymus	- small, moderate
1555	D	Microscopic	
		adrenal glands	- within normal limits
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits

E - Euthanized in extremis

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

50			
<u>50 mg/kg/day</u>			
1555	D	Microscopic	
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, tubular, bilateral, minimal
		•	- nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, eosinophilic, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1555	D	Microscopic	
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1555	D	Microscopic	
		skin	- alopecia/hypotrichosis, mild
			corresponds to macroscopic observation (skin - hair sparse)
			- cyst, keratin, minimal
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
		•	corresponds to macroscopic observation (thymus - small)
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats Individual Animal Listing - FEMALE

Individual Animal Listing - FEMALE Terminal

Group, Animal Number	Fate	Tissue	Observations	
50 mg/kg/day				
1555	D	Microscopic uterus with cervix vagina Cause of Death	within normal limitswithin normal limitspituitary tumor	
1556	E	Macroscopic lymph node, inguinal	 not identified, right, no grade draining node for mass c and mass d. draining node for mass a, left. 	
		lymph node, mandibular pituitary gland	 within normal limits draining node for mass b, right. enlarged, mild 	

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

E - Euthanized in extremis

D - Died on Study

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

50 mg/kg/day			
1556	E	Macroscopic	
		skin, subcutis	- mass, tan, right anogenital region, mass c, present
			approximately 1.2 cm in diameter.
			 mass, tan, right inguinal area, mass d, present
			approximately 1.4 cm in diameter.
			- mass, tan, right lateral neck, mass b, present
			corresponds to antemortem observation (nodule)
			approximately 1.2 cm in diameter.
			 mass, ulcerated, left anogenital region, mass a, present corresponds to antemortem observation (mass 1 skin discolored)
			approximately 3.0 cm in diameter, tan.
1556	E	Microscopic	approximately 0.0 cm in diameter, tail.
	_	adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1556	Е	Microscopic	
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, basophilic, minimal
			- hematopoiesis, extramedullary, minimal
		lung	- within normal limits
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1556	E	Microscopic	
		lymph node, mesenteric	- within normal limits
		mammary gland	- adenocarcinoma, malignant, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b; skin, subcutis - mass c; skin, subcutis - mass d)
			- hyperplasia, lobular, minimal
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- atrophy, acinar, mild
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1556	Е	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death corresponds to macroscopic observation (pituitary gland -
			enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, mild
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Fate	Tissue	Observations
E	Microscopic	
	thymus	 depletion, lymphoid, generalized, severe
		- hyperplasia, epithelial cell, minimal
	thyroid gland	- within normal limits
	tongue	- within normal limits
	trachea	- within normal limits
	ureters	- within normal limits
	urinary bladder	- within normal limits
	uterus with cervix	- metaplasia, squamous, minimal
	vagina	- within normal limits
	Cause of Death	- mammary tumor
Е	Macroscopic	
	pituitary gland	- enlarged, red, severe
	stomach, nonglandular	- irregular surface, mild
Е	Microscopic	
	adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal
	E	E Microscopic thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death E Macroscopic pituitary gland stomach, nonglandular E Microscopic

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

50 mg/kg/day 1557			
	E	Microscopic	
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- hyperplasia, transitional cell, unilateral, mild
		•	- mineralization, pelvic, bilateral, minimal
			- pyelitis, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1557	Е	Microscopic	
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hyperplasia, bile duct, minimal
			- infiltration, mononuclear cell, minimal
			- necrosis, focal, minimal
			- vacuolation, periportal, mild
		lung	- within normal limits
		lymph node, mandibular	- erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1557	E	Microscopic	
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- degeneration/necrosis, myofiber, minimal
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
557	E	Microscopic	
		stomach, nonglandular	 hyperplasia, epithelial, nonglandular, moderate
			corresponds to macroscopic observation (stomach, nonglandular - irregular surface)
			- inflammation, mild
			corresponds to macroscopic observation (stomach, nonglandular - irregular surface)
		thymus	 depletion, lymphoid, generalized, moderate
		thyroid gland	 carcinoma, c-cell, malignant, unilateral, primary, incidental, not cause of death
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- dilatation, gland/lumen, mild
		vagina	- within normal limits
		Cause of Death	- pituitary tumor
558	Е	Macroscopic	
		adrenal glands	- enlarged, left, minimal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

•	
E Macroscopic cavity, thoracic - fluid, clear, mini approximately 1 kidneys - discoloration, ta liver - discoloration, ta lymph node, axillary - within normal lir draining node for lymph node, inguinal - within normal lir	0 ml. ı, bilateral, minimal
kidneys - discoloration, ta liver - discoloration, ta lymph node, axillary - within normal lir draining node for lymph node, inguinal - within normal lir	0 ml. ı, bilateral, minimal
kidneys - discoloration, ta liver - discoloration, ta lymph node, axillary - within normal lir draining node for lymph node, inguinal - within normal lir	n, bilateral, minimal
liver - discoloration, ta lymph node, axillary - within normal lir draining node fo lymph node, inguinal - within normal lir	
lymph node, axillary - within normal lir draining node fo lymph node, inguinal - within normal lir	n, multiple lobes, minimal
draining node for supply the supply s	
lymph node, inguinal - within normal lin	its
• • • • •	mass a, left.
draining node for	its
	mass b, left.
pituitary gland - enlarged, red, n	oderate
skin, subcutis - mass, scabbed	mass a, left axillary area, present
corresponds to	ntemortem observation (mass 1)
approximately 2	0.0 cm in diameter, tan.
- mass, tan, mas	b, left anogenital region, present
approximately 2	0 x 1.0 x 1.0 cm.
spleen - enlarged, mild	

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1558	Е	Microscopic	
		adrenal glands	 adenoma, cortical, benign, unilateral, primary, incidental, not cause of death corresponds to macroscopic observation (adrenal glands -
			enlarged)
			 angiectasis/cystic degeneration, focal cortical, unilateral, minimal
			- hematopoiesis, extramedullary, bilateral, minimal
			- hyperplasia, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

50 mg/kg/day 1558 E	Microscopic harderian glands heart joint, tibiofemoral kidneys	 within normal limits within normal limits within normal limits dilatation, tubular, bilateral, mild hyaline, droplets, increased, bilateral, mild corresponds to macroscopic observation (kidneys - discoloration, tan) mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal nephropathy, chronic progressive, bilateral, minimal
	harderian glands heart joint, tibiofemoral	 within normal limits within normal limits dilatation, tubular, bilateral, mild hyaline, droplets, increased, bilateral, mild corresponds to macroscopic observation (kidneys - discoloration, tan) mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal
	heart joint, tibiofemoral	 within normal limits within normal limits dilatation, tubular, bilateral, mild hyaline, droplets, increased, bilateral, mild corresponds to macroscopic observation (kidneys - discoloration, tan) mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal
	joint, tibiofemoral	 within normal limits dilatation, tubular, bilateral, mild hyaline, droplets, increased, bilateral, mild corresponds to macroscopic observation (kidneys - discoloration, tan) mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal
		 dilatation, tubular, bilateral, mild hyaline, droplets, increased, bilateral, mild corresponds to macroscopic observation (kidneys - discoloration, tan) mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal
	kidneys	 hyaline, droplets, increased, bilateral, mild corresponds to macroscopic observation (kidneys - discoloration, tan) mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal
		corresponds to macroscopic observation (kidneys - discoloration, tan) - mineralization, pelvic, bilateral, minimal - mineralization, tubular, bilateral, minimal
		tan) - mineralization, pelvic, bilateral, minimal - mineralization, tubular, bilateral, minimal
		- mineralization, tubular, bilateral, minimal
		- nephropathy chronic progressive bilateral minimal
		riopiniopanity, cinionio progrecoivo, bilatorai, riininiai
	lacrimal glands, exorbital	- within normal limits
	large intestine, cecum	- within normal limits
	large intestine, colon	- within normal limits
	large intestine, rectum	- within normal limits
	larynx	- within normal limits
	liver	- degeneration, cystic, focal, minimal
		 infiltration, mononuclear cell, minimal
		 necrosis, hepatocytes, centrilobular, mild
		corresponds to macroscopic observation (liver - discoloration, tan)
	lung	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1558	Е	Microscopic	
		lymph node, axillary	- within normal limits
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	 erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenocarcinoma, malignant, primary, incidental, not cause of death
			corresponds to macroscopic observation (skin, subcutis - mass b)
			- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1558	Е	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		skin, subcutis	 fibrosarcoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, mild
			corresponds to macroscopic observation (spleen - enlarged)
		stomach, glandular	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1558	E	Microscopic stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits depletion, lymphoid, generalized, moderate within normal limits dilatation, gland/lumen, minimal within normal limits fibrosarcoma/fibroma
1559	S	Macroscopic lymph node, inguinal	 not identified, bilateral, no grade draining node for mass a, right. draining node for mass b, left.

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1559	S	Macroscopic	
		skin, subcutis	- mass, tan, mass a, right inguinal area, present
			corresponds to antemortem observation (mass 1)
			approximately 5.5 x 5.5 x 3.0 cm.
			- mass, tan, mass b, left inguinal area, present
			approximately 1.0 cm in diameter.
1559	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, moderate
		kidneys	- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, unilateral, minimal
		liver	- focus of cellular alteration, basophilic, mild
			- hematopoiesis, extramedullary, minimal
			- hyperplasia, bile duct, minimal
			 vacuolation, periportal, minimal
		lung	- histiocytosis, alveolar, minimal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1559	S	Microscopic	
		mammary gland pancreas	 adenocarcinoma, malignant, multiple, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b) within normal limits
		stomach, nonglandular	- within normal limits
		tongue	- within normal limits
		uterus with cervix	- within normal limits
1560	E	Macroscopic adrenal glands lymph node, mandibular pituitary gland skin, subcutis	 enlarged, tan, right, mild not identified, bilateral, no grade draining node for mass a. enlarged, tan, mild mass, ulcerated, mass a, ventral neck, present corresponds to antemortem observation (mass 1) approximately 5.0 x 4.5 x 3.0 cm, tan.

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1560	Е	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, moderate
			corresponds to macroscopic observation (adrenal glands - enlarged)
			 hyperplasia, focal cortical, unilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- hyperplasia, granulocytic, mild
		bone marrow, sternum	- hyperplasia, granulocytic, mild
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

So mg/kg/day So mg/kg/day So mineralization So mg/kg/day	Group, Animal Number	Fate	Tissue	Observations
1560 E Microscopic kidneys - mineralization, pelvic, bilateral, minimal - nephropathy, chronic progressive, unilateral, minimal - nephropathy, chronic progressive, unilateral, minimal - nephropathy, chronic progressive, unilateral, minimal - within normal limits - focus of cellular alteration, basophilic, minimal - hematopoiesis, extramedullary, minimal - hematopoiesis, extramedullary, minimal - hematopoiesis, extramedullary, minimal - within normal limits - not examined - lymph node, mandibular - not examined - within normal limits - adenocarcinoma, malignant, primary, mortality-independent - corresponds to macroscopic observation (skin, subcutis - mass a) - hyperplasia, lobular, mild - nerve, sciatic - nose, level a - within normal limits - ose, level a - within normal limits	50 mg/kg/day			
- nephropathy, chronic progressive, unilateral, minimal lacrimal glands, exorbital large intestine, cecum large intestine, colon large intestine, colon large intestine, rectum large intestine, rectum larynx liver liver - focus of cellular alteration, basophilic, minimal - hematopoiesis, extramedullary, minimal - hematopoiesis, extramedullary, minimal - hematopoiesis, extramedullary, minimal - hematopoiesis, extramedullary, minimal - within normal limits - not examined - within normal limits - not examined - within normal limits - adenocarcinoma, malignant, primary, mortality-independent - corresponds to macroscopic observation (skin, subcutis - mass a) - hyperplasia, lobular, mild - nerve, sciatic - within normal limits - nose, level a - within normal limits		E	Microscopic	
lacrimal glands, exorbital large intestine, cecum large intestine, colon large intestine, rectum large intestine, colon large intestine, colon large intestine, colon large intestine, colon limits large intestine, cecum limits large intestine, cecum limits large intestine, colon limits large intestine, colon limits large intestine, cecum limits large intestine, colon limits large intestine, within normal l			-	- mineralization, pelvic, bilateral, minimal
large intestine, cecum large intestine, colon large intestine, colon large intestine, rectum large intestine, rectum larynx liver liver lung lymph node, mandibular lymph node, mesenteric mammary gland lenge nerve, sciatic nose, level a nose, level b large intestine, cecum within normal limits - within normal limits				- nephropathy, chronic progressive, unilateral, minimal
large intestine, colon large intestine, rectum limits lumits limits limits lung lung lung lung lung lung lymph node, mandibular lymph node, mandibular lymph node, mesenteric mammary gland lung lung lung lung lung lunits lung lung lung lung lung lung lung lung			lacrimal glands, exorbital	- within normal limits
large intestine, rectum larynx - within normal limits liver - focus of cellular alteration, basophilic, minimal - hematopoiesis, extramedullary, minimal - hematopoiesis, extramedullary, minimal - within normal limits - within normal limits - within normal limits - not examined - lymph node, mandibular - lymph node, mesenteric - within normal limits - adenocarcinoma, malignant, primary, mortality-independent - corresponds to macroscopic observation (skin, subcutis - mass a) - hyperplasia, lobular, mild - nerve, sciatic - nose, level a - within normal limits			large intestine, cecum	- within normal limits
larynx within normal limits focus of cellular alteration, basophilic, minimal hematopoiesis, extramedullary, minimal lung			large intestine, colon	- within normal limits
liver - focus of cellular alteration, basophilic, minimal - hematopoiesis, extramedullary, minimal lung - within normal limits lymph node, mandibular lymph node, mesenteric mammary gland - adenocarcinoma, malignant, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a) - hyperplasia, lobular, mild nerve, sciatic nose, level a nose, level b - within normal limits			large intestine, rectum	- within normal limits
- hematopoiesis, extramedullary, minimal lung - within normal limits lymph node, mandibular - not examined lymph node, mesenteric - within normal limits mammary gland - adenocarcinoma, malignant, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a) - hyperplasia, lobular, mild nerve, sciatic nose, level a - within normal limits nose, level b - within normal limits			larynx	- within normal limits
lung			liver	- focus of cellular alteration, basophilic, minimal
lymph node, mandibular lymph node, mesenteric mammary gland - not examined within normal limits - adenocarcinoma, malignant, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a) - hyperplasia, lobular, mild nerve, sciatic nose, level a nose, level b - within normal limits - within normal limits - within normal limits				- hematopoiesis, extramedullary, minimal
lymph node, mesenteric - within normal limits mammary gland - adenocarcinoma, malignant, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a) hyperplasia, lobular, mild nerve, sciatic - within normal limits nose, level a - within normal limits nose, level b - within normal limits			lung	- within normal limits
mammary gland - adenocarcinoma, malignant, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a) - hyperplasia, lobular, mild nerve, sciatic nose, level a nose, level b - within normal limits - within normal limits			lymph node, mandibular	- not examined
corresponds to macroscopic observation (skin, subcutis - mass a) - hyperplasia, lobular, mild - within normal limits - within normal limits - within normal limits - nose, level b - within normal limits			lymph node, mesenteric	- within normal limits
- hyperplasia, lobular, mild nerve, sciatic - within normal limits nose, level a - within normal limits nose, level b - within normal limits			mammary gland	- adenocarcinoma, malignant, primary, mortality-independent
nerve, sciatic - within normal limits nose, level a - within normal limits nose, level b - within normal limits				corresponds to macroscopic observation (skin, subcutis - mass a)
nose, level a - within normal limits nose, level b - within normal limits				- hyperplasia, lobular, mild
nose, level b - within normal limits			nerve, sciatic	- within normal limits
			nose, level a	- within normal limits
nose, level c - within normal limits			nose, level b	- within normal limits
			nose, level c	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1560	Е	Microscopic	
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
50 mg/kg/day			
1560	E	Microscopic spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus	 within normal limits within normal limits within normal limits hematopoiesis, extramedullary, increased, minimal within normal limits within normal limits depletion, lymphoid, generalized, severe
		thyroid gland	 hyperplasia, epithelial cell, minimal adenoma, c-cell, benign, unilateral, primary, incidental, not cause of death
		tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits mammary tumor

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1566	D	Macroscopic	
		skin .	- hair sparse, dorsal cervical region, dorsal head, moderate
			corresponds to antemortem observation (hair sparse)
1566	D	Microscopic	
		adrenal glands	- within normal limits
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
			one of pair present
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1566	D	Microscopic	
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, mild
			- mineralization, tubular, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hypertrophy, hepatocyte, centrilobular, minimal
			- infiltration, mononuclear cell, minimal
		lung	- within normal limits
		· ·	lysis of red blood cells within capillaries.
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- within normal limits
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1566	D	Microscopic	
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- polyarteritis, mild
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- alopecia/hypotrichosis, mild
			corresponds to macroscopic observation (skin - hair sparse)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1566	D	Microscopic spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits hematopoiesis, extramedullary, increased, minimal within normal limits within normal limits depletion, lymphoid, generalized, moderate within normal limits hyperplasia, squamous cell, moderate inflammation, subacute/chronic, mild within normal limits dosing injury
1567	D	Macroscopic kidneys	- irregular surface, bilateral, mild

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1567	D	Macroscopic	
		lung with bronchi	 discoloration, red, multiple lobes, moderate
		pituitary gland	- enlarged, minimal
		skin	- hair sparse, head, right lateral thorax, moderate
			corresponds to antemortem observation (hair sparse)
1567	D	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1567	D	Microscopic	
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, unilateral, minimal
			- mineralization, tubular, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, mild
			corresponds to macroscopic observation (kidneys - irregular surface)
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 hypertrophy, hepatocyte, centrilobular, minimal
			- infiltration, mononuclear cell, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1567	D	Microscopic	
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	- within normal limits
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	 alopecia/hypotrichosis, mild corresponds to macroscopic observation (skin - hair sparse)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1567	D	Microscopic	
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
			- hyperplasia, epithelial cell, minimal
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- polyp, stromal, benign, primary, incidental, not cause of death
		vagina	- within normal limits
		non-correlated macro observation	- lung with bronchi - discoloration, red
			- pituitary gland - enlarged
		Cause of Death	- dosing injury

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1573	E	Macroscopic	
		adrenal glands	- enlarged, left, mild
		brain	- discoloration, tan, moderate
		kidneys	- discoloration, tan, pelvis, bilateral, mild
		liver	- focus/foci, tan, median lobe, right lateral lobe, mild
			- nodule, tan, left lateral lobe, present
			approximately 0.4 cm in diameter.
		lung with bronchi	- discoloration, pink, multiple lobes, mild
		lymph node, axillary	- within normal limits
			draining node for mass b, right.
		lymph node, iliac	- within normal limits
			draining node for mass d.
		lymph node, inguinal	- not identified, left, no grade
			draining node for mass a.
		lymph node, mesenteric	- within normal limits
			draining node for mass c.
		pancreas	- mass, tan, mass c, present
			approximately 0.6 cm in diameter.
		pituitary gland	- enlarged, red, severe

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1573	Е	Macroscopic	
		skin, subcutis	- mass, tan, mass b, right axillary area, present
		,	corresponds to antemortem observation (nodule)
			approximately 2.0 cm in diameter.
			- mass, ulcerated, mass a, left inguinal area, present
			corresponds to antemortem observation (mass 1)
			approximately 7.5 x 6.0 x 3.0 cm, tan.
		uterus with cervix	- mass, tan, mass d, present
			approximately 4.0 cm in diameter.
1573	Е	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral,
		and the granted	severe
			corresponds to macroscopic observation (adrenal glands - enlarged)
		aorta	- within normal limits
		bone marrow, femur	- hyperplasia, granulocytic, mild
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		•	

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

	Fate	Tissue	Observations
500 mg/kg/day			
1573	E	Microscopic brain	compression ventral (nituitor (tumor), mild
			 compression, ventral (pituitary tumor), mild within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- degeneration/atrophy, retina, unilateral, mild
		eyes, retina	- within normal limits
		galt harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, mild
		Kidneys	corresponds to macroscopic observation (kidneys - discoloration, tan)
			- edema, papilla, bilateral, mild
			corresponds to macroscopic observation (kidneys - discoloration, tan)
			- hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1573	E	Microscopic large intestine, cecum large intestine, colon large intestine, rectum larynx liver lung lymph node, axillary	 within normal limits within normal limits within normal limits within normal limits adenoma, hepatocellular, benign, primary, incidental, not cause of death corresponds to macroscopic observation (liver - nodule) focus of cellular alteration, basophilic, minimal hypertrophy, hepatocyte, centrilobular, mild necrosis, hepatocytes, centrilobular, mild corresponds to macroscopic observation (liver - focus/foci, tan) histiocytosis, alveolar, minimal within normal limits
		lymph node, iliac lymph node, mandibular lymph node, mesenteric	within normal limitswithin normal limitswithin normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1573	E	Microscopic	
		mammary gland	- adenocarcinoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			 fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass b)
			- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

500 mg/kg/day 1573			
	E	Microscopic	
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, mild
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1573	Е	Microscopic	
		uterus with cervix	 carcinoma, squamous cell, malignant, primary, incidental, not cause of death
			corresponds to macroscopic observation (uterus with cervix - mass d)
		vagina	- within normal limits
		non-correlated macro observation	- brain - discoloration, tan
			- lung with bronchi - discoloration, pink
			- pancreas - mass c
		Cause of Death	- mammary tumor
1574	E	Macroscopic	
		pituitary gland	- enlarged, red, severe
1574	E	Microscopic	•
1014		adrenal glands	 adenoma, cortical, benign, unilateral, primary, incidental, not cause of death
			 angiectasis/cystic degeneration, focal cortical, unilateral, moderate
			moderate

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1574	Е	Microscopic	
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
		•	- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1574	E	Microscopic	
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1574	Е	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- hyperplasia, epithelial, limiting ridge, minimal
		thymus	- depletion, lymphoid, generalized, moderate

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1574	E	Microscopic thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 hyperplasia, c-cell, focal, unilateral, mild within normal limits pituitary tumor
1575	D	Macroscopic all tissues	- within normal limits
1575	D	Microscopic adrenal glands aorta bone marrow, femur bone marrow, sternum bone, femur	 angiectasis/cystic degeneration, focal cortical, bilateral, mild within normal limits within normal limits within normal limits within normal limits

E - Euthanized in extremis

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1575	D	Microscopic	
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			- necrosis, papillary, bilateral, severe
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		-	

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1575	D	Microscopic	
		larynx	- within normal limits
		liver	- focus of cellular alteration, basophilic, minimal
			- focus of cellular alteration, eosinophilic, minimal
			- hyperplasia, bile duct, minimal
			 hypertrophy, hepatocyte, centrilobular, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, minimal
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations	
500 mg/kg/day				
1575	D	Microscopic		
		pharynx	- within normal limits	
		pituitary gland	- within normal limits	
		salivary gland, mandibular	- within normal limits	
		salivary gland, parotid	- within normal limits	
		salivary gland, sublingual	- within normal limits	
		skeletal muscle, biceps femoris	- within normal limits	
		skin	- within normal limits	
		small intestine, duodenum	- within normal limits	
		small intestine, ileum	- within normal limits	
		small intestine, jejunum	- within normal limits	
		spinal cord, cervical	- within normal limits	
		spinal cord, lumbar	- within normal limits	
		spinal cord, thoracic	- within normal limits	
		spleen	- within normal limits	
		stomach, glandular	- within normal limits	
		stomach, nonglandular	- within normal limits	
		thymus	- depletion, lymphoid, generalized, moderate	
			- hyperplasia, lymphoid, medulla, mild	

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1575	D	Microscopic thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 adenoma, c-cell, benign, unilateral, primary, incidental, not cause of death within normal limits within normal limits within normal limits hyperplasia, simple transitional cell, mild within normal limits within normal limits kidney inflammation/necrosis
1576	S	Macroscopic kidneys liver lymph node, inguinal skin, subcutis	 irregular surface, bilateral, mild focus/foci, tan, multiple lobes, mild not identified, left, no grade draining node for mass a. mass, tan, mass a, left inguinal area, present corresponds to antemortem observation (mass 1) approximately 5.0 x 9.0 x 8.0 cm.

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

S - Scheduled necropsy D - Died on Study

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1576	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1576	S	Microscopic	
		kidneys	- dilatation, tubular, bilateral, mild
			- edema, papilla, bilateral, minimal
			- hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			 nephropathy, chronic progressive, bilateral, mild
			corresponds to macroscopic observation (kidneys - irregular surface)
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1576	S	Microscopic	
		liver	 adenoma, hepatocellular, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (liver - focus/foci, tan)
			- degeneration, cystic, focal, minimal
			- focus of cellular alteration, basophilic, minimal
			- focus of cellular alteration, eosinophilic, moderate
			corresponds to macroscopic observation (liver - focus/foci, tan)
			- hypertrophy, hepatocyte, panlobular, mild
			- infiltration, mononuclear cell, minimal
			- necrosis, individual hepatocyte, mild
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, mild
		nerve, sciatic	 degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1576	S	Microscopic	
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- degeneration/necrosis, myofiber, minimal
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1576	S	Microscopic	
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	 adenoma, c-cell, benign, unilateral, primary, incidental, not cause of death
		tongue	 hyperplasia, squamous cell, mild
			- inflammation, subacute/chronic, mild
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- polyp, stromal, benign, primary, incidental, not cause of death
		vagina	- within normal limits
1577	Е	Macroscopic	
		lung with bronchi	- discoloration, tan, multiple lobes, moderate

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1577	Е	Macroscopic	
		lymph node, iliac	- within normal limits
			draining node for mass a, left.
		lymph node, inguinal	 not identified, right, no grade
			draining node for mass b.
		skin, subcutis	- abscess, left inguinal area, moderate
			corresponds to antemortem observation (nodule)
			- mass, tan, mass a, left anogenital region, present
			corresponds to antemortem observation (mass 1 swelling)
			approximately 5.0 cm in diameter.
			 mass, tan, mass b, right inguinal area, present
			corresponds to antemortem observation (mass 2)
			approximately 4.5 cm in diameter.
1577	Е	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
			 hyperplasia, focal medullary, unilateral, minimal
			 pheochromocytoma, benign, unilateral, primary, incidental, not cause of death

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations	
500 mg/kg/day				
1577	Е	Microscopic		
		aorta	- within normal limits	
		bone marrow, femur	- hyperplasia, granulocytic, minimal	
		bone marrow, sternum	- within normal limits	
		bone, femur	- within normal limits	
		bone, sternum	- within normal limits	
		brain	- within normal limits	
		esophagus	- within normal limits	
		eyes	- within normal limits	
		eyes, optic nerves	- within normal limits	
		eyes, retina	- within normal limits	
		galt	- within normal limits	
		harderian glands	- within normal limits	
		heart	- cardiomyopathy, minimal	
		joint, tibiofemoral	- within normal limits	
		joint, libiotemoral	- within normal limits	

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1577	E	Microscopic	
		kidneys	- cyst, unilateral, mild
			- dilatation, tubular, bilateral, mild
			- edema, papilla, bilateral, minimal
			- mineralization, pelvic, unilateral, minimal
			- mineralization, tubular, bilateral, minimal
			 nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- degeneration, cystic, focal, mild
			- hyperplasia, bile duct, mild
			 hypertrophy, hepatocyte, panlobular, mild
			 necrosis, hepatocytes, centrilobular, mild
		lung	- histiocytosis, alveolar, minimal
		lymph node, iliac	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1577	E	Microscopic	
		mammary gland	 adenocarcinoma, malignant, multiple, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis -
			abscess; skin, subcutis - mass a; skin, subcutis - mass b)
			- hyperplasia, lobular, minimal
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1577	Е	Microscopic	
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, mild
		stomach, glandular	- within normal limits
		stomach, nonglandular	- hyperplasia, epithelial, limiting ridge, minimal
		thymus	- depletion, lymphoid, generalized, moderate
			- hyperplasia, epithelial cell, minimal
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1577	E	Microscopic uterus with cervix vagina non-correlated macro observation Cause of Death	 metaplasia, squamous, minimal within normal limits lung with bronchi - discoloration, tan mammary tumor
1578	S	Macroscopic kidneys	- irregular surface, bilateral, mild
1578	S	Microscopic adrenal glands aorta bone marrow, femur bone marrow, sternum bone, femur bone, sternum brain esophagus eyes	 angiectasis/cystic degeneration, focal cortical, bilateral, mild within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1578	S	Microscopic eyes, optic nerves eyes, retina galt harderian glands heart joint, tibiofemoral kidneys	 within normal limits within normal limits within normal limits within normal limits cardiomyopathy, minimal within normal limits edema, papilla, bilateral, mild hyperplasia, transitional cell, bilateral, minimal mineralization, pelvic, bilateral, mild mineralization, tubular, bilateral, minimal nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular
		lacrimal glands, exorbital large intestine, cecum large intestine, colon large intestine, rectum larynx	surface) - within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1578	S	Microscopic	
		liver	- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, mild
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	- cyst, minimal
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1578	S	Microscopic	
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- degeneration/necrosis, myofiber, minimal
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	 adenoma, c-cell, benign, unilateral, primary, incidental, not cause of death
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1578	S	Microscopic	
		uterus with cervix	- hyperkeratosis, minimal
			- hyperplasia, squamous cell, mild
		vagina	- within normal limits
1579	E	Macroscopic	
		kidneys	- irregular surface, bilateral, mild
		lymph node, axillary	- not identified, right, no grade
			draining node for mass a
		pituitary gland	- enlarged, red, moderate
		skin	- hair sparse, ventral abdomen, mild
			corresponds to antemortem observation (hair sparse)
		skin, subcutis	- mass, ulcerated, mass a, right axillary area, present
			corresponds to antemortem observation (mass 1)
			approximately 6.0 x 5.0 x 4.0 cm, tan
1579	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal
			 hyperplasia, focal medullary, unilateral, moderate

S - Scheduled necropsy E - Euthanized *in extremis*

Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats Individual Animal Listing - FEMALE Terminal

MPI Research Study Number 125-141

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1579	Е	Microscopic	
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), minimal
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1579	E	Microscopic	
		kidneys	- dilatation, tubular, bilateral, minimal
			- edema, papilla, bilateral, mild
			- hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			 nephropathy, chronic progressive, bilateral, mild
			corresponds to macroscopic observation (kidneys - irregular surface)
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hypertrophy, hepatocyte, centrilobular, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1579	Е	Microscopic	
		mammary gland	- fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1579	Е	Microscopic	
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- alopecia/hypotrichosis, mild
			corresponds to macroscopic observation (skin - hair sparse)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- hyperplasia, epithelial, limiting ridge, minimal
		thymus	- depletion, lymphoid, generalized, moderate
			- hyperplasia, lymphoid, medulla, mild
		thyroid gland	- within normal limits
		tongue	- hyperplasia, squamous cell, mild
		ŭ	- inflammation, subacute/chronic, mild
		trachea	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1579	Е	Microscopic	
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- hyperplasia, endometrial, mild
			 hyperplasia, squamous cell, mild
		vagina	- within normal limits
		Cause of Death	- mammary tumor
1580	E	Macroscopic	
		pituitary gland	- enlarged, moderate
1580	E	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), moderate

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1580	E	Microscopic	
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, mild
			 nephropathy, chronic progressive, bilateral, mild
			- pyelitis, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1580	E	Microscopic	
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- atrophy, acinar, minimal
		parathyroid glands	- within normal limits
		. , ,	one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

500 mg/kg/day 1580 E Microscopic salivary gland, sublingual skeletal muscle, biceps femoris skin small intestine, duodenum small intestine, ileum small intestine, jejunum small intestine, jejunum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spieen stomach, glandular stomach, nonglandular thymus thymus thymus tongue trachea ureters Microscopic salivary gland, sublingual - within normal limits	Group, Animal Number	Fate	Tissue	Observations
1580 E Microscopic salivary gland, sublingual skeletal muscle, biceps femoris skin small intestine, duodenum small intestine, ileum small intestine, jejunum small intestine, jejunum spinal cord, cervical spinal cord, thoracic spinal cord, thoracic spinal cord, thoracic spinal, glandular stomach, nonglandular thymus thymus thymus thyroid gland tongue trachea - within normal limits stomach, glandular within normal limits - within normal limits	500 mg/kg/day			
skeletal muscle, biceps femoris skin - within normal limits small intestine, duodenum small intestine, ileum small intestine, jejunum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thymus tongue trachea - within normal limits		E	Microscopic	
skin - within normal limits small intestine, duodenum - within normal limits small intestine, ileum - within normal limits small intestine, jejunum - within normal limits spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe thyroid gland - hyperplasia, c-cell, focal, unilateral, minimal tongue - within normal limits trachea - within normal limits			salivary gland, sublingual	- within normal limits
small intestine, duodenum small intestine, ileum small intestine, jejunum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thymus trachea - within normal limits			skeletal muscle, biceps femoris	- within normal limits
small intestine, ileum - within normal limits small intestine, jejunum - within normal limits spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe thyroid gland - hyperplasia, c-cell, focal, unilateral, minimal tongue - within normal limits trachea - within normal limits			skin	- within normal limits
small intestine, jejunum - within normal limits spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe thyroid gland - hyperplasia, c-cell, focal, unilateral, minimal tongue - within normal limits trachea - within normal limits			small intestine, duodenum	- within normal limits
spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe thyroid gland - hyperplasia, c-cell, focal, unilateral, minimal tongue - within normal limits trachea - within normal limits			small intestine, ileum	- within normal limits
spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe thyroid gland - hyperplasia, c-cell, focal, unilateral, minimal tongue - within normal limits trachea - within normal limits			small intestine, jejunum	- within normal limits
spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe thyroid gland - hyperplasia, c-cell, focal, unilateral, minimal tongue - within normal limits trachea - within normal limits				- within normal limits
spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe thyroid gland - hyperplasia, c-cell, focal, unilateral, minimal tongue - within normal limits trachea - within normal limits			· · · · · ·	- within normal limits
spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe thyroid gland - hyperplasia, c-cell, focal, unilateral, minimal tongue - within normal limits trachea - within normal limits				- within normal limits
stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe thyroid gland - hyperplasia, c-cell, focal, unilateral, minimal tongue - within normal limits trachea - within normal limits			-	- within normal limits
stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe thyroid gland - hyperplasia, c-cell, focal, unilateral, minimal tongue - within normal limits trachea - within normal limits				- within normal limits
thymus - depletion, lymphoid, generalized, severe thyroid gland - hyperplasia, c-cell, focal, unilateral, minimal tongue - within normal limits trachea - within normal limits			_	- within normal limits
thyroid gland - hyperplasia, c-cell, focal, unilateral, minimal tongue - within normal limits trachea - within normal limits			_	- depletion, lymphoid, generalized, severe
tongue - within normal limits trachea - within normal limits			•	
trachea - within normal limits			•	
			•	- within normal limits
				- within normal limits
urinary bladder - within normal limits				- within normal limits
uterus with cervix - within normal limits				

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1580	Е	Microscopic	
		vagina	- within normal limits
		Cause of Death	- pituitary tumor
1581	S	Macroscopic	
		all tissues	- within normal limits
1581	S	Microscopic	
		adrenal glands	 hyperplasia, focal medullary, unilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits

S - Scheduled necropsy E - Euthanized *in extremis*

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1581	S	Microscopic	
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- edema, papilla, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, basophilic, minimal
			- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		, 0	

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1581	S	Microscopic	
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- degeneration/necrosis, myofiber, minimal
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1581	S	Microscopic small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina	 within normal limits depletion, lymphoid, generalized, moderate within normal limits
1582	E	Macroscopic kidneys	- irregular surface, bilateral, mild

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1582	E	Macroscopic	
		pituitary gland	- enlarged, severe
582	E	Microscopic	-
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1582	E	Microscopic	
		kidneys	- dilatation, tubular, bilateral, minimal
			- edema, papilla, bilateral, mild
			- hyperplasia, transitional cell, bilateral, mild
			- mineralization, pelvic, bilateral, mild
			- nephropathy, chronic progressive, bilateral, mild
			corresponds to macroscopic observation (kidneys - irregular surface)
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 adenoma, hepatocellular, benign, primary, incidental, not cause of death
			- degeneration, cystic, focal, minimal
			- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
			- infiltration, mononuclear cell, minimal
		lung	- within normal limits
		- 3	

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1582	E	Microscopic	
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- atrophy, acinar, minimal
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1582	E	Microscopic	
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
		-	- hyperplasia, epithelial cell, minimal
		thyroid gland	- hyperplasia, c-cell, focal, unilateral, minimal
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations	
500 mg/kg/day				
1582	E	Microscopic urinary bladder uterus with cervix vagina Cause of Death	within normal limitswithin normal limitswithin normal limitspituitary tumor	
1583 ^r	E	Macroscopic kidneys lymph node, axillary lymph node, inguinal	 irregular surface, bilateral, mild enlarged, right, mild draining node for mass a. not identified, right, no grade draining node for mass b. 	
		pituitary gland	- enlarged, mild	

E - Euthanized in extremis

Replacement animal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1583 ^r	E	Macroscopic	
		skin, subcutis	- abscess, left axillary area, mild
			- mass, red, mass b, right anogenital region, present
			corresponds to antemortem observation (mass 2)
			approximately 2.0 cm in diameter.
			- mass, ulcerated, mass a, right axillary area, present
			corresponds to antemortem observation (mass 1)
			approximately 2.5 x 4.0 x 1.0 cm, tan.
1583 ^r	E	Microscopic	
		adrenal glands	 hematopoiesis, extramedullary, bilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	 hyperplasia, granulocytic, mild
		bone marrow, sternum	- hyperplasia, granulocytic, mild
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits

E - Euthanized in extremis

Replacement animal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1583 ^r	E	Microscopic	
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, mild
			- edema, papilla, bilateral, mild
			- hydronephrosis, unilateral, mild
			 hyperplasia, transitional cell, bilateral, minimal
			- mineralization, tubular, bilateral, mild
			- nephropathy, chronic progressive, bilateral, moderate
			corresponds to macroscopic observation (kidneys - irregular surface)
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits

E - Euthanized *in extremis* Replacement animal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1583 ^r	E	Microscopic	
		liver	- hematopoiesis, extramedullary, minimal
			 hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, axillary	 hyperplasia, lymphocyte/plasmacyte, medulla, mild
			corresponds to macroscopic observation (lymph node, axillary - enlarged)
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenocarcinoma, malignant, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b)
			- hyperplasia, lobular, minimal
		nerve, sciatic	- within normal limits
		nose, level a	- inflammation, hair follicle/epidermis, minimal
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits

E - Euthanized in extremis

Replacement animal

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1583 ^r	E	Microscopic	
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		skin, subcutis	- abscess, mild
			corresponds to macroscopic observation (skin, subcutis - abscess)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits

E - Euthanized in extremis

Replacement animal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1583 ^r	E	Microscopic spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina	 within normal limits within normal limits hematopoiesis, extramedullary, increased, moderate within normal limits within normal limits depletion, lymphoid, generalized, severe within normal limits hyperplasia, squamous cell, moderate inflammation, subacute/chronic, mild within normal limits
1584 ^r	D	Cause of Death Macroscopic kidneys	 mammary tumor irregular surface, tan, bilateral, mild

E - Euthanized in extremis

D - Died on Study

Replacement animal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1584 ^r	D	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
			 hyperplasia, focal medullary, unilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits

D - Died on Study

Replacement animal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1584 ^r	D	Microscopic	
		kidneys	- edema, papilla, bilateral, minimal
		•	- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, mild
			- necrosis, papillary, bilateral, severe
			- nephropathy, chronic progressive, bilateral, mild
			corresponds to macroscopic observation (kidneys - irregular surface)
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- degeneration, cystic, focal, minimal
			- hypertrophy, hepatocyte, centrilobular, mild
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, minimal
		nerve, sciatic	- degeneration, axonal/myelin, minimal

D - Died on Study

Replacement animal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1584 ^r	D	Microscopic	
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	- within normal limits
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits

D - Died on Study

Replacement animal

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1584 ^r	D	Microscopic spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits within normal limits hematopoiesis, extramedullary, increased, minimal within normal limits within normal limits depletion, lymphoid, generalized, severe within normal limits hyperplasia, squamous cell, mild inflammation, subacute/chronic, mild within normal limits kidney inflammation/necrosis

D - Died on Study

Replacement animal

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1585	S	Macroscopic	
		liver	- mass, tan, mass a, right lateral lobe, present
			approximately 2.5 cm in diameter.
			- mass, tan, mass b, median lobe, present
			approximately 0.7 cm in diameter.
		lymph node, hepatic	- not identified, no grade
			draining node for mass a and mass b.
1585	S	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1585	S	Microscopic galt harderian glands heart joint, tibiofemoral kidneys lacrimal glands, exorbital large intestine, cecum large intestine, colon large intestine, rectum larynx	 within normal limits within normal limits cardiomyopathy, minimal within normal limits dilatation, tubular, unilateral, mild edema, papilla, bilateral, mild necrosis, papillary, unilateral, mild nephropathy, chronic progressive, bilateral, mild within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1585	S	Microscopic	
1585	5	lung lymph node, mandibular lymph node, mesenteric mammary gland nerve, sciatic nose, level a	 adenoma, hepatocellular, benign, multiple, primary, incidental, not cause of death corresponds to macroscopic observation (liver - mass a; liver - mass b) degeneration, cystic, focal, minimal hyperplasia, bile duct, minimal hypertrophy, hepatocyte, centrilobular, mild histiocytosis, alveolar, mild within normal limits within normal limits hyperplasia, lobular, mild degeneration, axonal/myelin, minimal within normal limits
		nose, level b nose, level c	 within normal limits within normal limits
		nose, level d	- within normal limits
		ovaries	- hyperplasia, sex-cord/stromal, unilateral, minimal
		oviducts	- within normal limits
		pancreas	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1585	S	Microscopic	
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	- within normal limits
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- degeneration/necrosis, myofiber, minimal
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1585	S	Microscopic thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina	 depletion, lymphoid, generalized, moderate hyperplasia, epithelial cell, mild within normal limits
1586	D	Macroscopic adrenal glands foot/feet pituitary gland	 enlarged, red, right, minimal absent portion/cannibalized, left foreleg/limb, no grade corresponds to antemortem observation (cannibalized/partially cannibalized) enlarged, red, mild

S - Scheduled necropsy D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1586	D	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, severe
			corresponds to macroscopic observation (adrenal glands - enlarged)
			- hyperplasia, focal cortical, unilateral, minimal
			 pheochromocytoma, benign, unilateral, primary, incidental, not cause of death
		aorta	- within normal limits
		bone marrow, femur	- hyperplasia, granulocytic, mild
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- not examined
			autolysis too severe for diagnosis
		galt	- not examined

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

500 mg/kg/day 1586			
1000	D	Microscopic	
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, mild
			- edema, papilla, bilateral, mild
			- mineralization, pelvic, unilateral, minimal
			- mineralization, tubular, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, moderate
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- not examined
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, minimal
		nerve, sciatic	- degeneration, axonal/myelin, minimal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1586	D	Microscopic	
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- not examined
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- not examined
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1586	D	Microscopic	
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- erosion/ulcer, limiting ridge, minimal
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits
		tongue	- hyperplasia, squamous cell, moderate
			- inflammation, subacute/chronic, mild
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- pituitary tumor

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1587	S	Macroscopic	
		adrenal glands	- enlarged, bilateral, mild
		liver	- mass, red, mass b, caudate lobe, present
			approximately 3.5 cm in diameter.
		lymph node, hepatic	- within normal limits
			draining node for mass b.
		lymph node, inguinal	- within normal limits
			draining node for mass a, right.
		mammary gland	 swollen/thickened, tan, generalized, mild
			corresponds to antemortem observation (swelling)
		skin, subcutis	 mass, tan, mass a, right anogenital region, present
			corresponds to antemortem observation (nodule)
			approximately 1.5 cm in diameter.
1587	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1587	S	Microscopic	
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- edema, papilla, bilateral, minimal
		•	- mineralization, pelvic, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		-	

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
00 mg/kg/day			
587	S	Microscopic	
587	5	lung lymph node, hepatic lymph node, inguinal lymph node, mandibular lymph node, mesenteric mammary gland	 adenoma, hepatocellular, benign, primary, incidental, not cause of death corresponds to macroscopic observation (liver - mass b) focus of cellular alteration, clear, minimal focus of cellular alteration, eosinophilic, minimal hypertrophy, hepatocyte, centrilobular, minimal histiocytosis, alveolar, minimal within normal limits within normal limits within normal limits within normal limits fibroadenoma, benign, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a)
			mammary tumor on 18 r-1 and 26-1 are the same tumor hyperplasia, lobular, minimal
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1587	S	Microscopic	
		nose, level d	- within normal limits
		ovaries	- hyperplasia, sex-cord/stromal, unilateral, mild
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- degeneration/necrosis, myofiber, minimal
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1587	S	Microscopic spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina non-correlated macro observation	 within normal limits hematopoiesis, extramedullary, increased, minimal within normal limits within normal limits depletion, lymphoid, generalized, severe within normal limits dilatation, gland/lumen, mild within normal limits adrenal glands - enlarged mammary gland - swollen/thickened
1588	Е	Macroscopic liver	- enlarged, multiple lobes, moderate

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1588	E	Macroscopic	
		lymph node, axillary	- within normal limits
			draining node for mass a, right.
		skin, subcutis	- mass, ulcerated, mass a, right axillary area, present
			corresponds to antemortem observation (mass 1)
			approximately 11.0 cm in diameter, tan.
1588	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal
			- hyperplasia, focal medullary, unilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	 hyperplasia, granulocytic, mild
		bone marrow, sternum	 hyperplasia, granulocytic, mild
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

	Fate	Tissue	Observations
500 mg/kg/day			
1588	Е	Microscopic	
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
			 mineralization, tubular, unilateral, minimal
			 nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- angiectasis, minimal
			- focus of cellular alteration, basophilic, minimal
			 focus of cellular alteration, eosinophilic, minimal
			 hypertrophy, hepatocyte, centrilobular, mild
			corresponds to macroscopic observation (liver - enlarged)
			- necrosis, focal, minimal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1588	E	Microscopic	
		lung	- histiocytosis, alveolar, minimal
		lymph node, axillary	- within normal limits
		lymph node, mandibular	- erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits
		mammary gland	- fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, minimal
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- atrophy, acinar, minimal
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	- hyperplasia, focal, pars distalis, minimal
		salivary gland, mandibular	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1588	Е	Microscopic	
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, mild
		stomach, glandular	- within normal limits
		stomach, nonglandular	- hyperplasia, epithelial, limiting ridge, minimal
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1588	E	Microscopic uterus with cervix vagina Cause of Death	within normal limitswithin normal limitsmammary tumor
1589	E	Macroscopic adrenal glands kidneys liver ovaries pituitary gland	 enlarged, red, right, mild cyst, clear, bilateral, moderate focus/foci, tan, left lateral lobe, mild cyst, clear, right, mild enlarged, severe
1589	E	Microscopic adrenal glands aorta bone marrow, femur	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate corresponds to macroscopic observation (adrenal glands - enlarged) within normal limits within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1589	E	Microscopic	
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, moderate
			corresponds to macroscopic observation (kidneys - cyst)
			- edema, papilla, bilateral, mild
			- mineralization, pelvic, bilateral, mild
			- mineralization, tubular, bilateral, mild
			- nephropathy, chronic progressive, bilateral, moderate
		lacrimal glands, exorbital	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1589	Е	Microscopic	
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- angiectasis, minimal
			 focus of cellular alteration, basophilic, moderate
			corresponds to macroscopic observation (liver - focus/foci, tan)
			- focus of cellular alteration, eosinophilic, moderate
			corresponds to macroscopic observation (liver - focus/foci, tan)
			 hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	 erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits
		mammary gland	 hyperplasia, lobular, minimal
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1589	E	Microscopic	
		ovaries	- cyst, unilateral, minimal
			corresponds to macroscopic observation (ovaries - cyst)
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1589	E	Microscopic spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits within normal limits within normal limits hematopoiesis, extramedullary, increased, minimal within normal limits within normal limits depletion, lymphoid, generalized, severe within normal limits dilatation, gland/lumen, minimal within normal limits pituitary tumor
1590	E	Macroscopic adrenal glands	- enlarged, right, mild

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1590	Е	Macroscopic	
		lymph node, inguinal	- not identified, right, no grade
			draining node for mass a.
		skin, subcutis	- mass, ulcerated, mass a, right inguinal area, present
			corresponds to antemortem observation (mass 1)
			approximately 3.0 cm in diameter. red.
1590	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, severe
			corresponds to macroscopic observation (adrenal glands - enlarged)
			 pheochromocytoma, benign, unilateral, primary, incidental, not cause of death
		aorta	- within normal limits
		bone marrow, femur	 hyperplasia, granulocytic, mild
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1590	E	Microscopic	
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, mild
		•	- edema, papilla, bilateral, mild
			- hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		101,117	With Hornar mino

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1590	Е	Microscopic	
		liver	- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
			- infiltration, mononuclear cell, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- adenocarcinoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
590	E	Microscopic	
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, mild
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
			- hyperplasia, epithelial cell, minimal

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1590	E	Microscopic thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits mammary tumor
1591	D	Macroscopic all tissues	- within normal limits
1591	D	Microscopic adrenal glands aorta bone marrow, femur bone marrow, sternum	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal within normal limits within normal limits within normal limits

E - Euthanized in extremis

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1591	D	Microscopic	
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- cataract, unilateral, mild
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- not examined
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, minimal
			- edema, papilla, bilateral, minimal
			- hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- necrosis, papillary, bilateral, moderate
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1591	D	Microscopic	
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hyperplasia, bile duct, minimal
			 hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, minimal
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- atrophy, acinar, mild
		parathyroid glands	- within normal limits
		. , ,	one of pair present

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

1591 D Microscopic pharynx - within normal limits hyperplasia, focal, pars distalis, minimal salivary gland, mandibular within normal limits salivary gland, parotid within normal limits salivary gland, sublingual within normal limits skeletal muscle, biceps femoris skin within normal limits small intestine, duodenum within normal limits small intestine, ileum within normal limits small intestine, jejunum within normal limits small intestine, jejunum within normal limits spinal cord, cervical within normal limits spinal cord, thoracic within normal limits spinal cord, thoracic within normal limits spinal cord, thoracic within normal limits stomach, glandular within normal limits stomach, nonglandular within normal limits stomach, nonglandular within normal limits depletion, lymphoid, generalized, severe	Group, Animal Number	Fate	Tissue	Observations	
Microscopic pharynx pituitary gland salivary gland, mandibular salivary gland, parotid salivary gland, sublingual skeletal muscle, biceps femoris skin small intestine, duodenum small intestine, ileum small intestine, jejunum small intestine, jejunum spinal cord, cervical spinal cord, tumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus - within normal limits - within normal limi	500 mg/kg/day				
pituitary gland - hyperplasia, focal, pars distalis, minimal salivary gland, mandibular - within normal limits salivary gland, sublingual - within normal limits skeletal muscle, biceps femoris skin - within normal limits small intestine, duodenum - within normal limits small intestine, ileum - within normal limits small intestine, jejunum - within normal limits spinal cord, cervical spinal cord, thoracic spleen - within normal limits stomach, glandular stomach, nonglandular thymus - depletion, lymphoid, generalized, severe		D	Microscopic		
salivary gland, mandibular salivary gland, parotid salivary gland, sublingual skeletal muscle, biceps femoris skin small intestine, duodenum small intestine, ileum small intestine, jejunum spinal cord, cervical spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus salivary gland, parotid within normal limits stomach, glandular within normal limits within normal limits within normal limits within normal limits			pharynx	- within normal limits	
salivary gland, parotid salivary gland, sublingual skeletal muscle, biceps femoris skin small intestine, duodenum small intestine, ileum small intestine, jejunum spinal cord, cervical spinal cord, thoracic spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus salivary gland, parotid swithin normal limits swithin normal limits within normal limits within normal limits swithin normal limits swithin normal limits swithin normal limits within normal limits			pituitary gland	- hyperplasia, focal, pars distalis, minimal	
salivary gland, sublingual - within normal limits skeletal muscle, biceps femoris - within normal limits skin - within normal limits small intestine, duodenum - within normal limits small intestine, ileum - within normal limits small intestine, jejunum - within normal limits small intestine, jejunum - within normal limits spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe			salivary gland, mandibular	- within normal limits	
skeletal muscle, biceps femoris skin - within normal limits small intestine, duodenum small intestine, ileum - within normal limits small intestine, jejunum - within normal limits small intestine, jejunum - within normal limits spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits			salivary gland, parotid	- within normal limits	
skin - within normal limits small intestine, duodenum - within normal limits small intestine, jejunum - within normal limits small intestine, jejunum - within normal limits spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe			salivary gland, sublingual	- within normal limits	
small intestine, duodenum small intestine, ileum small intestine, jejunum small intestine, jejunum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus - within normal limits			skeletal muscle, biceps femoris	- within normal limits	
small intestine, ileum - within normal limits small intestine, jejunum - within normal limits spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe			skin	- within normal limits	
small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus - within normal limits			small intestine, duodenum	- within normal limits	
spinal cord, cervical - within normal limits spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe			small intestine, ileum	- within normal limits	
spinal cord, lumbar - within normal limits spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe			small intestine, jejunum	- within normal limits	
spinal cord, thoracic - within normal limits spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe			spinal cord, cervical	- within normal limits	
spleen - within normal limits stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe			spinal cord, lumbar	- within normal limits	
stomach, glandular - within normal limits stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe			spinal cord, thoracic	- within normal limits	
stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe			spleen	- within normal limits	
stomach, nonglandular - within normal limits thymus - depletion, lymphoid, generalized, severe			stomach, glandular	- within normal limits	
			_	- within normal limits	
· · · · · · · · · · · · · · · · · · ·			thymus	- depletion, lymphoid, generalized, severe	
tnyroid giand - witnin normai iimits			thyroid gland	- within normal limits	
tongue - within normal limits				- within normal limits	

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1591	D	Microscopic trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits kidney inflammation/necrosis
1592	E	Macroscopic lymph node, inguinal	 not identified, right, no grade draining node for mass b. draining node for mass a, left.
		pituitary gland skin, subcutis	 enlarged, mild mass, tan, mass b, right inguinal area, present approximately 2.5 cm in diameter. mass, ulcerated, mass a, left inguinal area, present corresponds to antemortem observation (mass 1) approximately 3.0 cm in diameter, tan.
		stomach, glandular	- swollen/thickened, mucosa, mild

E - Euthanized in extremis

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1592	Е	Macroscopic	
		thymus	- small, moderate
1592	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- not examined
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1592	E	Microscopic	
		kidneys	- cyst, unilateral, minimal
			- edema, papilla, bilateral, mild
			- hyperplasia, transitional cell, bilateral, mild
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
			- macrophages, pigmented, minimal
			- necrosis, individual hepatocyte, minimal
		lung	- within normal limits
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	- erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1592	E	Microscopic	
		mammary gland	 adenocarcinoma, malignant, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b)
			 hyperplasia, lobular, moderate
		nerve, sciatic	 degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		. , ,	one of pair present
		pharynx	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1592	Е	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			- hyperplasia, diffuse, pars distalis, mild
			corresponds to macroscopic observation (pituitary gland - enlarged)
			adenoma is small.
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Soo mg/kg/day 1592 E Microscopic stomach, glandular - fibrosis, mild corresponds to macroscopic observation (stomach, glandular - swollen/thickened) - within normal limits thymus - not examined thyroid gland - within normal limits trachea - within normal limits trachea - within normal limits within normal limits - within normal limit	Group, Animal Number	Fate	Tissue	Observations
1592 Be within normal limits trachea ureters urinary bladder uterus with cervix vagina non-correlated macro observation cause of Death stomach glands or eyst, clear, right, mild 1593 Be within normal limits to macroscopic observation (stomach, glandular - swollen/thickened) ***********************************	500 mg/kg/day			
corresponds to macroscopic observation (stomach, glandular - swollen/thickened) stomach, nonglandular thymus - not examined thyroid gland - within normal limits tongue - within normal limits trachea ureters - within normal limits urinary bladder uterus with cervix vagina - within normal limits vagina - within normal limits - within normal lim		E	Microscopic	
stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina non-correlated macro observation Cause of Death Somethin normal limits swollen/thickened) within normal limits			stomach, glandular	- fibrosis, mild
thymus - not examined thyroid gland - within normal limits tongue - within normal limits trachea - within normal limits urinary bladder uterus with cervix - dilatation, gland/lumen, minimal vagina - within normal limits non-correlated macro observation Cause of Death - mammary tumor 1593 S Macroscopic adrenal glands - cyst, clear, right, mild				
thyroid gland - within normal limits tongue - within normal limits trachea - within normal limits ureters - within normal limits urinary bladder - within normal limits uterus with cervix - dilatation, gland/lumen, minimal vagina - within normal limits non-correlated macro observation Cause of Death - mammary tumor 1593 S Macroscopic adrenal glands - cyst, clear, right, mild			stomach, nonglandular	- within normal limits
tongue - within normal limits trachea - within normal limits ureters - within normal limits urinary bladder - within normal limits uterus with cervix - dilatation, gland/lumen, minimal vagina - within normal limits non-correlated macro observation cause of Death - thymus - small Cause of Death - mammary tumor 1593 S Macroscopic adrenal glands - cyst, clear, right, mild			thymus	- not examined
trachea - within normal limits ureters - within normal limits urinary bladder - within normal limits uterus with cervix - dilatation, gland/lumen, minimal vagina - within normal limits non-correlated macro observation Cause of Death - mammary tumor S Macroscopic adrenal glands - cyst, clear, right, mild			thyroid gland	- within normal limits
ureters - within normal limits urinary bladder - within normal limits uterus with cervix - dilatation, gland/lumen, minimal vagina - within normal limits non-correlated macro observation - thymus - small Cause of Death - mammary tumor S Macroscopic adrenal glands - cyst, clear, right, mild			tongue	- within normal limits
urinary bladder - within normal limits uterus with cervix - dilatation, gland/lumen, minimal vagina - within normal limits non-correlated macro observation Cause of Death - thymus - small cause of Death - mammary tumor 1593 S Macroscopic adrenal glands - cyst, clear, right, mild			trachea	- within normal limits
uterus with cervix - dilatation, gland/lumen, minimal vagina - within normal limits non-correlated macro observation Cause of Death - mammary tumor S Macroscopic adrenal glands - cyst, clear, right, mild			ureters	- within normal limits
vagina - within normal limits non-correlated macro observation - thymus - small Cause of Death - mammary tumor S Macroscopic adrenal glands - cyst, clear, right, mild			urinary bladder	- within normal limits
non-correlated macro observation - thymus - small Cause of Death - mammary tumor S Macroscopic adrenal glands - cyst, clear, right, mild			uterus with cervix	- dilatation, gland/lumen, minimal
Cause of Death - mammary tumor S Macroscopic adrenal glands - cyst, clear, right, mild			vagina	- within normal limits
1593 S Macroscopic adrenal glands - cyst, clear, right, mild			non-correlated macro observation	- thymus - small
adrenal glands - cyst, clear, right, mild			Cause of Death	- mammary tumor
	1593	S	Macroscopic	
- enlarged left mild			adrenal glands	- cyst, clear, right, mild
Gridiged, icit, iriid				- enlarged, left, mild

S - Scheduled necropsy E - Euthanized *in extremis*

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1593	S	Macroscopic	
		kidneys	- irregular surface, bilateral, mild
		lymph node, inguinal	- within normal limits
			draining node for mass a, left.
		skin, subcutis	- mass, tan, mass a, left anogenital region, present
			corresponds to antemortem observation (swelling)
			approximately 4.0 x 3.5 x 1.5 cm.
593	S	Microscopic	·
1090		adrenal glands	 adenoma, cortical, benign, unilateral, primary, incidental, not cause of death
			corresponds to macroscopic observation (adrenal glands - enlarged)
			 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
			corresponds to macroscopic observation (adrenal glands - cyst)
			- atrophy, cortical, unilateral, moderate
			one medulla present
		aorta	- within normal limits
		bone marrow, femur	- hyperplasia, granulocytic, mild

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations	
500 mg/kg/day				
1593	S	Microscopic bone marrow, sternum bone, femur bone, sternum brain esophagus eyes eyes, optic nerves eyes, retina galt harderian glands heart joint, tibiofemoral	 within normal limits 	

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1593	S	Microscopic	
		kidneys	- dilatation, tubular, bilateral, mild
		•	- edema, papilla, bilateral, mild
			- hydronephrosis, bilateral, mild
			- hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, unilateral, minimal
			- mineralization, tubular, bilateral, minimal
			 nephropathy, chronic progressive, bilateral, mild
			corresponds to macroscopic observation (kidneys - irregular surface)
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 hypertrophy, hepatocyte, centrilobular, minimal
		lung	- granuloma, minimal
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1593	S	Microscopic	
		mammary gland	- fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

500 mg/kg/day 1593			
	S	Microscopic	
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
			- hyperplasia, epithelial cell, minimal
		thyroid gland	- within normal limits
		tongue	- hyperplasia, squamous cell, moderate
			- inflammation, subacute/chronic, mild
		trachea	- within normal limits
		ureters	- dilatation, unilateral, mild
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1593	S	Microscopic	
		vagina .	- within normal limits
1594	S	Macroscopic	
		all tissues	- within normal limits
1594	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1594	S	Microscopic galt harderian glands heart joint, tibiofemoral kidneys	 within normal limits within normal limits within normal limits within normal limits hyperplasia, transitional cell, unilateral, minimal mineralization, pelvic, bilateral, minimal mineralization, tubular, unilateral, minimal nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital large intestine, cecum large intestine, colon large intestine, rectum larynx liver	 within normal limits angiectasis, minimal hematopoiesis, extramedullary, minimal hyperplasia, bile duct, minimal hypertrophy, hepatocyte, centrilobular, minimal within normal limits within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1594	S	Microscopic	
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- degeneration/necrosis, myofiber, minimal

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1594	S	Microscopic	
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
			- hyperplasia, epithelial cell, mild
		thyroid gland	- within normal limits
		tongue	- hyperplasia, squamous cell, moderate
			- inflammation, subacute/chronic, mild
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1594	S	Microscopic	
		uterus with cervix	- dilatation, gland/lumen, minimal
			- hyperplasia, squamous cell, mild
		vagina	- within normal limits
1595	S	Macroscopic	
		adrenal glands	- enlarged, right, moderate
		lymph node, mesenteric	- within normal limits
			draining node for mass a.
		stomach, nonglandular	- mass, tan, mass a, present
			approximately 0.8 cm in diameter.
1595	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, severe
			corresponds to macroscopic observation (adrenal glands - enlarged)
		aorta	- within normal limits
		bone marrow, femur	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

	Fate	Tissue	Observations
500 mg/kg/day			
595	S	Microscopic	
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- cataract, unilateral, mild
		eyes, optic nerves	- within normal limits
		eyes, retina	- detachment, retinal, unilateral, mild
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
			- nephropathy, chronic progressive, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		тат у п х	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1595	S	Microscopic	
		liver	- angiectasis, mild
			 focus of cellular alteration, basophilic, mild
			 hypertrophy, hepatocyte, centrilobular, minimal
		lung	 histiocytosis, alveolar, minimal
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	 hyperplasia, lobular, mild
		nerve, sciatic	 degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1595	S	Microscopic	
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	 degeneration/necrosis, myofiber, minimal
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- cyst, keratin, moderate
			corresponds to macroscopic observation (stomach, nonglandular - mass a)
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	- hyperplasia, follicular cell, unilateral, minimal
		tongue	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1595	S	Microscopic	
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
1596	D	Macroscopic	
		animal/whole body	- body fat depleted, mild
			corresponds to antemortem observation (thin)
		kidneys	- small, right, moderate
		lacrimal glands, exorbital	- small, bilateral, mild
		lung with bronchi	- focus/foci, tan, multiple lobes, mild
		spleen	- small, mild
		thymus	- small, severe
1596	D	Microscopic	
		adrenal glands	- within normal limits
		aorta	- within normal limits

S - Scheduled necropsy D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1596	D	Microscopic	
	_	bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- not examined
			autolysis too severe for diagnosis
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1596	D	Microscopic	
		kidneys	- fibrosis, bilateral, severe
			corresponds to macroscopic observation (kidneys - small)
			appears to be secondary to calculi.
			 hyperplasia, transitional cell, unilateral, minimal
			 mineralization, pelvic, unilateral, mild
			- mineralization, tubular, bilateral, minimal
		lacrimal glands, exorbital	 depletion, secretory, bilateral, severe
			corresponds to macroscopic observation (lacrimal glands, exorbital - small)
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, minimal
			corresponds to macroscopic observation (lung with bronchi - focus/foci, tan)
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1596	D	Microscopic	
		mammary gland	- within normal limits
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1596	D	Microscopic	
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	 depletion, lymphoid, generalized, moderate
			corresponds to macroscopic observation (spleen - small)
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
			corresponds to macroscopic observation (thymus - small)
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- kidneys; fibrosis; bilateral, severe

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1597	E	Macroscopic	
		kidneys	- irregular surface, bilateral, mild
		liver	 discoloration, brown, multiple lobes, moderate
		lymph node, inguinal	- within normal limits
			draining node for mass a, left.
		pituitary gland	- enlarged, red, moderate
		skin, subcutis	- mass, tan, mass a, left inguinal area, present
			corresponds to antemortem observation (mass 1)
			approximately 1.6 x 1.6 x 0.5 cm.
1597		thymus	- small, mild
	E	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1597	E	Microscopic eyes eyes, optic nerves eyes, retina galt harderian glands heart joint, tibiofemoral kidneys	 within normal limits cardiomyopathy, minimal within normal limits dilatation, tubular, bilateral, moderate corresponds to macroscopic observation (kidneys - irregular surface) edema, papilla, bilateral, mild hyperplasia, transitional cell, bilateral, minimal mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal necrosis, papillary, unilateral, minimal nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1597	E	Microscopic	
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- degeneration, cystic, focal, minimal
			 hypertrophy, hepatocyte, centrilobular, mild
			corresponds to macroscopic observation (liver - discoloration, brown)
			- macrophages, pigmented, minimal
			- necrosis, hepatocytes, centrilobular, mild
			corresponds to macroscopic observation (liver - discoloration, brown)
		lung	- histiocytosis, alveolar, mild
		lymph node, inguinal	- not examined
			misidentified tissue
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenoma, benign, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a)
		nerve, sciatic	- degeneration, axonal/myelin, minimal

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1597	Е	Microscopic	
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- cyst, unilateral, minimal
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- not examined
		skeletal muscle, biceps femoris	- degeneration/regeneration, myofiber, minimal
		skin	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1597	Е	Microscopic	
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
			corresponds to macroscopic observation (thymus - small)
			- hyperplasia, epithelial cell, minimal
		thyroid gland	- hyperplasia, c-cell, focal, bilateral, mild
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- dilatation, gland/lumen, minimal
		vagina	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1597	E	Microscopic Cause of Death	- pituitary tumor
1598	Е	Macroscopic	
		lymph node, inguinal	 not identified, left, no grade draining node for mass a.
		skin, subcutis	 mass, tan, mass a, left inguinal area, present approximately 2.0 cm diameter.
1598	Е	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
			 pheochromocytoma, benign, bilateral, primary, incidental, not cause of death
		aorta	- within normal limits
		bone marrow, femur	- hyperplasia, granulocytic, mild
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1598	Е	Microscopic	
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- edema, papilla, unilateral, minimal
			- hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, unilateral, mild
			- nephropathy, chronic progressive, bilateral, mild
		Leader Laborator and Bart	- pyelitis, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1598	E	Microscopic	
		liver	- focus of cellular alteration, basophilic, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- dilatation, sinus, minimal
		lymph node, mesenteric	- within normal limits
		mammary gland	- fibroadenoma, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- inflammation, mild
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- cyst, bilateral, minimal
		oviducts	- within normal limits
		pancreas	- hyperplasia, acinar cell, focal, minimal
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
598	E	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, mild
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, mild

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1598	Е	Microscopic	
		thyroid gland	 adenoma, c-cell, benign, unilateral, primary, incidental, not cause of death
			- hyperplasia, c-cell, focal, unilateral, minimal
		tongue	 carcinoma, squamous cell, malignant, primary, fatal, positive cause of death
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- hyperplasia, simple transitional cell, minimal
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- nose/oral tumor
1599	D	Macroscopic	
		liver	- mass, tan, mass a, median lobe, present
			approximately 4.0 x 4.0 x 2.0 cm.
		lymph node, hepatic	- within normal limits
			draining node for mass a.
		pituitary gland	- enlarged, red, mild

E - Euthanized in extremis

D - Died on Study

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1599	D	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, minimal
			 vacuolation, focal, bilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- not examined
			autolysis too severe for diagnosis
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
00 mg/kg/day			
599	D	Microscopic	
		kidneys	- mineralization, pelvic, bilateral, mild
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 carcinoma, hepatocellular, malignant, primary, fatal, positive cause of death
			corresponds to macroscopic observation (liver - mass a)
			 hypertrophy, hepatocyte, centrilobular, mild
		lung	- within normal limits
		lymph node, hepatic	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1599	D	Microscopic	
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- cyst, unilateral, mild
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1599	D	Microscopic small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits within normal limits within normal limits hematopoiesis, extramedullary, increased, mild within normal limits within normal limits depletion, lymphoid, generalized, moderate within normal limits
1600	Е	Macroscopic adrenal glands	- enlarged, left, mild

E - Euthanized in extremis

D - Died on Study

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

			Terminal
Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1600	E	Macroscopic	
		kidneys	- dilatation, pelvic, bilateral, mild
		lymph node, axillary	- within normal limits
			draining nodes for mass b, left and mass c, right.
		lymph node, mandibular	- within normal limits
			draining node for mass a, right.
		pituitary gland	- enlarged, mild
		skin, subcutis	- mass, firm, mass b, left axillary area, present
			corresponds to antemortem observation (mass 2)
			approximately 4.9 x 4.5 x 2.4 cm, tan.
			- mass, firm, mass c, right axillary area, present
			approximately 4.0 x 2.8 x 2.0 cm, tan.
			- mass, tan, mass a, cervical, right, present
			corresponds to antemortem observation (mass 1)
		otomoch glandular	approximately 8.7 x 8.6 x 2.6 cm.
1600	Е	stomach, glandular Microscopic	- swollen/thickened, mild
1000	E	adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral,
		aurenai gianus	moderate
			corresponds to macroscopic observation (adrenal glands - enlarged)

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations	
500 mg/kg/day				
1600	Е	Microscopic		
		aorta	- within normal limits	
		bone marrow, femur	- within normal limits	
		bone marrow, sternum	- within normal limits	
		bone, femur	- within normal limits	
		bone, sternum	- within normal limits	
		brain	- within normal limits	
		esophagus	- within normal limits	
		eyes	- within normal limits	
		eyes, optic nerves	- within normal limits	
		eyes, retina	- within normal limits	
		galt	- within normal limits	
		harderian glands	- within normal limits	
		heart	- cardiomyopathy, minimal	
		joint, tibiofemoral	- within normal limits	
		,,		

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1600	E	Microscopic	
		kidneys	- edema, papilla, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- necrosis, papillary, unilateral, moderate
			corresponds to macroscopic observation (kidneys - dilatation, pelvic)
			only one has appearence of pelvic dilatation (due to papillary necrosis).
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- degeneration, cystic, focal, minimal
			- focus of cellular alteration, basophilic, minimal
			- focus of cellular alteration, eosinophilic, minimal
			- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, minimal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1600	Е	Microscopic	
		lymph node, axillary	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenocarcinoma, malignant, primary, incidental, not cause of death
			corresponds to macroscopic observation (skin, subcutis - mass c)
			- fibroadenoma, benign, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b)
			- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1600	Е	Microscopic	
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		skin, subcutis	- fibrosarcoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass b)
			collision tumor with a fibroadenoma.
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1600	E	Microscopic spinal cord, lumbar spinal cord, thoracic spleen	 within normal limits degeneration, axonal/myelin, mild hematopoiesis, extramedullary, increased, minimal within normal limits
		stomach, glandular stomach, nonglandular thymus	 - within normal limits - hyperplasia, epithelial, limiting ridge, minimal - depletion, lymphoid, generalized, moderate - hyperplasia, epithelial cell, minimal
		thyroid gland tongue	 hyperplasia, c-cell, focal, unilateral, minimal hyperplasia, squamous cell, moderate inflammation, subacute/chronic, moderate
		trachea ureters urinary bladder uterus with cervix vagina non-correlated macro observation Cause of Death	 within normal limits stomach, glandular - swollen/thickened mammary tumor

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1601	D	Macroscopic	
		lymph node, inguinal	- not identified, bilateral, no grade
			draining node for mass a, b. may be encompassed in masses.
		mammary gland	 swollen/thickened, right inguinal area, mild
		pituitary gland	- enlarged, mild
		skin	 hair sparse, axillary, shoulder, left, mild
			corresponds to antemortem observation (hair sparse)
		skin, subcutis	 mass, tan, mass b, right inguinal area, present
			approximately 2.0 x 1.5 x 1.0 cm.
			- mass, ulcerated, mass a, left inguinal area, present
			corresponds to antemortem observation (mass 1)
	_		approximately 2.0 x 2.0 x 1.0 cm, tan.
1601	D	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1601	D	Microscopic	
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- edema, papilla, unilateral, minimal
			- hydronephrosis, unilateral, mild
			- mineralization, pelvic, unilateral, minimal
			- necrosis, papillary, unilateral, mild
			- nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1601	D	Microscopic	
		liver	- focus of cellular alteration, basophilic, moderate
			- necrosis, hepatocytes, centrilobular, moderate
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenocarcinoma, malignant, multiple, primary, mortality-independent
			corresponds to macroscopic observation (mammary gland - swollen/thickened; skin, subcutis - mass a; skin, subcutis - mass b)
			slide 18, 26-1, and 26-2.
			- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1601	D	Microscopic	
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	- hyperplasia, diffuse, pars distalis, mild
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- alopecia/hypotrichosis, mild
			corresponds to macroscopic observation (skin - hair sparse)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, mild

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1601	D	Microscopic	
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
		thyroid gland	 adenoma, follicular cell, benign, unilateral, primary, incidental, not cause of death
			- cyst, follicular, unilateral, mild
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
			one of pair present
		urinary bladder	- within normal limits
		uterus with cervix	- metaplasia, squamous, mild
		vagina	- within normal limits
		Cause of Death	- mammary tumor
1602	E	Macroscopic	
		adrenal glands	- enlarged, right, mild
		kidneys	- irregular surface, bilateral, mild
		,-	•

E - Euthanized in extremis

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1602	Е	Macroscopic	
		pituitary gland	- enlarged, red, moderate
1602	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, severe
			corresponds to macroscopic observation (adrenal glands - enlarged)
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1602	Е	Microscopic	
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, minimal
		•	- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, mild
			corresponds to macroscopic observation (kidneys - irregular surface)
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, mild
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1602	Е	Microscopic	
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- exudate, nasal passage, minimal
		nose, level b	- exudate, nasal passage, minimal
			- inflammation, minimal
			- metaplasia, squamous, minimal
		nose, level c	- erosion/ulcer, moderate
			 exudate, nasal passage, moderate
			- inflammation, mild
		nose, level d	- erosion/ulcer, moderate
			 exudate, nasal passage, moderate
			- inflammation, mild
		ovaries	- cyst, unilateral, mild
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
500 mg/kg/day 1602	E	Microscopic salivary gland, parotid salivary gland, sublingual skeletal muscle, biceps femoris skin small intestine, duodenum small intestine, ileum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder	 within normal limits depletion, lymphoid, generalized, severe within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1602	E	Microscopic uterus with cervix vagina Cause of Death	within normal limitswithin normal limitspituitary tumor
1603	E	Macroscopic lymph node, inguinal lymph node, mandibular pituitary gland skin, subcutis	 within normal limits draining node for mass a, right. within normal limits draining node for mass b, right. enlarged, red, moderate mass, tan, mass a, right anogenital region, present corresponds to antemortem observation (mass 1) approximately 8.0 cm in diameter. mass, tan, mass b, ventral neck, present corresponds to antemortem observation (mass 2) approximately 3.5 cm in diameter.
1603	E	Microscopic adrenal glands	- atrophy, cortical, bilateral, mild

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1603	Е	Microscopic	
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, minimal
		•	- edema, papilla, unilateral, minimal
			- hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, minimal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1603	E	Microscopic	
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, basophilic, minimal
			 hypertrophy, hepatocyte, centrilobular, mild
			- infiltration, mononuclear cell, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- adenocarcinoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass b)
			- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1603	Е	Microscopic	
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- cyst, unilateral, mild
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1603	E	Microscopic	
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	 depletion, lymphoid, generalized, moderate
			- hyperplasia, epithelial cell, minimal
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- dilatation, gland/lumen, minimal
		vagina	- within normal limits
		Cause of Death	- mammary tumor

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1604	D	Macroscopic	
		skin	- hair sparse, cranial, ventral thorax, moderate
			corresponds to antemortem observation (hair sparse)
1604	D	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
			- hyperplasia, focal medullary, bilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- hyperostosis, minimal
		bone, sternum	- hyperostosis, mild
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1604	D	Microscopic	
		joint, tibiofemoral	- within normal limits
		kidneys	- edema, papilla, bilateral, mild
			- mineralization, pelvic, bilateral, minimal
			 mineralization, tubular, bilateral, minimal
			 necrosis, papillary, bilateral, severe
			 nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 hyperplasia, bile duct, minimal
			 hypertrophy, hepatocyte, centrilobular, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- fibroadenoma, benign, primary, incidental, not cause of death
			slide 18.
			- hyperplasia, lobular, minimal

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1604	D	Microscopic	
		nerve, sciatic	- within normal limits
		nose, level a	- hyperostosis, minimal
			- inflammation, minimal
		nose, level b	- hyperostosis, mild
		nose, level c	- hyperostosis, mild
		nose, level d	- hyperostosis, mild
		ovaries	- cyst, unilateral, mild
			- fibrosis, unilateral, moderate
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	- hyperplasia, focal, pars distalis, mild
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1604	D	Microscopic	
		skin .	- alopecia/hypotrichosis, mild
			corresponds to macroscopic observation (skin - hair sparse)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- depletion, lymphoid, generalized, moderate
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1604	D	Microscopic	
		Cause of Death	 kidney inflammation/necrosis
1605	E	Macroscopic	
		clitoral glands	- enlarged, red, right, mild
			corresponds to antemortem observation (swelling)
		kidneys	- irregular surface, bilateral, minimal
		pituitary gland	- enlarged, red, severe
		stomach, glandular	 focus/foci, red, mucosa, mild
1605	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), mild

E - Euthanized in extremis

D - Died on Study

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
500 mg/kg/day 1605	E	Microscopic esophagus eyes eyes, optic nerves eyes, retina galt harderian glands heart joint, tibiofemoral kidneys lacrimal glands, exorbital large intestine, cecum large intestine, colon large intestine, rectum	 within normal limits edema, papilla, unilateral, minimal hyperplasia, transitional cell, unilateral, minimal mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) within normal limits within normal limits within normal limits within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1605	E	Microscopic	
		larynx	- within normal limits
		liver	 hypertrophy, hepatocyte, centrilobular, minimal
			- necrosis, focal, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- adenocarcinoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (clitoral glands - enlarged)
			- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- cyst, bilateral, mild
		oviducts	- within normal limits
		pancreas	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1605	Е	Microscopic	
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1605	Е	Microscopic	
		stomach, glandular	- erosion/ulcer, mild
			corresponds to macroscopic observation (stomach, glandular - focus/foci, red)
			- fibrosis, mild
		stomach, nonglandular	 erosion/ulcer, limiting ridge, mild
		thymus	 depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits
		tongue	 hyperplasia, squamous cell, minimal inflammation, subacute/chronic, minimal
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- pituitary tumor
1606	Е	Macroscopic	
		kidneys	- irregular surface, tan, bilateral, mild

E - Euthanized in extremis

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1606	Е	Macroscopic	
		liver	- focus/foci, tan, median lobe, mild
		lymph node, inguinal	- not identified, right, no grade
			draining node for mass a.
		pituitary gland	- enlarged, red, severe
		skin, subcutis	- mass, tan, mass a, right inguinal area, present
			corresponds to antemortem observation (mass 1)
			approximately 4.0 x 2.5 x 1.5 cm.
1606	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	 compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1606	E	Microscopic eyes, optic nerves eyes, retina galt harderian glands heart joint, tibiofemoral kidneys	 within normal limits within normal limits within normal limits within normal limits cardiomyopathy, minimal within normal limits dilatation, tubular, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) edema, papilla, bilateral, mild hydronephrosis, bilateral, mild hyperplasia, transitional cell, bilateral, mild mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) pyelitis, bilateral, minimal within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1606	Е	Microscopic	
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hyperplasia, bile duct, mild
			corresponds to macroscopic observation (liver - focus/foci, tan)
			 hypertrophy, hepatocyte, centrilobular, minimal
			 infiltration, mononuclear cell, minimal
			 vacuolation, focal, minimal
		lung	- within normal limits
		lymph node, mandibular	 erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits
		mammary gland	- adenocarcinoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, minimal
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1606	Е	Microscopic	
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1606	E	Microscopic	
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	 depletion, lymphoid, generalized, moderate
			 hyperplasia, epithelial cell, mild
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	 hyperplasia, simple transitional cell, minimal
			- inflammation, minimal
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- pituitary tumor

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1607	S	Macroscopic	
		eyes	- cloudy, right, mild
			corresponds to antemortem observation (eye discolored)
		liver	- mass, tan, mass a, median lobe, present
			approximately 2.0 cm in diameter.
			- mass, tan, mass b, left lateral lobe, present
			approximately 3.0 x 1.9 x 0.9 cm.
			- mass, tan, mass c, right lateral lobe, present
			approximately 1.1 x 0.8 x 1.0 cm.
			- mass, tan, mass d, caudate lobe, present
			approximately 1.7 x 1.5 x 1.3 cm.
		lymph node, hepatic	- within normal limits
			draining node for mass a, mass b, mass c, and mass d.
		pancreas	- enlarged, mild
		pituitary gland	- enlarged, moderate
1607	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, mild
			- hyperplasia, focal medullary, unilateral, minimal
		aorta	- within normal limits

S - Scheduled necropsy

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1607	S	Microscopic	
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- cataract, unilateral, moderate
		•	corresponds to macroscopic observation (eyes - cloudy)
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, mild
		joint, tibiofemoral	- within normal limits
		•	

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
<u>500 mg/kg/day</u> 1607	S	Microscopic kidneys	 edema, papilla, bilateral, mild hyperplasia, transitional cell, bilateral, minimal inflammation, acute, unilateral, mild mineralization, pelvic, bilateral, mild mineralization, tubular, bilateral, minimal
		lacrimal glands, exorbital large intestine, cecum large intestine, colon large intestine, rectum larynx	 nephropathy, chronic progressive, bilateral, mild within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1607	S	Microscopic	
		liver	 adenoma, hepatocellular, benign, multiple, primary, incidental, not cause of death
			corresponds to macroscopic observation (liver - mass b; liver - mass c; liver - mass d)
			 carcinoma, hepatocellular, malignant, primary, incidental, not cause of death
			corresponds to macroscopic observation (liver - mass a)
			- degeneration, cystic, focal, mild
			- focus of cellular alteration, basophilic, mild
			 hematopoiesis, extramedullary, minimal
			- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, panlobular, mild
		lung	- histiocytosis, alveolar, minimal
		lymph node, hepatic	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1607	S	Microscopic	
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- hyperplasia, acinar cell, focal, moderate
			corresponds to macroscopic observation (pancreas - enlarged)
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- degeneration/necrosis, myofiber, minimal
		skin	- within normal limits
		small intestine, duodenum	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1607	S	Microscopic small intestine, ileum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters	 within normal limits hematopoiesis, extramedullary, increased, minimal within normal limits within normal limits depletion, lymphoid, generalized, moderate hyperplasia, epithelial cell, minimal within normal limits
		urinary bladder uterus with cervix vagina	 within normal limits within normal limits within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1608	D	Macroscopic	
		kidneys	- irregular surface, right, mild
		liver	- focus/foci, white, left lateral lobe, moderate
		lymph node, axillary	- within normal limits
			draining node for mass a, right.
		pituitary gland	- enlarged, red, mild
		skin, subcutis	- mass, tan, mass a, right axillary area, present
			corresponds to antemortem observation (swelling)
			approximately 3.0 x 2.5 x 1.0 cm.
		uterus with cervix	- enlarged, horn, mild
1608	D	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits

D - Died on Study

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1608	D	Microscopic	
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- edema, papilla, unilateral, minimal
		•	- mineralization, pelvic, unilateral, mild
			- mineralization, tubular, unilateral, mild
			- necrosis, papillary, unilateral, moderate
			- nephropathy, chronic progressive, bilateral, mild
			corresponds to macroscopic observation (kidneys - irregular surface)
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
00 mg/kg/day			
608	D	Microscopic	
		liver	 carcinoma, hepatocellular, malignant, primary, incidental, not cause of death
			corresponds to macroscopic observation (liver - focus/foci, white)
			- degeneration, cystic, focal, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
			- infiltration, mononuclear cell, minimal
		lung	- within normal limits
		lymph node, axillary	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, minimal
		nerve, sciatic	 degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1608	D	Microscopic	
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1608	D	Microscopic spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits within normal limits within normal limits within normal limits not examined within normal limits dilatation, gland/lumen, mild corresponds to macroscopic observation (uterus with cervix - enlarged) granular cell tumor, benign, primary, incidental, not cause of death within normal limits pituitary tumor

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1609	D	Macroscopic	
		kidneys	- irregular surface, bilateral, mild
		lymph node, inguinal	- not identified, right, no grade
			draining node for mass a.
		pituitary gland	- enlarged, red, mild
		skin, subcutis	- mass, tan, mass a, right anogenital region, present
			corresponds to antemortem observation (mass 1)
			approximately 4.0 x 3.0 x 3.0 cm.
		stomach, nonglandular	 swollen/thickened, limiting ridge, mild
1609	D	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
			one medulla present
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

esophagus - within normal limits eyes - within normal limits eyes, optic nerves - within normal limits eyes, retina - within normal limits galt - within normal limits harderian glands - within normal limits heart - cardiomyopathy, minimal joint, tibiofemoral - within normal limits kidneys - edema, papilla, unilateral, minimal hyperplasia, transitional cell, bilateral, minimal hyperplasia, transitional cell, bilateral, minimal mineralization, pelvic, unilateral, minimal necrosis, papillary, bilateral, severe nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) lacrimal glands, exorbital - within normal limits	
Microscopic	
esophagus eyes eyes, optic nerves eyes, retina galt harderian glands heart joint, tibiofemoral kidneys edema, papilla, unilateral, minimal hyperplasia, transitional cell, bilateral, minimal hipperplasia, transitional cell, bilateral, minimal hipperplatia, papillary, bilateral, severe nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) lacrimal glands, exorbital ewithin normal limits within normal limits edema, papilla, unilateral, minimal hyperplasia, transitional cell, bilateral, minimal necrosis, papillary, bilateral, severe nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) within normal limits	
eyes, optic nerves eyes, retina eyes, retina galt within normal limits eyes, retina galt within normal limits cardiomyopathy, minimal ipoint, tibiofemoral within normal limits edema, papilla, unilateral, minimal hyperplasia, transitional cell, bilateral, minimal mineralization, pelvic, unilateral, minimal mineralization, pelvic, unilateral, severe nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) lacrimal glands, exorbital within normal limits	
eyes, retina galt - within normal limits harderian glands heart - cardiomyopathy, minimal joint, tibiofemoral kidneys - edema, papilla, unilateral, minimal - hyperplasia, transitional cell, bilateral, minimal - mineralization, pelvic, unilateral, minimal - necrosis, papillary, bilateral, severe - nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) - within normal limits	
eyes, retina galt - within normal limits harderian glands heart - cardiomyopathy, minimal joint, tibiofemoral kidneys - edema, papilla, unilateral, minimal - hyperplasia, transitional cell, bilateral, minimal - mineralization, pelvic, unilateral, minimal - necrosis, papillary, bilateral, severe - nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) - within normal limits	
harderian glands heart cardiomyopathy, minimal joint, tibiofemoral kidneys edema, papilla, unilateral, minimal hyperplasia, transitional cell, bilateral, minimal mineralization, pelvic, unilateral, minimal mineralization, pelvic, unilateral, minimal necrosis, papillary, bilateral, severe nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) lacrimal glands, exorbital within normal limits	
harderian glands heart joint, tibiofemoral kidneys - within normal limits - cardiomyopathy, minimal - within normal limits - within normal limits - within normal limits - within normal limits - edema, papilla, unilateral, minimal - hyperplasia, transitional cell, bilateral, minimal - mineralization, pelvic, unilateral, minimal - necrosis, papillary, bilateral, severe - nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) - within normal limits	
joint, tibiofemoral kidneys - within normal limits - edema, papilla, unilateral, minimal - hyperplasia, transitional cell, bilateral, minimal - mineralization, pelvic, unilateral, minimal - necrosis, papillary, bilateral, severe - nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) - within normal limits	
kidneys - edema, papilla, unilateral, minimal - hyperplasia, transitional cell, bilateral, minimal - mineralization, pelvic, unilateral, minimal - necrosis, papillary, bilateral, severe - nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) lacrimal glands, exorbital - within normal limits	
 hyperplasia, transitional cell, bilateral, minimal mineralization, pelvic, unilateral, minimal necrosis, papillary, bilateral, severe nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) lacrimal glands, exorbital 	
 mineralization, pelvic, unilateral, minimal necrosis, papillary, bilateral, severe nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) lacrimal glands, exorbital 	
 necrosis, papillary, bilateral, severe nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) lacrimal glands, exorbital within normal limits 	
 nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) lacrimal glands, exorbital within normal limits 	
 nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irreg surface) lacrimal glands, exorbital within normal limits 	
corresponds to macroscopic observation (kidneys - irreg surface) lacrimal glands, exorbital - within normal limits	
lacrimal glands, exorbital - within normal limits	rregular
.	
large intestine, cecum - within normal limits	
large intestine, colon - within normal limits	
large intestine, rectum - within normal limits	

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1609	D	Microscopic	
		larynx	- within normal limits
		liver	- hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, minimal
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- hyperplasia, acinar cell, focal, minimal
		parathyroid glands	- not examined
		pharynx	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1609	D	Microscopic	
		pituitary gland	- hyperplasia, diffuse, pars distalis, mild
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	 depletion, lymphoid, generalized, severe

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1609	D	Microscopic	
		thyroid gland	 carcinoma, follicular cell, malignant, unilateral, primary, incidental, not cause of death
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- dilatation, gland/lumen, mild
		vagina	- within normal limits
		non-correlated macro observation	- stomach, nonglandular - swollen/thickened
		Cause of Death	- kidney inflammation/necrosis
1610	Е	Macroscopic	
		pituitary gland	- enlarged, severe
1610	E	Microscopic	
		adrenal glands	- within normal limits
		aorta	- within normal limits
		bone marrow, femur	- within normal limits

E - Euthanized in extremis

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1610	E	Microscopic	
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, tubular, unilateral, minimal
			- nephropathy, chronic progressive, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
610	E	Microscopic	
		liver	- hematopoiesis, extramedullary, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1610	Е	Microscopic	
		pituitary gland	- adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1610	E	Microscopic	
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- pituitary tumor
1611	E	Macroscopic	
		lymph node, inguinal	- not identified, left, no grade
			draining node for mass a.
		pituitary gland	- enlarged, mild
		skin, subcutis	- mass, cystic, left inguinal area, mass a, present
			corresponds to antemortem observation (mass 1)
			mass a is approximately 6.5 cm in diameter, red, surrounded by approximately 97.0 ml. of fluid and a thin capsule.
1611	E	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1611	Е	Microscopic	
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- edema, papilla, unilateral, minimal
		,	- hyperplasia, transitional cell, unilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, mild
			-F F

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1611	E	Microscopic	
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- degeneration, cystic, focal, minimal
			- focus of cellular alteration, basophilic, mild
			- hypertrophy, hepatocyte, centrilobular, mild
			- infiltration, mononuclear cell, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits
		mammary gland	- adenocarcinoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, minimal
		nerve, sciatic	 degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1611	E	Microscopic	
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1611	E	Microscopic spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits depletion, lymphoid, generalized, moderate within normal limits dilatation, gland/lumen, minimal within normal limits mammary tumor
1612	S	Macroscopic all tissues	- within normal limits

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1612	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1612	S	Microscopic	
		kidneys	- edema, papilla, bilateral, minimal
			- hyperplasia, transitional cell, unilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- degeneration, cystic, focal, minimal
			 hypertrophy, hepatocyte, centrilobular, mild
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	 degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits

TRADE SECRET

Study Title H-28548: COMBINED CHRONIC TOXICITY/ONCOGENICITY STUDY 2-YEAR ORAL GAVAGE STUDY IN RATS

Laboratory Project ID: DuPont-18405-1238

Volume 13 of 13

Number of pages in volume: 196

TEST GUIDELINES: • U.S. EPA Health Effects Test Guidelines OPPTS 870.4300

Combined Chronic Toxicity/Carcinogenicity (1998)

 $\bullet\,$ OECD Guidelines for the Testing of Chemicals Section 4

(No. 453) Health Effects (2009)

• JMAFF Japan Agricultural Chemicals Regulation Law

12 Nousan No. 8147 (2000)

• EEC Methods for the Determination of Toxicity Method B.33

Combined Chronic/Carcinogenicity test, Directive 88/302/EC

(1988)

AUTHOR: Lisa Craig, B.S.

STUDY COMPLETED ON: March 28, 2013

APPLICANT/SPONSOR: E.I. du Pont de Nemours and Company

Wilmington, Delaware 19898

U.S.A.

PERFORMING LABORATORY: MPI Research, Inc.

54943 North Main Street

Mattawan, Michigan 49071-8353

U.S.A.

WORK REQUEST NUMBER: 18405

SERVICE CODE NUMBER: 1238

MPI RESEARCH STUDY NUMBER: 125-141

Unpublished Work

Copyright ©2013 E.I. du Pont de Nemours and Company

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1612	S	Microscopic	
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- not examined
		pancreas	- within normal limits
		parathyroid glands	- hyperplasia, focal, bilateral, minimal
		pharynx	- within normal limits
		pituitary gland	- within normal limits
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- degeneration/necrosis, myofiber, minimal
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1612	S	Microscopic	
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
			- hyperplasia, epithelial cell, minimal
		thyroid gland	 adenoma, c-cell, benign, unilateral, primary, incidental, not cause of death
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
1613	S	Macroscopic	
		adrenal glands	- enlarged, bilateral, mild
		kidneys	- focus/foci, tan, right, mild
		kidneys	- focus/foci, tan, right, mild

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1613	S	Macroscopic	
		liver	- focus/foci, tan, caudate lobe, mild
			- mass, tan, mass c, median lobe, present
			approximately 2.0 cm in diameter.
		lymph node, hepatic	- within normal limits
			draining node for mass c.
		lymph node, inguinal	 not identified, bilateral, no grade
			draining node for mass a, left and mass b, right.
		skin, subcutis	 cyst, red, left anogenital region, moderate
			- mass, tan, mass a, left inguinal area, present
			corresponds to antemortem observation (mass 1)
			approximately 8.0 cm in diameter.
			 mass, tan, mass b, right inguinal area, present
			corresponds to antemortem observation (mass 2)
			approximately 5.5 cm in diameter.
1613	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
			corresponds to macroscopic observation (adrenal glands - enlarged)
			no medulla present

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations	
500 mg/kg/day				
1613	S	Microscopic		
		aorta	- within normal limits	
		bone marrow, femur	- within normal limits	
		bone marrow, sternum	- within normal limits	
		bone, femur	- within normal limits	
		bone, sternum	- within normal limits	
		brain	- within normal limits	
		esophagus	- within normal limits	
		eyes	- within normal limits	
		eyes, optic nerves	- within normal limits	
		eyes, retina	- within normal limits	
		galt	- within normal limits	
		harderian glands	- within normal limits	
		heart	- within normal limits	
		joint, tibiofemoral	- within normal limits	
		•		

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1613	S	Microscopic	
		kidneys	- cyst, unilateral, moderate
			corresponds to macroscopic observation (kidneys - focus/foci, tan)
			- hydronephrosis, unilateral, mild
			 hyperplasia, transitional cell, unilateral, minimal mineralization, pelvic, unilateral, minimal
			- nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1613	S	Microscopic	
		liver	 adenoma, hepatocellular, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (liver - mass c) - angiectasis, mild
			- focus of cellular alteration, basophilic, minimal
			- focus of cellular alteration, eosinophilic, mild
			- hyperplasia, bile duct, minimal
			 hypertrophy, hepatocyte, centrilobular, mild
		lung	- within normal limits
		lymph node, hepatic	- not examined
			misidentified tissue
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
613	S	Microscopic	
		mammary gland	- adenoma, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (skin, subcutis - cyst)
			- fibroadenoma, benign, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b)
			- hyperplasia, lobular, minimal
		nerve, sciatic	 degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
500 mg/kg/day 1613	S	Microscopic salivary gland, mandibular salivary gland, parotid salivary gland, sublingual skeletal muscle, biceps femoris skin small intestine, duodenum small intestine, ileum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue	 within normal limits within normal limits degeneration/necrosis, myofiber, minimal within normal limits hematopoiesis, extramedullary, increased, minimal within normal limits within normal limits depletion, lymphoid, generalized, moderate within normal limits within normal limits within normal limits
		trachea ureters	within normal limitsdilatation, unilateral, mild

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1613	S	Microscopic urinary bladder uterus with cervix vagina non-correlated macro observation	 within normal limits dilatation, gland/lumen, minimal within normal limits liver - focus/foci, tan
1614	D	Macroscopic cavity, thoracic kidneys mediastinum	 fluid, red, moderate approximately 7.5 ml. irregular surface, bilateral, mild enlarged, red, moderate red area continues along esophagus to thyroid glands.
1614	D	Microscopic adrenal glands aorta bone marrow, femur bone marrow, sternum bone, femur	 angiectasis/cystic degeneration, focal cortical, bilateral, mild within normal limits within normal limits within normal limits within normal limits

S - Scheduled necropsy D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1614	D	Microscopic	
		bone, sternum	- within normal limits
		brain	- within normal limits
		cavity, thoracic	- hemorrhage, severe
			corresponds to macroscopic observation (mediastinum - enlarged)
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, mild
			- edema, papilla, bilateral, mild
			- hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			 nephropathy, chronic progressive, bilateral, mild
			corresponds to macroscopic observation (kidneys - irregular
			surface)
		lacrimal glands, exorbital	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1614	D	Microscopic large intestine, cecum large intestine, colon large intestine, rectum larynx liver lung lymph node, mandibular lymph node, mesenteric mammary gland nerve, sciatic nose, level a nose, level b nose, level c nose, level d ovaries oviducts pancreas	 within normal limits within normal limits within normal limits within normal limits focus of cellular alteration, eosinophilic, minimal hypertrophy, hepatocyte, centrilobular, minimal within normal limits within normal limits within normal limits hyperplasia, lobular, mild within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1614	D	Microscopic	
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	- within normal limits
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- hyperplasia, epithelial, limiting ridge, minimal

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1614	D	Microscopic	
		thymus	 depletion, lymphoid, generalized, moderate
			 hyperplasia, epithelial cell, minimal
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- dosing injury
1615	D	Macroscopic	
		adrenal glands	- cyst, red, right, mild
		kidneys	- enlarged, bilateral, mild
		liver	- mass, tan, mass a, median lobe, present
			approximately 2.5 x 2.0 x 1.0 cm.
			- mass, tan, mass b, right lateral lobe, present
			approximately 0.9 x 0.6 x 0.6 cm.

D - Died on Study

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1615	D	Macroscopic	
		lung with bronchi	- focus/foci, tan, multiple lobes, mild
		lymph node, hepatic	- within normal limits
			draining node for mass a and mass b.
		mammary gland	- swollen/thickened, generalized, mild
			corresponds to antemortem observation (nodule)
			cervical region, anogenital, left and right inguinal areas most affected.
		pituitary gland	- enlarged, red, severe
		stomach, glandular	- swollen/thickened, mucosa, limiting ridge, mild
1615	D	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
			corresponds to macroscopic observation (adrenal glands - cyst)
			- hyperplasia, focal medullary, unilateral, mild
			 pheochromocytoma, malignant, unilateral, primary, incidental, not cause of death
		aorta	- within normal limits
		bone marrow, femur	- within normal limits

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1615	D	Microscopic bone marrow, sternum bone, femur bone, sternum brain esophagus eyes eyes, optic nerves eyes, retina galt harderian glands heart joint, tibiofemoral	 within normal limits within normal limits within normal limits compression, ventral (pituitary tumor), moderate within normal limits hyperplasia, focal, unilateral, mild cardiomyopathy, mild within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1615	D	Microscopic	
		kidneys	- dilatation, tubular, bilateral, mild
			- edema, papilla, bilateral, mild
			- hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, bilateral, mild
			- mineralization, tubular, bilateral, minimal
			- necrosis, papillary, unilateral, mild
			 nephropathy, chronic progressive, bilateral, moderate
			corresponds to macroscopic observation (kidneys - enlarged)
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1615	D	Microscopic	
		liver	 adenoma, hepatocellular, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (liver - mass b)
			 carcinoma, hepatocellular, malignant, primary, incidental, not cause of death
			corresponds to macroscopic observation (liver - mass a)
			 focus of cellular alteration, basophilic, minimal
			 hypertrophy, hepatocyte, centrilobular, minimal
			- necrosis, focal, mild
			 vacuolation, periportal, minimal
		lung	- histiocytosis, alveolar, mild
			corresponds to macroscopic observation (lung with bronchi - focus/foci, tan)
		lymph node, hepatic	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
			corresponds to macroscopic observation (mammary gland - swollen/thickened)
		nerve, sciatic	- degeneration, axonal/myelin, minimal

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1615	D	Microscopic	
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- cyst, unilateral, minimal
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1615	D	Microscopic	
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
			- hyperplasia, epithelial cell, minimal
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		non-correlated macro observation	- stomach, glandular - swollen/thickened
		Cause of Death	- pituitary tumor

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1616	D	Macroscopic	
		adrenal glands	- enlarged, left, minimal
		liver	- nodule, tan, median lobe, present
			approximately 0.4 cm in diameter.
		lymph node, iliac	- within normal limits
			draining node for mass b, bilateral.
		lymph node, mandibular	- within normal limits
			draining node for mass a, left.
		pituitary gland	- enlarged, tan, mild
		skin	 hair sparse, dorsal thoracic region, mild
			corresponds to antemortem observation (hair sparse)
		skin, subcutis	- mass, tan, mass a, left lateral neck, present
			corresponds to antemortem observation (swelling)
			approximately 4.0 x 3.0 x 1.5 cm.
		stomach, nonglandular	 swollen/thickened, limiting ridge, mild
		uterus with cervix	- mass, tan, mass b, body, present
			approximately 12.0 x 4.0 x 4.0 cm.
1616	D	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
			corresponds to macroscopic observation (adrenal glands - enlarged)

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Fate	Tienue		
	Tissue	Observations	
D	Microscopic		
	aorta	- within normal limits	
	bone marrow, femur	- within normal limits	
	bone marrow, sternum	- within normal limits	
	bone, femur	- within normal limits	
	bone, sternum	- within normal limits	
	brain	- within normal limits	
	esophagus	- within normal limits	
	eyes	- within normal limits	
	eyes, optic nerves	- within normal limits	
	eyes, retina	- not examined	
	•	autolysis too severe for diagnosis	
	galt	- within normal limits	
		- within normal limits	
	heart	- cardiomyopathy, minimal	
	joint, tibiofemoral	- within normal limits	
	D	aorta bone marrow, femur bone marrow, sternum bone, femur bone, sternum brain esophagus eyes eyes, optic nerves eyes, retina galt harderian glands	aorta - within normal limits bone marrow, femur - within normal limits bone, femur - within normal limits bone, femur - within normal limits bone, sternum - within normal limits brain - within normal limits esophagus - within normal limits eyes - within normal limits eyes, optic nerves - within normal limits eyes, retina - not examined autolysis too severe for diagnosis galt - within normal limits harderian glands - within normal limits heart - cardiomyopathy, minimal

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1616	D	Microscopic	
		kidneys	- dilatation, tubular, bilateral, minimal
			- edema, papilla, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, mild
			 nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
	large intestine, colon	- within normal limits	
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 adenoma, hepatocellular, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (liver - nodule)
			 hypertrophy, hepatocyte, centrilobular, minimal
			 necrosis, hepatocytes, centrilobular, moderate
		lung	 histiocytosis, alveolar, minimal
		lymph node, iliac	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1616	D	Microscopic	
		mammary gland	- fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, minimal
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1616	D	Microscopic	
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- alopecia/hypotrichosis, moderate
			corresponds to macroscopic observation (skin - hair sparse)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, mild
		stomach, glandular	- mineralization, mild
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

	Tissue	Observations
D	Microscopic	
	uterus with cervix	 schwannoma, malignant, primary, fatal, positive cause of death corresponds to macroscopic observation (uterus with cervix - mass b)
	vagina	- within normal limits
	non-correlated macro observation	- stomach, nonglandular - swollen/thickened
	Cause of Death	- uterus tumor
Ε	Macroscopic	
	adrenal glands	- cyst, clear, left, moderate
		cyst burst.
	lymph node, axillary	- discoloration, red, right, mild
		draining node for mass a.
	pituitary gland	- enlarged, red, severe
	skin, subcutis	- mass, tan, mass a, right axillary area, present
		corresponds to antemortem observation (swelling)
		approximately 5.0 x 3.5 x 2.0 cm.
		vagina non-correlated macro observation Cause of Death E Macroscopic adrenal glands lymph node, axillary pituitary gland

E - Euthanized in extremis

D - Died on Study

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1617	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, moderate
			corresponds to macroscopic observation (adrenal glands - cyst)
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	 compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
617	E	Microscopic	
		kidneys	- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
			- necrosis, focal, minimal
		lung	- within normal limits
		lymph node, axillary	- erythrocytosis/erythrophagocytosis, sinus, mild
			corresponds to macroscopic observation (lymph node, axillary - discoloration, red)
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1617	E	Microscopic	
		mammary gland	- fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1617	E	Microscopic	
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1617	Е	Microscopic	
		vagina .	- within normal limits
		Cause of Death	- pituitary tumor
1618 S	S	Macroscopic	
		all tissues	- within normal limits
1618	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1618	S	Microscopic	
		eyes, retina	- within normal limits
			one of pair present
		galt	- within normal limits
		harderian glands	- hyperplasia, focal, unilateral, minimal
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, minimal
			- edema, papilla, bilateral, mild
			 hyperplasia, transitional cell, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			 nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- degeneration, cystic, focal, minimal
			 hypertrophy, hepatocyte, centrilobular, minimal
		lung	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1618	S	Microscopic	
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1618	S	Microscopic	
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- not examined
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1619	Е	Macroscopic	
		lymph node, axillary	- not identified, right, no grade
			draining node for mass a.
		lymph node, inguinal	- not identified, left, no grade
			draining node for mass b.
		skin, subcutis	- mass, tan, mass b, left inguinal area, present
			corresponds to antemortem observation (mass 2)
			approximately 6.0 x 6.0 x 2.5 cm.
			- mass, ulcerated, mass a, right axillary area, present
			corresponds to antemortem observation (mass 1)
			approximately 8.5 x 7.5 x 4.0 cm, tan.
		trachea	- fluid, clear, frothy, mild
1619	E	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1619	E	Microscopic	
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, eosinophilic, minimal
			- hematopoiesis, extramedullary, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
			,,

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1619	Е	Microscopic	
		lung	- fibrosis, minimal
		-	- histiocytosis, alveolar, minimal
			- inflammation, acute, minimal
		lymph node, mandibular	- erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits
		mammary gland	- fibroadenoma, benign, multiple, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b)
			- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	 adenoma, islet cell, benign, primary, incidental, not cause of death
		parathyroid glands	- not examined

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1619	Е	Microscopic	
		pharynx	- within normal limits
		pituitary gland	- within normal limits
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
			- hyperplasia, epithelial cell, minimal
		thyroid gland	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1619	Е	Microscopic	
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- mammary tumor
1620	E	Macroscopic	
		lymph node, iliac	- within normal limits
			draining node for mass a, bilateral.
		skin, subcutis	- mass, ulcerated, mass a, anogenital region, present
			corresponds to antemortem observation (mass 1)
			approximately 4.0 cm in diameter, tan.
		uterus with cervix	- cyst, clear, body, moderate
			- enlarged, body, mild
1620	E	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild

E - Euthanized in extremis

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1620	E	Microscopic	
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		cavity, abdominal	- sarcoma, stromal, malignant, secondary
			corresponds to macroscopic observation (uterus with cervix - cyst)
			adjacent to uterus.
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1620	E	Microscopic	
		kidneys	- mineralization, pelvic, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hyperplasia, bile duct, minimal
			 hypertrophy, hepatocyte, centrilobular, minimal
			- leukocytosis, sinusoidal, minimal
			- necrosis, focal, moderate
		lung	- histiocytosis, alveolar, minimal
		lymph node, iliac	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations	
500 mg/kg/day				
1620	Е	Microscopic		
		nose, level c	- within normal limits	
		nose, level d	- within normal limits	
		ovaries	- within normal limits	
		oviducts	- within normal limits	
		pancreas	- within normal limits	
		parathyroid glands	- not examined	
		pharynx	- within normal limits	
		pituitary gland	- within normal limits	
		salivary gland, mandibular	- within normal limits	
		salivary gland, parotid	- within normal limits	
		salivary gland, sublingual	- within normal limits	
		skeletal muscle, biceps femoris	- within normal limits	
		skin	- within normal limits	
		small intestine, duodenum	- within normal limits	
		small intestine, ileum	- within normal limits	
		small intestine, jejunum	- within normal limits	
		spinal cord, cervical	- within normal limits	
		spinal cord, lumbar	- within normal limits	
		spinal cord, thoracic	- within normal limits	
		•		

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1620	E	Microscopic	
		spleen	- hematopoiesis, extramedullary, increased, mild
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
			- hyperplasia, epithelial cell, minimal
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- hyperplasia, cervical fibromuscular, moderate
			corresponds to macroscopic observation (uterus with cervix - enlarged)
			 sarcoma, stromal, malignant, primary, fatal, positive cause of death
			corresponds to macroscopic observation (skin, subcutis - mass a)
		vagina	- hyperplasia, fibromuscular, moderate
		Cause of Death	- uterus tumor

DuPont-18405-1238

S - Scheduled necropsy

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations	
500 mg/kg/day				
1621	S	Macroscopic		
		liver	- mass, red, mass a, median lobe, present	
			approximately 1.0 x 0.4 x 0.4 cm.	
		lymph node, hepatic	- not identified, no grade	
			draining node for mass a.	
		pituitary gland	- cyst, red, mild	
1621	S	Microscopic		
		adrenal glands	- within normal limits	
		aorta	- within normal limits	
		bone marrow, femur	- within normal limits	
		bone marrow, sternum	- within normal limits	
		bone, femur	- within normal limits	
		bone, sternum	- within normal limits	
		brain	- within normal limits	
		esophagus	- within normal limits	
		eyes	- within normal limits	
		eyes, optic nerves	- within normal limits	
		eyes, retina	- within normal limits	
		galt	- within normal limits	

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1621	S	Microscopic	
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			 nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 adenoma, hepatocellular, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (liver - mass a)
			- degeneration, cystic, focal, minimal
			- focus of cellular alteration, basophilic, minimal
			- focus of cellular alteration, eosinophilic, minimal
			- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Inimal Number	Fate	Tissue	Observations
500 mg/kg/day			
1621	S	Microscopic	
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	 adenoma, islet cell, benign, primary, incidental, not cause of death
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - cyst)
		salivary gland, mandibular	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1621	S	Microscopic	
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		•	

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1621	S	Microscopic uterus with cervix vagina	within normal limitswithin normal limits
1622	D	Macroscopic liver lung with bronchi stomach, nonglandular	 focus/foci, tan, median lobe, left lateral lobe, mild focus/foci, tan, multiple lobes, mild swollen/thickened, limiting ridge, mild
1622	D	Microscopic adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal hyperplasia, focal cortical, unilateral, mild
		aorta bone marrow, femur bone marrow, sternum bone, femur bone, sternum brain	 within normal limits

S - Scheduled necropsy D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1622	D	Microscopic	
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
			- necrosis, papillary, bilateral, severe
			 nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1622	D	Microscopic	
		liver	 adenoma, hepatocellular, benign, multiple, primary, incidental, not cause of death
			corresponds to macroscopic observation (liver - focus/foci, tan)
			- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
		lung	- histiocytosis, alveolar, mild
			corresponds to macroscopic observation (lung with bronchi - focus/foci, tan)
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, minimal
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations	
500 mg/kg/day				
1622	D	Microscopic		
		parathyroid glands	- not examined	
		pharynx	- within normal limits	
		pituitary gland	- hyperplasia, focal, pars distalis, mild	
		salivary gland, mandibular	- within normal limits	
		salivary gland, parotid	- within normal limits	
		salivary gland, sublingual	- within normal limits	
		skeletal muscle, biceps femoris	- within normal limits	
		skin	- within normal limits	
		small intestine, duodenum	- within normal limits	
		small intestine, ileum	- within normal limits	
		small intestine, jejunum	- within normal limits	
		spinal cord, cervical	- within normal limits	
		spinal cord, lumbar	- within normal limits	
		spinal cord, thoracic	- within normal limits	
		spleen	- within normal limits	
		stomach, glandular	- within normal limits	
		stomach, nonglandular	- within normal limits	
		thymus	- depletion, lymphoid, generalized, moderate	
		thyroid gland	- within normal limits	

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1622	D	Microscopic	
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		non-correlated macro observation	- stomach, nonglandular - swollen/thickened
		Cause of Death	- kidney inflammation/necrosis
1623	S	Macroscopic	
		adrenal glands	- enlarged, right, moderate
		lung with bronchi	 focus/foci, white, multiple lobes, mild
		lymph node, axillary	- within normal limits
			draining node for mass a, right.
		lymph node, inguinal	- within normal limits
			draining node for mass b, right.
		ovaries	- cyst, clear, left, mild
		pituitary gland	- enlarged, mild

S - Scheduled necropsy D - Died on Study

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1623	S	Macroscopic	
		skin	- nodule, tan, dorsal lumbar region, present
			corresponds to antemortem observation (nodule)
			approximately 0.4 cm in diameter.
		skin, subcutis	- mass, tan, mass a, right axillary area, present
			approximately 2.2 x 1.5 x 1.0 cm.
			- mass, tan, mass b, right lateral abdomen, present
			approximately 1.2 cm in diameter.
		stomach, glandular	- swollen/thickened, moderate
1623	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, severe
			corresponds to macroscopic observation (adrenal glands - enlarged)
		aorta	- within normal limits
		bone marrow, femur	- hyperplasia, granulocytic, mild
		bone marrow, sternum	- hyperplasia, granulocytic, minimal
		bone, femur	- within normal limits
		bone, sternum	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

500 mg/kg/day 1623	S		
	S		
	_	Microscopic	
		brain .	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- degeneration/atrophy, retina, unilateral, mild
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
		•	- nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, basophilic, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
			- infiltration, mononuclear cell, minimal

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
00 mg/kg/day			
623	S	Microscopic	
		lung	- histiocytosis, alveolar, minimal
		lymph node, axillary	- within normal limits
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenocarcinoma, malignant, primary, incidental, not cause of death
			corresponds to macroscopic observation (skin, subcutis - mass b)
			 fibroadenoma, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, moderate
		nerve, sciatic	 degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- cyst, unilateral, mild
			corresponds to macroscopic observation (ovaries - cyst)
		oviducts	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
00 mg/kg/day			
623	S	Microscopic	
		pancreas	- hyperplasia, acinar cell, focal, mild
		parathyroid glands	- not examined
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- degeneration/necrosis, myofiber, minimal
		skin	 keratoacanthoma, benign, primary, mortality-independent corresponds to macroscopic observation (skin - nodule)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1623	S	Microscopic	
		spleen	- within normal limits
		stomach, glandular	- leiomyoma, benign, primary, incidental, not cause of death
		stomach, nonglandular	- cyst, keratin, moderate
			corresponds to macroscopic observation (stomach, glandular - swollen/thickened)
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	 adenoma, c-cell, benign, unilateral, primary, incidental, not cause of death
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		non-correlated macro observation	- lung with bronchi - focus/foci, white
1624	Е	Macroscopic	
		lymph node, axillary	- within normal limits
		- · · · · · · · ·	draining node for mass b, right.

S - Scheduled necropsy E - Euthanized *in extremis*

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1624	E	Macroscopic	
		lymph node, mandibular	- within normal limits
			draining node for mass a, right.
		pituitary gland	- enlarged, red, severe
		skin	- hair sparse, generalized, mild
		skin, subcutis	- mass, tan, mass a, cervical, present
			corresponds to antemortem observation (mass 1)
			approximately 2.0 cm in diameter, right.
			- mass, tan, mass b, right axillary area, present
			corresponds to antemortem observation (nodule)
			approximately 3.5 cm in diameter.
1624	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
		aorta	- within normal limits
		bone marrow, femur	- hyperplasia, granulocytic, mild
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1624	E	Microscopic	
		brain	- compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
		•	- mineralization, tubular, unilateral, minimal
			- nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
			γ _Γ Ελ.) Ε

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1624	E	Microscopic	
		lung	- histiocytosis, alveolar, minimal
		lymph node, axillary	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- adenocarcinoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass b)
			 fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			 hyperplasia, lobular, mild
		nerve, sciatic	 degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1624	E	Microscopic	
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- alopecia/hypotrichosis, moderate
			corresponds to macroscopic observation (skin - hair sparse)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1624	Е	Microscopic	
		stomach, nonglandular	- within normal limits
		thymus	 depletion, lymphoid, generalized, moderate
			 hyperplasia, epithelial cell, mild
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- pituitary tumor
1625	D	Macroscopic	
		adipose tissue	- swollen/thickened, mild
			near hilus of liver. small, round, orange granules are on the surface.
		cavity, abdominal	- fluid, red, mild
			approximately 2.4 ml.

E - Euthanized in extremis

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1625	D	Macroscopic	
		lymph node, mandibular	- enlarged, red, mild
		skin	- hair sparse, left lateral neck, moderate
			corresponds to antemortem observation (hair sparse)
		spleen	- enlarged, moderate
1625	D	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, minimal
		aorta	- within normal limits
		bile duct, extrahepatic	- calculus/calculi, moderate
			bile stained.
			- dilatation, moderate
			corresponds to macroscopic observation (adipose tissue - swollen/thickened)
		bone marrow, femur	- bacterial colonies, mild
			- hyperplasia, granulocytic, mild
		bone marrow, sternum	- proliferation, fibro-osseous, moderate
		bone, femur	- within normal limits
		bone, sternum	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1625	D	Microscopic	
		brain	- bacterial colonies, minimal
			- inflammation, embolic, minimal
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- not examined
			autolysis too severe for diagnosis
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- bacterial colonies, mild
			- inflammation, moderate
			- thrombus, moderate
			left ventricle.
		joint, tibiofemoral	- within normal limits
		kidneys	- bacterial colonies, unilateral, minimal
			- edema, papilla, bilateral, minimal
			 inflammation, embolic, unilateral, minimal
			 mineralization, pelvic, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1625	D	Microscopic	
		large intestine, cecum	 hypertrophy/hyperplasia, goblet cell, moderate
		large intestine, colon	- hypertrophy/hyperplasia, goblet cell, moderate
		large intestine, rectum	- hypertrophy/hyperplasia, goblet cell, moderate
		larynx	- within normal limits
		liver	- fibrosis, severe
			- inflammation, chronic-active, moderate
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- hyperplasia, lymphocyte/plasmacyte, medulla, mild
		, , , , , , , , , , , ,	corresponds to macroscopic observation (lymph node, mandibular - enlarged)
		lymph node, mediastinal	- hyperplasia, lymphocyte/plasmacyte, medulla, mild
			slide 14.
		lymph node, mesenteric	- hyperplasia, lymphocyte/plasmacyte, medulla, moderate
		mammary gland	- within normal limits
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
625	D	Microscopic	
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	 adenoma, islet cell, benign, primary, incidental, not cause of death slide 26-1.
			- bacterial colonies, severe
			within blood vessels.
		parathyroid glands	- within normal limits
		paratryroid glarido	one of pair present
		pharynx	- within normal limits
		pituitary gland	- cyst, mild
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- edema, mild
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- alopecia/hypotrichosis, moderate
			corresponds to macroscopic observation (skin - hair sparse)
		small intestine, duodenum	 hypertrophy/hyperplasia, goblet cell, mild
		small intestine, ileum	 hypertrophy/hyperplasia, goblet cell, moderate

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1625	D	Microscopic	
		small intestine, jejunum	 hypertrophy/hyperplasia, goblet cell, moderate
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, moderate
			corresponds to macroscopic observation (spleen - enlarged)
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	 depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits
		tongue	- erosion/ulcer, moderate
			 hyperplasia, squamous cell, mild
			- inflammation, subacute/chronic, mild
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- inflammation/septicemia

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1626	Е	Macroscopic	
		liver	- focus/foci, tan, median lobe, mild
		lung with bronchi	- focus/foci, tan, multiple lobes, mild
		lymph node, axillary	- within normal limits
			draining node for mass a and mass b, right.
		lymph node, inguinal	- within normal limits
			draining node for mass c, right.
		ovaries	- cyst, clear, right, mild
		pituitary gland	- enlarged, moderate
		skin, subcutis	- mass, tan, mass b, right axillary area, present
			approximately 2.0 cm in diameter.
			- mass, tan, mass c, right anogenital region, present
			approximately 1.5 cm in diameter.
			- mass, ulcerated, mass a, right axillary area, present
			corresponds to antemortem observation (mass 1)
			approximately 4.0 x 2.0 x 1.2 cm, tan.
		stomach, glandular	- focus/foci, red, mucosa, mild
		stomach, nonglandular	- swollen/thickened, limiting ridge, mild
		thymus	- small, severe

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1626	Е	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, minimal
			- hyperplasia, focal medullary, unilateral, minimal
			- vacuolation, focal, unilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- hyperplasia, granulocytic, mild
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1626	E	Microscopic	
		kidneys	- edema, papilla, unilateral, minimal
			- hyperplasia, transitional cell, unilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			 nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- degeneration, cystic, focal, minimal
			- focus of cellular alteration, eosinophilic, moderate
			corresponds to macroscopic observation (liver - focus/foci, tan)
			- hyperplasia, bile duct, minimal
			 hypertrophy, hepatocyte, centrilobular, mild
			 infiltration, mononuclear cell, minimal
		lung	 histiocytosis, alveolar, mild
			corresponds to macroscopic observation (lung with bronchi - focus/foci, tan)
		lymph node, axillary	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1626	E	Microscopic	
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- adenocarcinoma, malignant, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a)
			fibroadenoma, benign, multiple, primary, incidental, not cause of death
			corresponds to macroscopic observation (skin, subcutis - mass b; skin, subcutis - mass c)
			- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	 cyst, unilateral, minimal corresponds to macroscopic observation (ovaries - cyst)
		oviducts	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1626	Е	Microscopic	
		pancreas	- atrophy, acinar, minimal
			- fibrosis, minimal
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1626	Е	Microscopic	
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, mild
		stomach, glandular	- erosion/ulcer, mild
			corresponds to macroscopic observation (stomach, glandular - focus/foci, red)
		stomach, nonglandular	 hyperplasia, epithelial, limiting ridge, moderate
			corresponds to macroscopic observation (stomach, nonglandular - swollen/thickened)
		thymus	 depletion, lymphoid, generalized, severe
			corresponds to macroscopic observation (thymus - small)
		thyroid gland	 hyperplasia, c-cell, focal, unilateral, mild
		tongue	- hyperplasia, squamous cell, mild
			- inflammation, subacute/chronic, mild
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	 polyp, stromal, benign, primary, incidental, not cause of death
		vagina	- within normal limits
		Cause of Death	- mammary tumor

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1627	E	Macroscopic	
		lymph node, axillary	- within normal limits
			draining node for mass a, right.
		skin, subcutis	- mass, ulcerated, mass a, right axillary area, present
			corresponds to antemortem observation (mass 1 scabbed area)
			approximately 3.0 cm in diameter, tan.
1627	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- hyperplasia, granulocytic, minimal
		bone marrow, sternum	- hyperplasia, granulocytic, minimal
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
500 mg/kg/day 1627	E	Microscopic galt harderian glands heart joint, tibiofemoral kidneys lacrimal glands, exorbital large intestine, cecum large intestine, colon large intestine, rectum larynx liver lung lymph node, axillary	 within normal limits within normal limits within normal limits within normal limits dilatation, tubular, bilateral, mild hydronephrosis, unilateral, mild hyperplasia, transitional cell, unilateral, minimal mineralization, pelvic, unilateral, minimal mineralization, tubular, bilateral, minimal nephropathy, chronic progressive, bilateral, mild within normal limits hematopoiesis, extramedullary, minimal hypertrophy, hepatocyte, centrilobular, minimal histiocytosis, alveolar, minimal within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
00 mg/kg/day			
627	Е	Microscopic	
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- adenocarcinoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	- within normal limits
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
500 mg/kg/day 1627	E	Microscopic salivary gland, sublingual skeletal muscle, biceps femoris skin small intestine, duodenum small intestine, ileum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix	 within normal limits hematopoiesis, extramedullary, increased, mild within normal limits hyperplasia, epithelial, limiting ridge, minimal depletion, lymphoid, generalized, severe within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

			remina	
Group, Animal Number	Fate	Tissue	Observations	
500 mg/kg/day				
1627	E	Microscopic		
		vagina	- within normal limits	
		Cause of Death	- mammary tumor	
1628	S	Macroscopic		
		uterus with cervix	- enlarged, horn, mild	
1628	S	Microscopic		
		adrenal glands	- within normal limits	
		aorta	- within normal limits	
		bone marrow, femur	- within normal limits	
		bone marrow, sternum	- within normal limits	
		bone, femur	- within normal limits	
		bone, sternum	- within normal limits	
		brain	- within normal limits	
		esophagus	- within normal limits	
		eyes	- within normal limits	
		-	- within normal limits	
		eyes, retina	- within normal limits	
		-		
		eyes, optic nerves		

S - Scheduled necropsy E - Euthanized *in extremis*

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1628	S	Microscopic	
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, unilateral, minimal
		•	- mineralization, tubular, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- focus of cellular alteration, basophilic, mild
			- focus of cellular alteration, clear, minimal
			- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
			- infiltration, mononuclear cell, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1628	S	Microscopic	
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- hyperplasia, sex-cord/stromal, bilateral, mild
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1628	S	Microscopic	
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, minimal
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	 polyp, stromal, benign, primary, incidental, not cause of death corresponds to macroscopic observation (uterus with cervix - enlarged)
		vagina	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1629	D	Macroscopic	
		kidneys	- irregular surface, red, bilateral, mild
		lymph node, iliac	- within normal limits
			draining node for mass b, right.
		lymph node, inguinal	- within normal limits
			draining node for mass a, left.
		skin, subcutis	- mass, tan, mass a, left inguinal area, present
			approximately 1.0 x 1.0 x 0.5 cm.
		uterus with cervix	- mass, tan, mass b, horn, present
			approximately 4.0 x 3.0 x 1.5 cm.
1629	D	Microscopic	
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Microscopic eyes - within normal limits eyes, retina galt - within normal limits eyes, retina galt - within normal limits eyes, retina galt - within normal limits eart - cardiomyopathy, minimal ipints edema, papilla, bilateral, minimal mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal necrosis, papillary, bilateral, minida necr	Group, Animal Number	Fate	Tissue	Observations
Microscopic eyes - within normal limits eyes, optic nerves - within normal limits eyes, retina galt - within normal limits harderian glands - within normal limits heart - cardiomyopathy, minimal joint, tibiofemoral - within normal limits kidneys - edema, papilla, bilateral, minimal mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal mineralization, tubular, bilateral, minimal necrosis, papillary, bilateral, moderate nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) lacrimal glands, exorbital large intestine, cecum - within normal limits	00 mg/kg/day			
eyes, optic nerves eyes, retina galt harderian glands heart joint, tibiofemoral kidneys edema, papilla, bilateral, minimal mineralization, pelvic, bilateral, minimal mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal necrosis, papillary, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) lacrimal glands, exorbital large intestine, cecum within normal limits within normal limits - within normal limits		D	Microscopic	
eyes, retina galt - within normal limits yalt - within normal limits - cardiomyopathy, minimal - cardiomyopathy, minimal - within normal limits - within normal limits - edema, papilla, bilateral, minimal - mineralization, pelvic, bilateral, minimal - mineralization, tubular, bilateral, minimal - necrosis, papillary, bilateral, moderate - nephropathy, chronic progressive, bilateral, mild - corresponds to macroscopic observation (kidneys - irregular surface) lacrimal glands, exorbital large intestine, cecum - within normal limits - within normal limits			-	- within normal limits
galt			eyes, optic nerves	- within normal limits
harderian glands heart joint, tibiofemoral kidneys - within normal limits - mineralization, pelvic, bilateral, minimal - mineralization, tubular, bilateral, minimal - necrosis, papillary, bilateral, moderate - nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) lacrimal glands, exorbital large intestine, cecum - within normal limits - within normal limits			eyes, retina	- within normal limits
harderian glands heart joint, tibiofemoral kidneys - within normal limits - edema, papilla, bilateral, minimal - mineralization, pelvic, bilateral, minimal - mineralization, tubular, bilateral, minimal - necrosis, papillary, bilateral, moderate - nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) lacrimal glands, exorbital large intestine, cecum - within normal limits - within normal limits			galt	- within normal limits
heart joint, tibiofemoral kidneys - cardiomyopathy, minimal - within normal limits - edema, papilla, bilateral, minimal - mineralization, pelvic, bilateral, minimal - mineralization, tubular, bilateral, minimal - mecrosis, papillary, bilateral, moderate - nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) lacrimal glands, exorbital large intestine, cecum - within normal limits - within normal limits				- within normal limits
kidneys - edema, papilla, bilateral, minimal - mineralization, pelvic, bilateral, minimal - mineralization, tubular, bilateral, minimal - necrosis, papillary, bilateral, moderate - nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) lacrimal glands, exorbital large intestine, cecum - within normal limits			heart	- cardiomyopathy, minimal
 mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal necrosis, papillary, bilateral, moderate nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) lacrimal glands, exorbital within normal limits within normal limits 			joint, tibiofemoral	- within normal limits
 mineralization, pelvic, bilateral, minimal mineralization, tubular, bilateral, minimal necrosis, papillary, bilateral, moderate nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) lacrimal glands, exorbital within normal limits within normal limits 			kidneys	- edema, papilla, bilateral, minimal
 necrosis, papillary, bilateral, moderate nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) lacrimal glands, exorbital within normal limits within normal limits 			•	
 necrosis, papillary, bilateral, moderate nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) lacrimal glands, exorbital within normal limits within normal limits 				- mineralization, tubular, bilateral, minimal
- nephropathy, chronic progressive, bilateral, mild corresponds to macroscopic observation (kidneys - irregular surface) lacrimal glands, exorbital large intestine, cecum - within normal limits - within normal limits				
corresponds to macroscopic observation (kidneys - irregular surface) lacrimal glands, exorbital - within normal limits large intestine, cecum - within normal limits				
lacrimal glands, exorbital - within normal limits large intestine, cecum - within normal limits				corresponds to macroscopic observation (kidneys - irregular
9 ,			lacrimal glands, exorbital	- within normal limits
			large intestine, cecum	- within normal limits
			large intestine, colon	- within normal limits
large intestine, rectum - within normal limits			large intestine, rectum	- within normal limits
larynx - within normal limits			larynx	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
00 mg/kg/day			
629	D	Microscopic	
		liver	- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
		lung	- within normal limits
		lymph node, iliac	- within normal limits
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- fibroadenoma, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1629	D	Microscopic	
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1629	D	Microscopic	
		tongue	- hyperplasia, squamous cell, moderate
		3	- inflammation, subacute/chronic, mild
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- polyp, stromal, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (uterus with cervix - mass b)
		vagina	- within normal limits
		Cause of Death	- kidney inflammation/necrosis
1630	D	Macroscopic	
		lymph node, axillary	- within normal limits
			draining node for mass a, left.
		ovaries	- cyst, clear, right, mild
		pituitary gland	- enlarged, red, moderate

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1630	D	Magragania	
1030	D	Macroscopic	many tan many a left avillary area present
		skin, subcutis	- mass, tan, mass a, left axillary area, present
			corresponds to antemortem observation (mass 1)
			approximately 3.0 cm in diameter.
		uterus with cervix	- cyst, clear, horn, mild
1630	D	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), minimal
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		-	- within normal limits
		galt	- WILLIII HOTHIAI IIIIIIIS

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

<u>500 mg/kg/day</u> 1630	D		
	D		
	U	Microscopic	
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- edema, papilla, bilateral, minimal
			- hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hypertrophy, hepatocyte, centrilobular, minimal
			- vacuolation, periportal, minimal
		lung	- histiocytosis, alveolar, mild
		lymph node, axillary	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1630	D	Microscopic	
		mammary gland	 adenocarcinoma, malignant, primary, incidental, not cause of death slide 18. hyperplasia, lobular, mild
		nerve, sciatic	- hyperplasia, lobdial, fillid - degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1630	D	Microscopic	
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		skin, subcutis	- fibrosarcoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1630	D	Microscopic	
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- dilatation, gland/lumen, mild
			corresponds to macroscopic observation (uterus with cervix - cyst)
		vagina	- within normal limits
		non-correlated macro observation	- ovaries - cyst
		Cause of Death	- pituitary tumor
1631	S	Macroscopic	
		all tissues	- within normal limits
1631	S	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits

S - Scheduled necropsy D - Died on Study

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1631	S	Microscopic	
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- mineralization, pelvic, bilateral, minimal
			 nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1631	S	Microscopic	
		liver	- focus of cellular alteration, basophilic, minimal
			- focus of cellular alteration, eosinophilic, minimal
			- hematopoiesis, extramedullary, minimal
			- hyperplasia, bile duct, minimal
			 hypertrophy, hepatocyte, centrilobular, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, minimal
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1631	S	Microscopic	
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- degeneration/necrosis, myofiber, minimal
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
			- hyperplasia, epithelial cell, mild

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1631	S	Microscopic thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina	 within normal limits polyp, stromal, benign, primary, incidental, not cause of death within normal limits
1632	S	Macroscopic skin	 hair sparse, left lateral neck, right lateral neck, mild corresponds to antemortem observation (hair sparse)
1632	S	Microscopic adrenal glands aorta bone marrow, femur bone marrow, sternum	 angiectasis/cystic degeneration, focal cortical, unilateral, minimal within normal limits within normal limits within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1632	S	Microscopic	
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- edema, papilla, bilateral, mild
			- hyperplasia, transitional cell, bilateral, mild
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		-	

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1632	S	Microscopic	
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, mild
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- atrophy, acinar, minimal
			- hyperplasia, acinar cell, focal, mild
		parathyroid glands	- within normal limits
			one of pair present

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1632	S	Microscopic	
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- degeneration/necrosis, myofiber, minimal
		skin	- alopecia/hypotrichosis, mild
			corresponds to macroscopic observation (skin - hair sparse)
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, moderate

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1632	S	Microscopic thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina	 within normal limits hyperplasia, cervical fibromuscular, mild within normal limits
1633	S	Macroscopic lymph node, inguinal pituitary gland skin, subcutis	 not identified, right, no grade draining node for mass a. enlarged, red, mild mass, tan, mass a, right inguinal area, present corresponds to antemortem observation (mass 1) approximately 4.0 x 3.0 x 2.0 cm.
1633	S	Microscopic adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, mild hyperplasia, focal cortical, unilateral, minimal

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations	
500 mg/kg/day				
1633	S	Microscopic		
		aorta	- within normal limits	
		bone marrow, femur	- within normal limits	
		bone marrow, sternum	- within normal limits	
		bone, femur	- within normal limits	
		bone, sternum	- within normal limits	
		brain	- within normal limits	
		esophagus	- within normal limits	
		eyes	- within normal limits	
		eyes, optic nerves	- within normal limits	
		eyes, retina	- within normal limits	
		galt	- within normal limits	
		harderian glands	- within normal limits	
		heart	- within normal limits	
		joint, tibiofemoral	- within normal limits	
		•		

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1633	S	Microscopic	
		kidneys	- dilatation, tubular, bilateral, mild
			- edema, papilla, bilateral, mild
			 hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			 mineralization, tubular, bilateral, minimal
			 necrosis, papillary, bilateral, moderate
			 nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hypertrophy, hepatocyte, centrilobular, minimal
			- infiltration, mononuclear cell, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenocarcinoma, malignant, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a)
		nerve, sciatic	- degeneration, axonal/myelin, minimal

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1633	S	Microscopic	
		nose, level a	- inflammation, minimal
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- atrophy, acinar, minimal
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- degeneration/necrosis, myofiber, minimal
		skin	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1633	S	Microscopic	
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- depletion, lymphoid, generalized, severe
			- hyperplasia, epithelial cell, mild
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- dilatation, gland/lumen, minimal
			- hyperplasia, squamous cell, minimal
		vagina	- within normal limits
		-	

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1634	E	Macroscopic	
		lymph node, inguinal	 not identified, bilateral, no grade
			draining node for mass a, left and mass b, right.
		ovaries	- cyst, red, left, moderate
		pituitary gland	- enlarged, red, mild
		skin, subcutis	- mass, tan, mass a, left anogenital region, present
			corresponds to antemortem observation (mass 1)
			approximately 5.0 x 5.0 x 3.0 cm.
			 mass, ulcerated, mass b, right anogenital region, present
			corresponds to antemortem observation (mass 2)
			approximately 3.5 cm in diameter, tan.
1634	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
			one medulla present
		aorta	- within normal limits
		bone marrow, femur	 hyperplasia, granulocytic, mild
		bone marrow, sternum	 hyperplasia, granulocytic, minimal
		bone, femur	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1634	Е	Microscopic	
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal
		joint, tibiofemoral	- within normal limits
		kidneys	- hyperplasia, transitional cell, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, minimal
			- pyelitis, bilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1634	Е	Microscopic	
		liver	- hematopoiesis, extramedullary, minimal
			 hypertrophy, hepatocyte, centrilobular, mild
			- necrosis, focal, minimal
		lung	- histiocytosis, alveolar, minimal
		lymph node, mandibular	 erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenocarcinoma, malignant, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass b)
			- fibroadenoma, benign, primary, mortality-independent
			corresponds to macroscopic observation (skin, subcutis - mass a)
			- hyperplasia, lobular, mild
		nerve, sciatic	 degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	 hemangiosarcoma, malignant, unilateral, primary, incidental, not cause of death
			corresponds to macroscopic observation (ovaries - cyst)
		oviducts	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1634	E	Microscopic	
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1634	E	Microscopic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 hematopoiesis, extramedullary, increased, mild within normal limits within normal limits depletion, lymphoid, generalized, moderate within normal limits mammary tumor
1635	E	Macroscopic lymph node, inguinal	 not identified, right, no grade draining node for mass a.

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1635	E	Macroscopic	
		skin, subcutis	- mass, ulcerated, mass a, right inguinal area, present
			corresponds to antemortem observation (mass 1)
			approximately 6.5 cm in diameter, tan.
1635	E	Microscopic	
		adrenal glands	- within normal limits
		aorta	- within normal limits
		bone marrow, femur	- hyperplasia, granulocytic, mild
		bone marrow, sternum	- hyperplasia, granulocytic, mild
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- cardiomyopathy, minimal

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1635	E	Microscopic	
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, mild
			- edema, papilla, bilateral, minimal
			 hyperplasia, transitional cell, bilateral, minimal
			 mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			 nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 hematopoiesis, extramedullary, minimal
			 hypertrophy, hepatocyte, centrilobular, mild
			 necrosis, hepatocytes, centrilobular, moderate
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1635	Е	Microscopic	
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		skin, subcutis	 fibroma, benign, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a)
		small intestine, duodenum	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1635	E	Microscopic small intestine, ileum small intestine, jejunum spinal cord, cervical spinal cord, lumbar spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus	 within normal limits hematopoiesis, extramedullary, increased, mild within normal limits within normal limits depletion, lymphoid, generalized, severe
		thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits fibrosarcoma/fibroma

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1636	E	Macroscopic	
		liver	- focus/foci, tan, multifocal, multiple lobes, moderate
		lymph node, axillary	- within normal limits
			left is draining node for mass a. right is draining node for mass c.
		lymph node, iliac	- within normal limits
			right and left are draining nodes for mass e.
		lymph node, inguinal	- within normal limits
			left is draining node for mass b. right is draining node for mass d.
		pituitary gland	- enlarged, tan, mild

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1636	E	Macroscopic	
		skin, subcutis	 mass, tan, mass a, left axillary area, present corresponds to antemortem observation (mass 1) approximately 3.5 x 3.5 x 1.7 cm. mass, tan, mass c, right axillary area, present corresponds to antemortem observation (mass 3) approximately 4.8 x 3.7 x 1.8 cm. mass, tan, mass d, right inguinal area, present corresponds to antemortem observation (swelling) approximately 1.8 x 1.0 x 0.6 cm. mass, tan, mass e, anogenital region, present corresponds to antemortem observation (swelling) approximately 5.5 x 4.0 x 2.0 cm. mass, ulcerated, mass b, left inguinal area, present corresponds to antemortem observation (mass 2)
1636	Е	Microscopic	approximately 4.5 x 3.5 x 2.0 cm and tan in color.
	_	adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, minimal hyperplasia, focal medullary, bilateral, mild

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1636	E	Microscopic	
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- within normal limits
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- mineralization, tubular, bilateral, minimal
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
00 mg/kg/day			
636	E	Microscopic	
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 hematopoiesis, extramedullary, minimal
			 hyperplasia, bile duct, minimal
			 hypertrophy, hepatocyte, centrilobular, minimal
			 infiltration, mononuclear cell, minimal
			 necrosis, hepatocytes, centrilobular, moderate
			corresponds to macroscopic observation (liver - focus/foci, tan)
		lung	 adenocarcinoma, malignant, secondary
			- histiocytosis, alveolar, minimal
		lymph node, axillary	- within normal limits
		lymph node, iliac	- within normal limits
		lymph node, inguinal	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1636	Е	Microscopic	
		mammary gland	 adenocarcinoma, malignant, multiple, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass b; skin, subcutis - mass d) fibroadenoma, benign, multiple, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass c; akin, subcutis - mass c)
			skin, subcutis - mass e) - hyperplasia, lobular, minimal
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- not examined
		pharynx	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1636	Е	Microscopic	
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- hematopoiesis, extramedullary, increased, moderate
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		thymus	- not examined

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1636	E	Microscopic thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits dilatation, gland/lumen, minimal granular cell tumor, benign, primary, incidental, not cause of death mammary tumor
1637	E	Macroscopic lymph node, axillary lymph node, inguinal lymph node, mandibular pituitary gland	 within normal limits draining node for mass e, right. not identified, right, no grade draining node for mass a and mass b. within normal limits draining node for mass c, right and mass d, left. enlarged, red, severe

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1637	E	Macroscopic	
		skin, subcutis	- mass, red, mass d, ventral neck, left, present
			corresponds to antemortem observation (nodule)
			approximately 2.0 x 2.0 x 1.0 cm.
			- mass, tan, mass a, right inguinal area, present
			corresponds to antemortem observation (mass 1)
			approximately 7.0 x 6.5 x 2.5 cm.
			 mass, tan, mass b, right anogenital region, present
			approximately 4.0 x 2.5 x 2.0 cm.
			 mass, tan, mass c, ventral neck, right, present
			corresponds to antemortem observation (nodule)
			approximately 3.0 x 2.5 x 1.0 cm.
			- mass, tan, mass e, right axillary area, present
			corresponds to antemortem observation (swelling)
			approximately 3.0 x 1.5 x 1.0 cm.
1637	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, bilateral, moderate
		aorta	- within normal limits

E - Euthanized in extremis

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1637	Е	Microscopic	
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), moderate
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, mild
			- mineralization, pelvic, bilateral, minimal
			- necrosis, papillary, bilateral, moderate
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1637	E	Microscopic large intestine, colon large intestine, rectum larynx liver	 within normal limits within normal limits within normal limits hypertrophy, hepatocyte, centrilobular, minimal infiltration, mononuclear cell, minimal necrosis, focal, minimal vacuolation, median cleft, mild histiocytosis, alveolar, minimal not examined
		lymph node, axillary lymph node, mandibular lymph node, mesenteric	misidentified tissue within normal limits within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1637	E	Microscopic	
		mammary gland	 adenocarcinoma, malignant, multiple, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass b; skin, subcutis - mass d) fibroadenoma, benign, multiple, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a; skin, subcutis - mass c; skin, subcutis - mass e)
			- hyperplasia, lobular, mild
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	 foreign material, mild plant.
		nose, level d	 foreign material, mild plant.
		ovaries	- cyst, unilateral, mild
		oviducts	- within normal limits
		pancreas	- within normal limits

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

DuPont-18405-1238

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1637	E	Microscopic	
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1637	E	Microscopic stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits within normal limits depletion, lymphoid, generalized, severe within normal limits pituitary tumor
1638	E	Macroscopic kidneys lung with bronchi lymph node, iliac	 focus/foci, white, left, mild focus/foci, black, multiple lobes, moderate enlarged, left, mild draining node for mass a, bilateral.

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1638	E	Macroscopic	
		skin, subcutis	- mass, ulcerated, mass a, anogenital region, bilateral, present
			corresponds to antemortem observation (mass 2 mass 1) approximately 12.2 x 6.5 x 4.5 cm, tan with some fluid present.
1638	E	Microscopic	
		adrenal glands	 angiectasis/cystic degeneration, focal cortical, unilateral, minimal
		aorta	- within normal limits
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		bone, tibia	- proliferation, fibro-osseous, mild
		brain	- within normal limits
		cavity, abdominal	- adenocarcinoma, malignant, secondary
			corresponds to macroscopic observation (lymph node, iliac - enlarged)
		esophagus	- within normal limits
		eyes	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1638	Е	Microscopic	
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- adenocarcinoma, malignant, unilateral, secondary
			corresponds to macroscopic observation (kidneys - focus/foci, white)
			from mammary tumor.
			- edema, papilla, bilateral, minimal
			- hyperplasia, transitional cell, bilateral, minimal
			- mineralization, pelvic, bilateral, mild
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1638	Е	Microscopic	
		liver	- hematopoiesis, extramedullary, minimal
			- hyperplasia, bile duct, minimal
			- hypertrophy, hepatocyte, centrilobular, minimal
			- necrosis, focal, mild
			- necrosis, individual hepatocyte, mild
		lung	- adenocarcinoma, malignant, secondary
			corresponds to macroscopic observation (lung with bronchi - focus/foci, black)
			from mammary tumor.
			- hemorrhage, mild
			- macrophages, pigmented alveolar, mild
		lymph node, iliac	- within normal limits
		lymph node, mandibular	- erythrocytosis/erythrophagocytosis, sinus, minimal
		lymph node, mesenteric	- within normal limits
		mammary gland	 adenocarcinoma, malignant, primary, mortality-independent corresponds to macroscopic observation (skin, subcutis - mass a)
		nerve, sciatic	- degeneration, axonal/myelin, minimal
		nose, level a	- within normal limits
		nose, level b	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1638	Е	Microscopic	
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- cyst, bilateral, minimal
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, incidental, not cause of death
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1638	E	Microscopic spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland	 within normal limits hematopoiesis, extramedullary, increased, mild within normal limits hyperplasia, epithelial, limiting ridge, minimal depletion, lymphoid, generalized, moderate hyperplasia, epithelial cell, minimal adenoma, c-cell, benign, unilateral, primary, incidental, not
			cause of death - hyperplasia, follicular cell, unilateral, mild - within normal limits
		tongue trachea	- within normal limits - within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix vagina Cause of Death	 polyp, stromal, benign, primary, incidental, not cause of death within normal limits mammary tumor

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations	
500 mg/kg/day				
1639	D	Macroscopic		
		all tissues	- within normal limits	
1639	D	Microscopic		
		adrenal glands	- within normal limits	
		aorta	- within normal limits	
		bone marrow, femur	- within normal limits	
		bone marrow, sternum	- within normal limits	
		bone, femur	- within normal limits	
		bone, sternum	- within normal limits	
		brain	- within normal limits	
		esophagus	- within normal limits	
		eyes	- within normal limits	
		eyes, optic nerves	- within normal limits	
		eyes, retina	- within normal limits	
		galt	- within normal limits	
		harderian glands	- within normal limits	
		heart	- within normal limits	
		joint, tibiofemoral	- within normal limits	

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1639	D	Microscopic	
		kidneys	- cyst, unilateral, minimal
		•	- mineralization, tubular, unilateral, minimal
		lacrimal glands, exorbital	- within normal limits
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	- hypertrophy, hepatocyte, centrilobular, minimal
			- infiltration, mononuclear cell, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- within normal limits
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1639	D	Microscopic	
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
		pharynx	- within normal limits
		pituitary gland	- within normal limits
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits
		spinal cord, thoracic	- within normal limits
		spleen	- within normal limits
		stomach, glandular	- within normal limits
		stomach, nonglandular	- within normal limits
		-	

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Individual Animal Listing - FEMALE

Terminal

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1639	D	Microscopic	
		thymus	- within normal limits
		thyroid gland	- within normal limits
		tongue	- within normal limits
		trachea	- within normal limits
		ureters	- within normal limits
		urinary bladder	- within normal limits
		uterus with cervix	- within normal limits
		vagina	- within normal limits
		Cause of Death	- dosing injury
1640	E	Macroscopic	
		adipose tissue	- focus/foci, yellow, mild
		·	white adipose tissue cranial to kidney on right side.
		pituitary gland	- enlarged, red, moderate
1640	E	Microscopic	-
		adrenal glands	- angiectasis/cystic degeneration, focal cortical, bilateral, mild
		aorta	- within normal limits

E - Euthanized in extremis

D - Died on Study

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1640	E	Microscopic	
		bone marrow, femur	- within normal limits
		bone marrow, sternum	- within normal limits
		bone, femur	- within normal limits
		bone, sternum	- within normal limits
		brain	- compression, ventral (pituitary tumor), mild
		esophagus	- within normal limits
		eyes	- within normal limits
		eyes, optic nerves	- within normal limits
		eyes, retina	- within normal limits
		galt	- within normal limits
		harderian glands	- within normal limits
		heart	- within normal limits
		joint, tibiofemoral	- within normal limits
		kidneys	- dilatation, tubular, bilateral, minimal
			- edema, papilla, unilateral, minimal
			- mineralization, pelvic, bilateral, minimal
			- necrosis, papillary, unilateral, severe
			- nephropathy, chronic progressive, bilateral, mild
		lacrimal glands, exorbital	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1640	E	Microscopic	
		large intestine, cecum	- within normal limits
		large intestine, colon	- within normal limits
		large intestine, rectum	- within normal limits
		larynx	- within normal limits
		liver	 hypertrophy, hepatocyte, centrilobular, minimal
			- infiltration, mononuclear cell, minimal
		lung	- within normal limits
		lymph node, mandibular	- within normal limits
		lymph node, mesenteric	- within normal limits
		mammary gland	- hyperplasia, lobular, minimal
		mesentery/peritoneum	- necrosis, fat, mild
			corresponds to macroscopic observation (adipose tissue - focus/foci, yellow)
		nerve, sciatic	- within normal limits
		nose, level a	- within normal limits
		nose, level b	- within normal limits
		nose, level c	- within normal limits
		nose, level d	- within normal limits
		ovaries	- within normal limits

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

MPI Research Study Number 125-141 Dupont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1640	E	Microscopic	
		oviducts	- within normal limits
		pancreas	- within normal limits
		parathyroid glands	- within normal limits
			one of pair present
		pharynx	- within normal limits
		pituitary gland	 adenoma, pars distalis, benign, primary, fatal, positive cause of death
			corresponds to macroscopic observation (pituitary gland - enlarged)
		salivary gland, mandibular	- within normal limits
		salivary gland, parotid	- within normal limits
		salivary gland, sublingual	- within normal limits
		skeletal muscle, biceps femoris	- within normal limits
		skin	- within normal limits
		small intestine, duodenum	- within normal limits
		small intestine, ileum	- within normal limits
		small intestine, jejunum	- within normal limits
		spinal cord, cervical	- within normal limits
		spinal cord, lumbar	- within normal limits

DuPont-18405-1238

MPI Research Study Number 125-141

Dupont-18405-1238
H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats

Group, Animal Number	Fate	Tissue	Observations
500 mg/kg/day			
1640	E	Microscopic spinal cord, thoracic spleen stomach, glandular stomach, nonglandular thymus thyroid gland tongue trachea ureters urinary bladder uterus with cervix vagina Cause of Death	 within normal limits within normal limits within normal limits within normal limits depletion, lymphoid, generalized, severe within normal limits pituitary tumor

Appendix K
Section 2
Pathology Peer Review Statement

TRADE SECRET

Unpublished Work Copyright [©]2013 E.I. du Pont de Nemours and Company

STUDY TITLE: Anatomic Pathology Peer Review Report for

H-28548: Combined Chronic Toxicity/Oncogenicity Study

2-Year Oral Gavage Study in Rats

AUTHOR: Steven R. Frame, D.V.M., Ph.D., Diplomate ACVP

ANATOMIC PATHOLOGY PEER

REVIEW REPORT COMPLETED: March 25, 2013

PERFORMING LABORATORY: E.I. du Pont de Nemours and Company

DuPont Haskell Global Centers for Health & Environmental Sciences

P.O. Box 50

Newark, Delaware 19714

U.S.A.

TESTING FACILITY: MPI Research, Inc.

54943 North Main Street

Mattawan, Michigan 49071-9399

U.S.A.

LABORATORY PROJECT ID: DuPont-18405-1238

WORK REQUEST NUMBER: 18405

SERVICE CODE NUMBER: 1238

SPONSOR: E.I. du Pont de Nemours and Company

Wilmington, Delaware 19898

U.S.A.

TESTING FACILITY STUDY 125-141

Number:

GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT

The work performed at DuPont Haskell was conducted in compliance with U.S. EPA TSCA (40 CFR part 792) Good Laboratory Practice Standards, which are compatible with current OECD Good Laboratory Practices.

Sponsor: E.I. du Pont de Nemours and Company Wilmington, Delaware 19898

	U.S.A.	
Principal Investigator:	Steven R. Frame, D.V.M., Ph.D., Diplomate ACVP Senior Research Fellow and Manager E.I. du Pont de Nemours and Company	<u>25Mwh</u> 2013 Date
Sponsor:	Sponsor Representative	

QUALITY ASSURANCE STATEMENT

MPI Research Number 125-141 Work Request Number: 18405 Service Code Number: 1238

Key inspections for the above referenced study's Peer Pathology Report were completed by the Quality Assurance Unit of DuPont Haskell and the findings were submitted on the following dates:

		Date R	Reported to:	
	Principal	PI	Study	SD
Audit Dates	Investigator (PI)	Management	Director (SD)	Management
Report/Records:				
March 15, 17, 2013	March 18, 2013	March 18, 2013	March 18, 2013	March 19, 2013

Robert CRhen 25-MAR-2013 Reported by: Date Robert C. Rhea RQAP-GLP

Quality Assurance Auditor

CERTIFICATION

I, the undersigned, declare that these results provide accurate data obtained from this study.

Issued by Principal Investigator:

Senior Research Fellow and Manager

SUMMARY

Gross observations, organ weights, microscopic findings, and the pathology report of this 2-year oral gavage study in rats with H-28548 were peer reviewed according to the DuPont Haskell Recommendations for Tissue Examination in Pathology Peer Reviews. The peer review pathologist is in agreement with the conclusions of the study pathologist as given in the pathology report.

INTRODUCTION

This report documents the peer review of pathology data, including gross observations, organ weights, and microscopic findings for this study.

METHODS

A peer review of the gross observations, organ weights, microscopic findings, and the pathology report for DuPont-18405-1238 was conducted for male and female Crl:CD(SD) rats by a peer review pathologist. The peer review was conducted at MPI Research, Inc., 54943 North Main Street, Mattawan, Michigan, U.S.A. 49071-9399 and at DuPont Haskell Global Centers for Health & Environmental Sciences, P.O. Box 50, Newark, Delaware, U.S.A. 19714.

Twelve-Month Interim

For the twelve-month interim sacrifice, sections of all available tissues from the following animals in the male and female high-dose groups (Groups 4 and 5, respectively) were reviewed microscopically:

Males: 1241, 1245, and 1250

Females: 1561, 1565, and 1570

In addition, liver and testes from male rats; liver and kidneys from females rats; and all neoplasms in all male and female groups were examined microscopically.

Terminal (or 24-Month Terminal)

For the terminal sacrifice, sections of all available tissues from the following animals were reviewed microscopically:

Terminal S	acrifice	
Male Groups:	1	4
Animal Number(s):	1011	1256
	1029	1269
	1037	1275
	1050	1294
	1051	1298
	1057	1305
	1058	1316
Female Groups:	1	5
Animal Number(s):	1323	1591
	1336	1610
	1342	1619
	1358	1625
	1364	1628
	1384	1633
	1392	1634

In addition, liver, pancreas, and testes in males, and liver, kidneys, stomach, tongue, pancreas, and lungs in females were examined microscopically from all groups as potential target organs or to clarify findings in the high dose groups. All neoplasms in all two-year groups were also examined.

For both the 12-month interim and terminal sacrifice, other selected tissues were examined as necessary by the reviewing pathologist to clarify diagnostic terms and confirm microscopic findings. The pathology report and the summary incidence tables for gross findings, organ weight changes, and microscopic findings were also reviewed.

RESULTS

The quality of the histopathology sections and accountability of tissues for examination were good, and there was good agreement between the study pathologist and peer review pathologist regarding severity grading and diagnoses of lesions. Terminology and diagnoses were agreed upon by the study pathologist and the peer review pathologist for all the organs, and this agreement is reflected in the final report.

CONCLUSIONS

A peer review of the gross observations, organ weights, microscopic findings, and the pathology report for DuPont-18405-1238 was conducted according to DuPont Haskell Recommendations for Tissue Examination in Pathology Peer Reviews. The peer review pathologist is in agreement with the interpretations and conclusions of the study pathologist as given in the pathology report.

RECORDS AND SAMPLE STORAGE

For the work conducted at DuPont Haskell, the anatomic pathology peer review report will be retained at DuPont Haskell, Newark, Delaware or Iron Mountain Records Management, Wilmington, Delaware.

Appendix L MPI Research Computer Systems

MPI Research Computer Systems

The computer systems used during the conduct of this study are presented in the following table.

MPI Research Computer Systems			
Provantis W8.0:	Client-server, Oracle-based system used for electronic documentation and data management from compound receipt through reporting.		
Siemens Environmental Monitoring			
vMPI1 and Niagara Framework®			
Software System v2.3:	Environmental monitoring, alarming, and reporting applications.		
MPI Research ExyLIMS v3.0:	A comprehensive laboratory information management system used to manage data, including but not limited to: instrumentation, test articles, standards, and samples.		
MPI Archiving System (MArcS) v2.0:	In-house developed application for automated storage and retrieval information for archiveable materials (e.g., lab books, study data, wet tissues, slides, etc.).		
Enterprise Reporting System – Table			
Production System v1.14	In-house developed reporting system used primarily for reporting of Provantis [™] data.		
eDocs v3.3:	Electronic document management system.		
Master Schedule v2.2:	Maintains the master schedule for the company.		
MasterControl QAAD v8.0:	A quality management system, consisting of the QAAD and QAADLink applications, used to automate the Quality Assurance process for regulatory compliance.		
SAS [®] v9.1:	The SAS® System is an integrated system of software products that enables a user to perform data entry, retrieval, data management, reporting, graphics, statistical analysis, and applications development.		
docuBridge® v3.6/5.1:	Electronic publishing system.		
Microsoft® Office Professional	5 r		
2003/2010:	Suite of integrated productivity tools including word and data processing and communications software.		

Additional information is available in the MPI Research, Inc., company document titled "Computer Systems Information."

Appendix M Protocol and Amendments

Work Request Number 18405

Service Code 1238

DuPont Report Number – 18405-1238

Protocol

July 8, 2010

TABLE OF CONTENTS

1.	INTRODUCTION	4
1.1.	Study Number	4
1.2.	Study Title	4
1.3.	Sponsor	4
1.4.	Sponsor Representative	4
1.5.	Objective	4
1.6.	Regulatory Guideline	4
1.7.	Good Laboratory Practice	5
1.8.	\mathcal{E}	
1.9.	1 3	
1.10	O. Personnel	6
1.11	1 ,	
1.12	2. Quality Assurance	7
1.13	\mathcal{C}	
1.14	4. Declaration of Intent	7
2.	Test and Control Articles	
2.1.	r	
2.2.	· · · · · · · · · · · · · · · · · · ·	
2.3.	J	
2.4.	J	
2.5.	r	
2.6.	1	
2.7.	1	
3.	Test System	
3.1.	1	
3.2.		
3.3.		
3.4.	Justification of Test System	10
3.5.	Expected Age	10
3.6.	Expected Body Weight	10
3.7.	Number of Animals	10
3.8.	Husbandry	11
3.9.	Sentinel Animals	12
4.	Study Design	
5.	Test and control Article Administration.	
5.1.		
5.2.		
5.3.	1 2	
5.4.		
5.5.		
6.	Antemortem Study Evaluations	15

6.1.	Ophthalmoscopic Examinations	15
6.2.	Cageside Observations	15
6.3.	Detailed Clinical Examinations	16
6.4.	Body Weights	16
6.5.	Food Consumption	16
6.6.	Clinical Pathology	16
7. Eu	ıthanasia	19
7.1.	Moribundity	19
7.2.	Method of Euthanasia	19
7.3.	Final Disposition	19
8. Po	stmortem Study Evaluations	19
9. St	atistics	
9.1.	Group Pair-Wise Comparisons (Levene's/ANOVA-Dunnett's/Welch's)	
9.2.	Log Transformation with Group Pair-wise Comparisons	
9.3.	Rank Transformation with Dunnett's Test	25
9.4.	Survival Analysis	25
9.5.	Tumor Analysis	25
10. St	udy Reports	26
10.1.	Progress/Status Reports	26
10.2.	Final Report	26
11. Da	ata and Specimen Retention.	27
12. A1	nimal Welfare	27
13. A ₁	pproval	28
13.1.	Date of Sponsor Approval	28
13.2.	Study Director Approval/Study Initiation	28
13.3.	MPI Research Management Approval	28

1. INTRODUCTION

1.1. Study Number

DuPont Work Request/Study Code Number: DuPont-18405/1238

DuPont Report Number: 18405-1238 MPI Research Study Number: 125-141

1.2. Study Title

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study

in Rats

1.3. Sponsor

E.I. du Pont de Nemours and Company Wilmington, Delaware 19898, U.S.A.

1.4. Sponsor Representative

Susan A. MacKenzie, V.M.D., Ph.D., D.A.B.T. Senior Research Toxicologist DuPont Haskell Global Centers for Health and Environmental Sciences P.O. Box 50

Newark, Delaware 19714 U.S.A.

Telephone: 302-366-6389 Telefax: 302-366-5211

E-mail: Susan.A.MacKenzie@USA.dupont.com

1.5. Objective

The objective of this study is to evaluate the potential chronic toxicity and oncogenicity of H-28548 when administered via oral gavage over the major portion of the life span of the test animals.

1.6. Regulatory Guideline

This protocol meets the United States Environmental Protection Agency, Office of Prevention, Pesticides, and Toxic Substances, Guideline 870.4300, Combined chronic toxicity/carcinogenicity, August 1998. The experimental design and methods are also based on the Organization for Economic Cooperation and Development (OECD) Guideline 453, September 2009, the Japanese Ministry of Agriculture, Forestry and Fisheries Guidelines for Data Requirements for Supporting Registration of Pesticides, No. 12-Nousan-8147, Notification by Director-General dated 24 November, 2000, and the Commission Directive 88/302/EEC B.33 Combined Chronic/Carcinogenicity test, *Methods for the Determination of Toxicity* (1988).

MPI Research Study Number: 125-141 Page 4 of 28

1.7. Good Laboratory Practice

This nonclinical laboratory study will be conducted in accordance with the United States Environmental Protection Agency FIFRA Good Laboratory Practice (GLP) Standards, 40 CFR Part 160, Toxic Substance Control Act Good Laboratory Practice Standards, 40 CFR Part 792, the Organization for Economic Cooperation and Development (OECD) Principles of Good Laboratory Practice ENV/MC/CHEM(98)17, and the Japanese Good Laboratory Practice Standards, 11 Nohsan No. 6283 and as changed in 12 Nohsan No. 8628, and 13 Seisan No. 1660.

1.8. Testing Facility

MPI Research, Inc. 54943 North Main Street Mattawan, MI 49071-9399 U.S.A.

MPI Research is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International).

1.9. Computer Systems

The following are the proposed computer systems to be used during the conduct of this study. The actual systems used will be documented in the final report.

MPI	Research	Computer	Systems
-----	----------	----------	----------------

Provantis[™]: Client-server, Oracle-based system primarily used

for toxicology studies.

Niagara Framework® Software Environmental monitoring, alarming, and

System or Siemens Environmental reporting application.

Monitoring System (EMS):

Dispense: Automates the test article control processes.

Microsoft® Windows XP: Used in conjunction with Empower 2 software

Empower 2: Empower 2 Chromatographic Data System used

to quantitatively determine the amounts of analytes in samples, including test articles in

formulation.

MPI Archiving System (MArcS): In-house developed application for automated

storage and retrieval information for archiveable materials (e.g. lab books, study data, wet tissues,

slides, etc.).

Enterprise Reporting System – Table In-house developed reporting system used

Production System (TPS): primarily for reporting of Provantis[™] data.

Master Schedule: Maintains the master schedule for the company.

MPI Research Study Number: 125-141 Page 5 of 28

SAS[®]: The SAS[®] System is an integrated system of

software products that enables a user to perform data entry, retrieval, data management, reporting, graphics, statistical analysis, and applications

development.

Microsoft[®] Office 2003 Professional: Bundle of integrated productivity tools including

word and data processing and communications software. Contains the utilities Microsoft[®] Access, Excel, InfoPath, Outlook, PowerPoint,

Publisher, and Word.

docuBridge[®]: Electronic publishing system.

1.10. Personnel

1.10.1. Study Director

Lisa Craig, B.S.

Telephone: 269-668-3336 ext. 1367

Telefax: 269-668-4151

E-mail: lisa.craig@mpiresearch.com

1.10.2. Alternate Contact

Chris N. Papagiannis, B.S.

Telephone: 269-668-3336 ext. 1392

Telefax: 269-668-4151

E-mail: chris.papagiannis@mpiresearch.com

1.11. Proposed Study Schedule

Study Initiation Date (EPA and OECD): Date Study Director signs Study Approval-

(Date Study Director signs Study Initiation Line in this protocol

Approval-Initiation Line in the protocol)

Experimental Starting Date (OECD): July 15, 2010

(Date of the first data collection directly

from the study)

Experimental Start Date (EPA): July 29, 2010

(Date of first test article exposure)

Experimental Termination Date (EPA): August 3, 2012

(Date of last animal termination)

Experimental Completion Date (OECD): Date Anatomic Pathology Contributor

(Date of the last data collection directly report is signed

from the study)

Draft Report Mail Date: To be added by amendment

MPI Research Study Number: 125-141 Page 6 of 28

1.12. Quality Assurance

This study will be subjected to periodic inspections and the data, draft and final reports will be reviewed by the Quality Assurance Department of MPI Research in accordance with MPI Research's Standard Operating Procedures. Study quality assurance inspection records will be made available to the Sponsor Representatives during visits to MPI Research.

1.13. Alteration of Design

Alterations of this protocol may be made as the study progresses. No changes in the protocol will be made without the specific written request or consent of the Sponsor. In the event that the Sponsor authorizes a protocol change verbally, MPI Research will honor such change. However, written authorization will be obtained thereafter. All protocol amendments and justifications will be documented, signed, and dated by the Study Director and Sponsor. The protocol and all amendments will be issued to the Sponsor as well as at MPI Research.

1.14. Declaration of Intent

This study may be submitted to an Organization for Economic Cooperation and Development (OECD) member country, the United States Environmental Protection Agency (EPA), and/or other country regulatory bodies.

2. TEST AND CONTROL ARTICLES

2.1. Description of Test Article

2.1.1. Identity

HFPO Dimer Acid Ammonium Salt

Haskell number: 28548

R&D Lot Number: E109540-44A

A description, lot number, storage conditions, expiration date, safe handling procedures, physical properties, as well as other relevant information will be documented in the study data.

2.1.2. Test Article Properties

The Sponsor will provide a certificate of analysis (COA) documentation on the purity, composition, stability, and other pertinent information, unless otherwise noted.

2.2. Test Article Preparation

The bulk test article will be stored at room temperature. The test article formulations will be adjusted for a purity of 84%. The test article will be mixed with deionized water to achieve the desired dose volumes. The vehicle and method of preparation will be determined based upon physical characteristics of the test article and size of batches required. Fresh formulations will be prepared for each concentration weekly and stored at room temperature when not in use.

MPI Research Study Number: 125-141 Page 7 of 28

2.3. Test Article Analysis

Test article formulations prepared for the study will be evaluated for homogeneity and concentration. Room temperature stability (at least 14 days) which covers the concentration range to be used in this study has been established in MPI Research Study Number 125-128. No further stability analysis is necessary.

Appropriate samples (see table below) will be taken while the preparations are stirring. Homogeneity will be evaluated again if the batch size changes by more than 50% during the study or if a new concentration is outside of the range of concentrations previously evaluated. Following acceptance of the analytical results (signing of the final report) by the Study Director, or at the Study Director's discretion, backup samples will be discarded.

Analytical Sample Collection Table

Sample Type	Concentrations to Sample	Stratum		or of Samples poncentration Analyzed	Back up	Sample Volume (mL)	Intervals
Homogeneity Analyses ^a	All (except control)	Top Middle Bottom	6 6 6	2 2 2	4 4 4	1 1 1	Week 1
Concentration Analyses ^a	All (including control)	Middle	6	2	4	1	Weeks 1-4, every 3 months thereafter

^a: The samples will be stored frozen at approximately -20 °C pending analyses or final disposition.

2.4. Analyses

All analytical work will be conducted by MPI Research, Inc., State College, PA using an analytical method developed by MPI Research and validated under MPI Research Study Number 125-128. The work performed in conjunction with this study will be conducted in compliance with GLPs and subject to review by the Quality Assurance Unit (QAU) of that laboratory. The findings of their QAU will be submitted to the Principal Investigator and the Principal Investigator's Management as well as to the MPI Research Study Director and MPI Research Management. A final report, including a Quality Assurance Statement, will be prepared and submitted to MPI Research for inclusion as an appendix in the main study final report. Samples will be shipped on dry ice on Monday through Wednesday for next day delivery. The primary contact will be notified prior to each shipment.

Principal Investigator (Formulation Analyses)	Primary Contact for Sample Shipment
Sharon Lupo 3058 Research Drive State College, PA 16801	Attn: Sample Control 3048 Research Drive State College, PA 16801
Telephone: 814-272-1039	Telephone: 814-272-1039

MPI Research Study Number: 125-141 Page 8 of 28

Telefax: 814-231-1580	Telefax: 814-231-1580
E-mail: Sharon.lupo@mpiresearch.com	E-mail: SC1SampleReceiving@mpiresearch.com

2.5. Reserve Sample

A reserve sample from each batch of test article used in this study will be collected and stored at MPI Research in a secure area with the appropriate environmental controls. If multiple studies are conducted with the same test article, a common reserve sample may be taken and labeled appropriately.

2.6. Test Article Disposition

Any remaining test article will be returned to the Sponsor after completion of the study. The test article will be shipped to the following address:

Laura N. Smith
E.I. du Pont de Nemours and Company
Stine Haskell Research Center
Building S120/103
1090 Elkton Road
Newark, DE 19714

M = C -- :41 -- :11 1 - - - - 4: C - 4 -- -: - - 4 -

Ms. Smith will be notified prior to shipment.

302-366-5542

2.7. Description of Vehicle

2.7.1. Identity

Telephone:

Deionized water

A description, lot number, storage conditions, expiration date, safe handling procedures, physical properties, as well as other relevant information will be documented in the study data.

2.7.2. Vehicle/Control Article Properties

The vehicle used will be from deionized tap water at the Testing Facility.

3. TEST SYSTEM

3.1. Species

Rat

3.2. Strain

CD® [Crl:CD(SD)]

MPI Research Study Number: 125-141 Page 9 of 28

3.3. Source

Charles River Laboratories

3.4. Justification of Test System

The current state of scientific knowledge and the applicable guidelines cited previously in this protocol do not provide acceptable alternatives, *in vitro* or otherwise, to the use of live animals to accomplish the purpose of this study. "The development of knowledge necessary for the improvement of the health and well-being of humans as well as other animals requires *in vivo* experimentation with a wide variety of animal species." "Whole animals are essential in research and testing because they best reflect the dynamic interactions between the various cells, tissues, and organs comprising the human body."

The rat is a frequently used model for evaluating the toxicity of various classes of chemicals and for which there is a large historical database.

3.5. Expected Age

The test animals will be approximately 4-5 weeks of age at arrival. All animals placed on study will be less than 8 weeks of age at the start of dosing.

3.6. Expected Body Weight

The males will weigh approximately 100 to 125 g and the females will weigh approximately 76 to 100 g at arrival, as measured within 3 days of arrival. The actual range may vary but will be documented in the data.

3.7. Number of Animals

3.7.1. Number Ordered

Males: 400 Females: 400

3.7.2. Number on Study (includes 25 sentinel animals per sex)

Males: 345 Females: 345

Females will be nulliparous and non-pregnant.

3.7.3. Justification for Number on Study

This study was designed to use the fewest number of animals possible, consistent with the objective of the study, the scientific needs of the Sponsor, contemporary scientific standards, and in consideration of applicable regulatory requirements cited previously in this protocol.

¹ "Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training", Federal Register, 1985 May 20; 50(97).

MPI Research Study Number: 125-141 Page 10 of 28

² "Position Statement on the Use of Animals in Research", 1993 Feb 26; NIH Guide 22(8).

This study is designed to use the smallest number of animals possible that will allow sufficient group sizes for meaningful statistical analysis of data.

3.7.4. Selection for Study

All animals placed on study will have body weights that fall within $\pm 20\%$ of the mean body weight for each sex. If not enough animals fall within this weight range to satisfy the number of animals required to go on study, the Study Director will be notified to ascertain the appropriate action to be taken.

Animals considered suitable for study will be weighed prior to treatment. After the appropriate number of animals with the highest and lowest body weights has been excluded, the remaining required number of animals on study will be randomized, by sex, into treatment groups using a standard, by weight, measured value randomization procedure.

3.7.5. Method of Identification

Each animal will be assigned an animal number to be used in ProvantisTM and will be implanted with a microchip bearing a unique identification number. The individual animal number, implant number, and the MPI Research study number will comprise a unique identification for each animal. The animal cage will be identified by the study number, animal number, group number, and sex.

3.8. Husbandry

3.8.1. Acclimation

All animals will be permitted an acclimation period of approximately 2 weeks. During this acclimation period, all animals will be observed daily for any clinical signs of disease and all animals will be given a detailed clinical examination prior to selection for study. All animals with any evidence of disease or physical abnormalities will not be selected for study. The week prior to dose initiation, animals will be administered a sham dose of tap water on at least 2 occasions in the same manner and at the same volume intended for use during the study period.

3.8.2. Housing

The animals will be pair-housed (same sex) in solid-bottom cages (polyboxes). In order to foster the rat's natural chewing instinct and keep their teeth at a healthy length, approved chew toys (e.g. Nylabone) will be offered.

3.8.3. Environmental Conditions

Fluorescent lighting will be provided via an automatic timer for approximately 12 hours per day. On occasion, the dark cycle may be interrupted intermittently due to study-related activities. Temperature and humidity will be monitored and recorded daily and maintained to the maximum extent possible between 64 to 79° F and 30 to 70%, respectively.

MPI Research Study Number: 125-141 Page 11 of 28

3.8.4. Diet and Drinking Water

3.8.4.1. Basal Diet

The basal diet will be block Lab Diet[®] Certified Rodent Diet #5002, PMI Nutrition International, Inc. This diet will be available *ad libitum* unless designated otherwise. Each lot number used will be identified in the study records.

3.8.4.2. Basal Diet Contaminants

The Study Director is not aware of any potential contaminants likely to be present in the certified diet that would interfere with the results of this study. Therefore, no analyses other than those routinely performed by the feed supplier will be conducted.

3.8.4.3. Water

Tap water will be supplied *ad libitum* via an automatic water system unless otherwise indicated.

3.8.4.4. Water Contaminants

The drinking water used will be monitored for specified contaminants at periodic intervals according to MPI Research Standard Operating Procedures. The Study Director is not aware of any potential contaminants likely to be present in the water that would interfere with the results of this study. Therefore, no analyses other than those mentioned in this protocol will be conducted

3.9. Sentinel Animals

A health screen will be conducted pretest and at 6, 12, 18, and 24 months on 3-5 males and 3-5 females (depending on survival) using sentinel animals selected with a computerized randomization and euthanized via carbon dioxide inhalation for this purpose. If insufficient animals are available due to survival, fewer animals may be submitted for evaluation (Study Director consulted) and this will be noted in the final report. Approximately 1-2 mL of blood will be collected via the vena cava and serum obtained. Blood samples will be processed to serum and placed into 2 aliquots of approximate equal volume. Serum samples will be stored at approximately -20°C. A gross necropsy will be performed at the time of blood collection. Gross lesions will be recorded. No tissues will be saved. Any sentinel animal that is found dead or euthanized *in extremis* will receive a gross necropsy and gross lesions will be saved for possible histopathologic evaluation.

The serum will be evaluated as indicated below:

3.9.1. Pretest and at months 12 and 24

- Pneumonia Virus
- Reovirus Type 3
- Theiler's Encephalomyelitis Virus (GD-7)
- Lymphocytic Choriomeningitis Virus

MPI Research Study Number: 125-141 Page 12 of 28

- Sendai Virus
- Mycoplasma Pulmonis
- Kilham Rat Virus
- Rat Coronavirus/Sialodacryoadenitis Virus
- Toolan's H-1 Virus
- Rat Parvovirus

3.9.2. At months 6 and 18

- Sendai Virus
- Kilham Rat Virus
- Rat Coronavirus/Sialodacryoadenitis Virus
- Toolan's H-1 Virus
- Rat Parvovirus
- Mycoplasma Pulmonis

Initial testing will be performed at MPI Research. For positive or inconclusive results, confirmation testing will be performed by BioReliance. Samples will be sent at ambient temperature to the following address, if necessary.

Principal Investigator: Dr. Arlene Leon BioReliance Corporation 9900 Blackwell Road Rockville, MD 20850

Telephone: 301-610-2641 Telefax: 301-610-2587

Any actions based on the results of the health screen will be determined after consultation with the Sponsor. Testing will not be conducted in accordance with GLPs. This will be included as a GLP exception in the final report. Results of these analyses will be maintained in the study file.

4. STUDY DESIGN

G		Number of Animals									
R				Clin	ical	12-M	Ionth	Terr	ninal	Micro	scopic
O		Ini	tial	Patho	logya	Inte		Neci	opsy	Patho	ology ^c
U				1 atiio	1059	Necro	psy ^{a, b}				
P	Dose Level										
	(mg/kg/day)	M	F	M	F	M	F	M	F	M	F
1	0	80	80	10	10	10	10	70	70	80	80
2	0.1	80	-	10	-	10	-	70	-	AR	-
3	1	80	80	10	10	10	10	70	70	AR	AR
4	50	80	80	10	10	10	10	70	70	80	AR
5	500	-	80	-	10	-	10	-	70	-	80
89*	-	25	25	-	-	-	-	_	_	_	-

a: Hematology, and clinical chemistry will be performed on 10 animals/sex/group at 3 months. Hematology, coagulation, clinical chemistry, and urinalysis evaluations will be conducted on 10 animals/sex/group at 6 and 12 months. Differential blood smear will be prepared on all animals designated for necropsy at 12 months, all survivors at 12, 18, and 24 months (termination), and all animals euthanized in extremis.

5. TEST AND CONTROL ARTICLE ADMINISTRATION

5.1. Route of Administration

The test and control articles will be administered by gavage.

5.2. Justification for Route of Administration and Dose Selection

The oral gavage route was selected as the most efficient way to administer an accurate dose.

In a previous study (DuPont-17751-1026), Crl:CD(SD) rats (10/sex/dose) were dosed with the test substance by oral gavage for at least 90 days at daily doses of 0, 0.1, 10, or 100 mg/kg/day for males and 0, 10, 100, or 1000 mg/kg/day for females. In the 1000 mg/kg/day group, three females died prior to scheduled sacrifice and others displayed clinical signs. No other test substance-related effects were observed in surviving animals in all groups on body weight or nutritional parameters, clinical or ophthalmological observations, or neurobehavioral parameters.

Test substance-related findings included regenerative anemia (males: 100 mg/kg/day; females: 1000 mg/kg/day), clinical chemistry effects consistent with PPAR α activation (males: $\geq 10 \text{ mg/kg/day}$; females: 100 - 1000 mg/kg/day), and increased liver weights and associated hepatocellular hypertrophy (males: $\geq 10 \text{ mg/kg/day}$; females: 1000 mg/kg/day). Similar liver effects were observed at $\geq 3 \text{ mg/kg/day}$ in males and 300 mg/kg/day in females in a rat 28-day gavage study (DuPont-24447). Increased kidney weights were observed in males and females at $\geq 10 \text{ mg/kg/day}$. In females, renal papillary necrosis and/or renal

MPI Research Study Number: 125-141 Page 14 of 28

b: An interim necropsy will be conducted at 12 months on 10 animals/sex/group.

c: Animals from both the 12 month interim and terminal necropsies, and other animals as required..

AR = As Required: 1) Target tissues identified by high dose group evaluations, 2) Tissues in all animals found dead or euthanized in a moribund condition, and 3) gross lesions.

^{*}Sentinel animals

tubular necrosis were observed in the two females found dead prior to scheduled sacrifice and in one female that survived to the scheduled sacrifice. Clinical and anatomic pathology parameters were fully or partially (male hematology effects; liver weights) reversible after an approximate 4-week recovery period.

Based on the results of the 90-day and 28-day studies, doses selected for this study were 0, 0.1, 1, and 50 mg/kg/day in males and 1, 50, and 500 mg/kg/day in females. The high dose is expected to produce effects on clinical chemistry and liver weight and microscopic pathology in males and females, without producing excessive liver toxicity. The middle dose may produce liver and clinical chemistry in either sex but could be a no-observed-adverse-effect level (NOAEL). The low dose is expected to be a NOAEL in both males and females.

5.3. Frequency and Duration of Administration

The test and control articles will be administered once per day, at approximately the same time of day (i.e., if the Day 1 dose occurs in the am, then subsequent doses should be delivered in the am for the study duration), for at least 104 weeks. The animals will be dosed up to the day prior to scheduled necropsy.

5.4. Dose Volume

10 mL/kg/dose

5.5. Test Article Administration

For administration, the test and control articles will be dosed via oral gavage in accordance with SOP TMA-1. The control animals will receive the control article at the same volume as the test article. Individual doses will be based on the most recent body weights.

6. ANTEMORTEM STUDY EVALUATIONS

6.1. Ophthalmoscopic Examinations

All animals in all groups will be examined prior to exposure and all surviving animals prior to the scheduled necropsy (interim and terminal) in accordance with SOP TOX-61. The ophthalmological examinations will be conducted by a veterinary ophthalmologist.

6.2. Cageside Observations

All animals will be observed at least twice a day for morbidity, mortality, injury, and availability of food and water in accordance with SOP ACU-65. The afternoon cageside observation will be conducted at the same approximate time of day (\pm 2 hours). Beginning on Week 53, a third mortality check in the evening will also be conducted. Any animals in poor health will be identified for further monitoring and possible euthanasia.

Any abnormal findings noted in the morning cageside observation will be recorded by exception (i.e., 'no abnormalities detected' will not be captured on a daily basis for every animal).

MPI Research Study Number: 125-141 Page 15 of 28

6.3. Detailed Clinical Examinations

A detailed clinical examination of each animal will be performed once during each study week in accordance with SOP TOX-2. Observations will include, but will not be limited to, evaluation of the skin, fur, eyes, ears, nose, oral cavity, thorax, abdomen, external genitalia, limbs and feet, respiratory and circulatory effects, autonomic effects such as salivation, and nervous system effects including tremors, convulsions, reactivity to handling, bizarre behavior, and palpation of tissue masses in accordance with SOP TOX-3.

6.4. Body Weights

Body weights will be measured and recorded within 3 days of arrival, at least once prior to randomization, weekly during the first 13 weeks starting on Day 1 (prior to dosing), and every other week thereafter in accordance with SOP TOX-4. The individual and mean group mean body weights gain will be calculated and reported weekly (starting on Week -1), for the first quarter (Weeks 1-13), the first year (Weeks 1-52), and the entire study (Weeks 1-104).

6.5. Food Consumption

Food consumption will be measured and recorded pretest (Week -1), weekly during the first 13 weeks, and for 2 weeks intervals starting at Week 14 (i.e., food consumption will represent a 14 day interval) in accordance with SOP TOX-5. Food consumption will be measured for the cage and divided by the number of surviving animals. The individual and mean group mean food consumption and food efficiency will be calculated and reported weekly (starting on Week -1), for the first quarter (Weeks 1-13), the first year (Weeks 1-52), and the entire study (Weeks 1-104).

6.6. Clinical Pathology

The animals will have free access to drinking water but will be fasted overnight (no more than 16 hours) prior to sample collection. Blood samples (approximately 3 mL) taken at non-terminal intervals will be taken via the sublingual vein. Blood samples (3-5 mL) taken at necropsy will be taken via the vena cava. Blood samples (0.5 mL) for blood smears taken from animals not scheduled for full clinical pathology evaluation or euthanized *in extremis*, where possible, will be taken via the sublingual vein. Where possible, the animals designated for clinical pathology evaluations at 3 and 6 months will be the same animals evaluated at 12 months.

The order of bleeding and analysis will be alternating (one animal from each dose group, then repeating) to reduce handling and time biases. If samples need to be recollected for hematology, coagulation, or urinalysis for sample quality purposes (e.g., clotted sample), animals do not need to be fasted.

The following clinical pathology tests will be conducted.

MPI Research Study Number: 125-141 Page 16 of 28

6.6.1. Hematology

6.6.1.1. Number of Animals

10/sex/group at 3, 6 and 12 months (Animals designated for chronic toxicity evaluation)

6.6.1.2. Collection Intervals

3, 6, and 12 months

6.6.1.3. Parameters Evaluated

- leukocyte count (total and absolute differential)
- erythrocyte count
- hemoglobin
- hematocrit
- mean corpuscular hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin concentration (calculated)
- absolute reticulocytes
- platelet count
- blood cell morphology

6.6.2. Coagulation

6.6.2.1. Number of Animals

10/sex/group at 6 and 12 months (Animals designated for chronic toxicity evaluation)

6.6.2.2. Collection Intervals

6 and 12 months

6.6.2.3. Parameters Evaluated

- prothrombin time
- activated partial thromboplastin time

6.6.3. Clinical Chemistry

6.6.3.1. Number of Animals

10/sex/group at 3, 6, and 12 months (Animals designated for chronic toxicity evaluation)

6.6.3.2. Collection Intervals

3, 6, and 12 months

6.6.3.3. Parameters Evaluated

- alanine aminotransferase
- alkaline phosphatase
- sorbitol dehydrogenase
- total protein

MPI Research Study Number: 125-141 Page 17 of 28

- albumin
- globulin and A/G (albumin/globulin) ratio (calculated)
- urea nitrogen
- creatinine
- total cholesterol
- triglycerides
- total bilirubin (with direct bilirubin if total bilirubin exceeds 1 mg/dl)
- aspartate aminotransferase
- total bile acids
- glucose
- calcium
- phosphorus
- electrolytes (sodium, potassium, and chloride
- gamma glutamyl transferase

6.6.4. Urinalysis

Animals will be placed in stainless steel metabolism cages for at least 12 hours to collect urine.

6.6.4.1. Number of Animals

10/sex/group at 6 and 12 months (Animals designated for chronic toxicity evaluation)

6.6.4.2. Collection Intervals

6 and 12 months

6.6.4.3. Parameters Evaluated

- volume
- specific gravity
- pH
- color and appearance
- protein
- glucose
- bilirubin
- ketones
- blood
- urobilinogen
- microscopy of centrifuged sediment

6.6.5. Peripheral Blood Smears

6.6.5.1. Number of Animals

All surviving animals (animals designated for carcinogenicity evaluation) and just prior to necropsy for animals euthanized *in extremis*

MPI Research Study Number: 125-141 Page 18 of 28

6.6.5.2. Collection Intervals

12 and 18 months and prior to termination (24 months)

Peripheral blood smears will be prepared and held for possible future analysis from all surviving animals at 12, 18, and 24 months (study termination). The total and differential leukocyte count will be made on those animals in the control and highest dose group (Groups 1 and 4 or 5) at termination. If these data, or data from the pathology examination, indicate a need, then the blood smears from the other dose groups and/or earlier time point will also be examined. If clinical observations suggest a deterioration of health of the animals during the study, a differential blood count of the affected animals will be performed.

7. EUTHANASIA

7.1. Moribundity

Any moribund animals, as defined by a Testing Facility Standard Operating Procedure (ACU-47), will be euthanized for humane reasons and to prevent the loss of tissues through autolysis. All animals euthanized *in extremis* or found dead will be subjected to a routine necropsy. Where practical, a full set of tissues as listed in the Postmortem Study Evaluations portion of this protocol will be collected and preserved in the appropriate fixative.

7.2. Method of Euthanasia

Euthanasia will be by carbon dioxide inhalation followed by a MPI Research SOP (NEC-12) approved method to ensure death, e.g. exsanguination.

7.3. Final Disposition

All surviving animals placed on study will be euthanized at their scheduled necropsy or, if necessary, euthanized *in extremis*. Extra animals obtained for this study, but not placed on study, will be transferred to either an MPI Research stock or training colony, or euthanized and discarded. The final disposition of each animal will be documented in the study records.

8. POSTMORTEM STUDY EVALUATIONS

Complete necropsy examinations will be performed under procedures approved by a veterinary pathologist on all animals dying spontaneously, euthanized *in extremis*, or euthanized at scheduled necropsies in accordance with SOP NEC-42. Examinations will be performed 7 days a week. Animals that are found dead after regular working hours will be refrigerated overnight and necropsies performed at the start of the next working day. At the appropriate intervals (after 12 and 24 months), all appropriate animals will be euthanized and examined.

The animals will be examined carefully for external abnormalities including palpable masses. The skin will be reflected from a ventral midline incision, and any subcutaneous masses will be identified and correlated with antemortem findings. The abdominal, thoracic, and cranial cavities will be examined for abnormalities and the organs removed, examined, and, where

MPI Research Study Number: 125-141 Page 19 of 28

required, placed in fixative. The pituitary will be fixed *in situ*. The eyes and testes will be fixed using a modified Davidson's fixative³. All other tissues will be fixed in neutral buffered formalin. Formalin will be infused into the lung via the trachea and into the urinary bladder.

Body weight and the organ weights identified in the following table will be recorded for all animals at scheduled necropsies and appropriate organ weight ratios will be calculated (relative to body and brain weights). Paired organs will be weighed together. A combined weight of the thyroid gland with the bilateral parathyroid post fixation will be obtained. Organs will not be weighed for animals dying spontaneously or euthanized *in extremis*.

Microscopic examination of fixed hematoxylin and eosin-stained paraffin sections will be performed on sections of tissues and from the groups identified in the following table and all animals dying spontaneously or euthanized *in extremis*.

Organs or Tissues to be Weighed, Preserved, and Microscopically Examined

Tissue	Organ Weight Taken	Collected and Preserved	Microscopic Examination (Groups) ^a 1, 4/5 2-3/4	
Adrenal gland	X	X	X	
Aorta		X	X	
Bone with bone marrow, femur		X	X	
Bone with bone marrow, sternum		X	X	
Bone marrow smear ^b		X		
Brain (cerebrum, midbrain, cerebellum, medulla/pons)	X	X	X	
Coagulating gland		X	X	
Epididymis	X	X	X	
Esophagus		X	X	
Eye (with retina and optic nerve)		X	X	
$GALT^c$		X	X	
Harderian gland		X	X	

³ Latendresse JR, Warbrittion AR, Jonassen H, Creasy DM. Fixation of testes and eyes using a modified Davidson's fluid: comparison with Bouin's fluid and conventional Davidson's fluid. Toxicol Pathol. 2002 Jul-Aug;30(4):524-33.

MPI Research Study Number: 125-141 Page 20 of 28

Tissue	Organ Weight Taken	Collected and Preserved	Microse Examin (Grou 1, 4/5	ation
Heart	X	X	X	
Joint, tibiofemoral		X	X	
Kidney	X	X	X	
Lacrimal gland, exorbital		X	X	
Large intestine, cecum		X	X	
Large intestine, colon		X	X	
Large intestine, rectum		X	X	
Larynx		X	X	
Liver	X	X	X	
Lung with bronchi		X	X	
Lymph node, mandibular		X	X	
Lymph node, mesenteric		X	X	
Mammary gland (process females only)		X	X	
Nerve, sciatic		X	X	
Nose (4 sections)		X	X	
Ovary with oviduct	X	X	X	
Pancreas		X	X	
Pharynx		X	X	
Pituitary		X	X	
Prostate		X	X	
Salivary gland, mandibular		X	X	
Salivary gland, parotid		X	X	
Salivary gland, sublingual		X	X	
Seminal vesicles		X	X	
Skeletal muscle, biceps femoris		X	X	
Skin		X	X	
Small intestine, duodenum		X	X	
Small intestine, ileum		X	X	

Tissue	Organ Weight Taken	Collected and Preserved	Microscopic Examination (Groups) ^a	
			1, 4/5	2-3/4
Small intestine, jejunum		X	X	
Spinal cord, cervical		X	X	
Spinal cord, lumbar		X	X	
Spinal cord, thoracic		X	X	
Spleen	X	X	X	
Stomach, glandular		X	X	
Stomach, nonglandular		X	X	
Target Organs ^d		X	X	X
Testis	X	X	X	
Thymus		X	X	
Thyroid gland (with parathyroid) ^e	X	X	X	
Tongue		X	X	
Trachea		X	X	
Ureters		X	X	
Urinary bladder		X	X	
Uterus with cervix	X	X	X	
Vagina		X	X	
Gross lesions		X	X	X
Tissue masses with regional lymph node		X	X	X

^a Microscopic examination will be conducted in controls and in Group 4 males and Group 5 females, the respective high dose for each sex.

^b Bone marrow smears will be prepared only for animals necropsied at scheduled intervals. Evaluation will be performed at the discretion of the Study Director and/or Sponsor (additional cost).

^c Gut associated lymphoid tissue

^d Target organs (and target organ gross lesions) will be designated by the Study Director, Pathologist and/or Sponsor based on experimental findings (additional cost).

^e Parathyroids cannot always be identified macroscopically. They will be examined if in the plane of section and in all cases where they are noted as grossly enlarged.

^f A regional lymph node drains the region where a tissue mass is located.

The presence of test article-related lesions in animals from the high dose group will require microscopic examination of the affected target tissue(s) in all animals from the lower dose groups. If mortality in the high dose groups is sufficiently high to preclude assessment of a potential toxic response, all protocol-required tissues from all animals in the next lower dose group will be examined after consultation with the Sponsor (additional cost).

The pathologist may use special stains and techniques as needed to aid in the diagnosis of specific lesions. If after routine sectioning, a tissue is missed, the block will be resectioned once or the tissue re-embedded for resectioning. If the tissue is still missing, the block will not be resectioned unless the missing tissue is determined to be a target organ. In this case, the tissue will be resectioned until located or until it is determined that it is not present in the block or in wet tissue. All missing tissues will be identified in the pathology portion of the final report. Tissues that are unintentionally sectioned or present in the plane with a required tissue, though not required by protocol, will be examined and documented, if abnormal.

A pathologist other than the study pathologist will perform a formal peer review of the histopathologic findings. This review will consist of an examination of all tissues determined to be target organs by the study pathologist, all neoplasms diagnosed in the study and all tissues from 10% of the animals selected randomly from control and high dose groups. Other selected tissues may be examined at the discretion of the reviewing pathologist. A signed statement by the reviewing pathologist will appear in the final report.

9. STATISTICS

The following is the proposed analysis plan to be used when data assumptions are met. If there are deviations to this plan due to violations of assumptions or if any other techniques are used (Sponsor consulted), they will be documented in the final report.

Table of Statistical Comparisons

Control Group	Treatment Groups
1	2, 3, 4, 5

The above table defines the set(s) of comparisons to be used in the statistical analyses described below. If more than one set of comparisons is required, all analyses will be conducted separately on each set unless stated otherwise. Data for each sex within a set will also be analyzed separately.

The raw data will be tabulated within each time interval, and the mean and standard deviation will be presented for each endpoint by sex and group. For each endpoint, treatment groups will be compared to the control group using the analysis outlined below. Data for some endpoints, as indicated, will be transformed by either a log or rank transformation prior to conducting the specified analysis.

MPI Research Study Number: 125-141 Page 23 of 28

Endpoints	Type of Analysis
Body Weight Body Weight Gain Food Consumption Hematology (except Leukocyte Counts) Coagulation Clinical Chemistry Organ Weights Absolute Weights Relative to Body and Brain Weight	Group Pair-wise Comparisons
Leukocyte Counts Total Leukocyte Counts Differential Leukocyte Counts	Log Transformation Group Pair-wise Comparisons (Levene's/ANOVA-Dunnet's/Welch's)
Urinalysis Urine Volume Specific Gravity pH	Rank Transformation with Dunnett's Test
Mortality Data	Survival Analysis
Tumor Data	Tumor Analysis
Non-Tumor Microscopic Pathology Data	To be determined if required

9.1. Group Pair-Wise Comparisons (Levene's/ANOVA-Dunnett's/Welch's)

If sample sizes for all groups are 3 or greater, Levene's test⁴ will be used to assess homogeneity of group variances for each specified endpoint (see table above) and for all collection intervals. If Levene's test is not significant ($p \ge 0.01$), a pooled estimate of the variance (Mean Square Error or MSE) will be computed from a one-way analysis of variance (ANOVA) and utilized by a Dunnett's⁵ comparison of each treatment group with the control group. If Levene's test is significant (p < 0.01), comparisons with the control group will be made using Welch's t-test⁶ with a Bonferroni correction.

In the case that sample size is less than 3 for at least one treatment group, Levene's method cannot be implemented. Groups with sample sizes less than 3 will be excluded from the analysis and control-treatment pair-wise comparisons that satisfy the sample size assumption (n>3) will be conducted using Welch's t-test with a Bonferroni correction.

MPI Research Study Number: 125-141 Page 24 of 28

⁴ Milliken GA, Johnson DE. Analysis of messy data. London: Chapman and Hall: 1992.

⁵ Dunnett, CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955;50:1096-1121.

⁶ Welch BL. The significance of difference between two means when the population variances are unequal. Biometrika 1937;29:350-362.

If there are only 2 groups involved, the above methodology applies and the Dunnett's test reduces to a Student's t-test⁷.

Results of all pair-wise comparisons will be reported at the 0.05 and 0.01 significance levels. All endpoints will be analyzed using two-tailed tests unless indicated otherwise.

9.2. Log Transformation with Group Pair-wise Comparisons

Historical data indicates that leukocyte counts (total and differential) are not normally distributed; therefore, a log transformation will be performed on these data. The transformed data will then be analyzed as described in the Group Pair-wise Comparisons section.

9.3. Rank Transformation with Dunnett's Test

Historical data indicate that this endpoint has unpredictable distribution characteristics, thus analysis would be enhanced by use of a non-parametric test. For each specified endpoint (see table above) and for each collection interval, a rank transformation will be performed. The transformed data will then be analyzed using Dunnett's test, to compare each treatment group with the control group.

If sample size for the control group is 2 or greater, Dunnett's test will be used to compare each treatment group having a non-zero sample size with the control group.

If there are only 2 groups involved, the above methodology applies and the Dunnett's test reduces to a Student's t-test⁷. Results of all pair-wise comparisons will be reported at the 0.05 and 0.01 significance levels. All endpoints will be analyzed using two-tailed tests unless indicated otherwise.

9.4. Survival Analysis

Intercurrent mortality data will be analyzed using the Kaplan-Meier product-limit method. An overall test comparing all groups will be conducted using a log-rank test⁸. If this overall test is significant (p<0.05) and there are more than two groups, then a follow up analysis will be done where each treatment group will be compared to the control group using a log-rank test.

Results of all pair-wise comparisons will be reported at the 0.05 and 0.01 significance levels. All endpoints will be analyzed using two-tailed tests.

9.5. Tumor Analysis

Tumor incidence data will be analyzed using both survival adjusted and unadjusted tests. The unadjusted tests will be based on the incidence and number of sites examined for each tumor type. The Cochran-Armitage trend test⁹ will be calculated and Fisher's exact test¹⁰

MPI Research Study Number: 125-141 Page 25 of 28

⁷ Steel RGD, Torrie JH. Principles and Procedures of Statistics. A biometrical approach. New York: McGraw-Hill: 1980.

⁸ Allison PD. Survival analysis using the SAS system: A Practical Guide. Cary (NC). SAS Institute Inc.; 1995.

⁹ Agresti A. Categorical data analysis. 2nd ed. New York: John Wiley and Sons; 2002.

will be used to compare each treatment group with the control group. The survival adjusted test will be conducted according to the prevalence/mortality methods described by Peto et al. ¹¹. Evaluation criteria (p-values of significance) will be applied differently for rare tumors (background rate of 1% or less) and common tumors (background rate greater than 1%) ¹². The evaluation criteria are given in the following table.

Evaluation Criteria for Common and Rare Tumors

Test for Positive Trends	Control-High Pair-wise Comparisons
Common and rare tumors will be tested at	Common and rare tumors will be tested at
0.005 and 0.025 significance levels,	0.01 and 0.05 significance levels,
respectively	respectively

Electronic data will be provided for this study with the final report. The format of the data sets will be prepared following the guidelines of the United States Environmental Protection Agency (EPA).

10. STUDY REPORTS

10.1. Progress/Status Reports

Regular progress reports will be submitted to the Sponsor weekly for the first 5 weeks and biweekly reports through the first quarter (Week 13). Thereafter, progress reports will be sent approximately once per month.

10.2. Final Report

After completion of the study, a comprehensive draft report containing the results of all tests, analyses, observations and measurements required by this protocol, and an interpretative summary of the study results will be submitted to the Sponsor. The report will include all items required by the applicable regulatory agency. After receipt of any Sponsor comments, 1 copy (unbound) of the final report will be issued. An electronic copy (PDF) will be provided with the final report. This electronic copy will be searchable, hyperlinked (including headings, tables, figures, references, and all tables of contents), and bookmarked. One electronic copy will be in Microsoft Word, where possible. The electronic copies can be sent on CDs.

Six months after issuance of the draft report, if no requested revisions or instructions to finalize have been communicated by the Sponsor, the draft report will be issued as a final

¹⁰ Zar JH. Biostatistical Analysis. 4th ed. New Jersey: Prentice Hall; 1999.

¹¹ Peto R, Pike MC, Day NE, Gray RG, Lee PN, Parish S, Pete J, Richards S, Wahrendorf J. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In: Long-term and short-term screening assays for carcinogens: a critical appraisal. Annex to Supplement 2. p. 311-426. International Agency for Research on Cancer, Lyon; 1980.

¹² Haseman JK. A reexamination of false-positive rates for carcinogenesis studies. Fund Appl Toxicol 1983;3:334-339.

report, signed by the Study Director, and submitted to the Sponsor. Any modifications or changes to the draft report requested 6 months after issuance of the draft will be performed at additional cost to the Sponsor.

11. DATA AND SPECIMEN RETENTION

All raw data, documentation, records, protocol, specimens, samples and the final report generated as a result of this study will be retained at MPI Research or an MPI Research contracted archive facility for a period of 1 year following the issuance of the draft report. The Sponsor will be contacted annually by MPI Research Archive staff regarding the retained material and will be responsible for the incurred costs for the return, disposal, or continued storage of any study generated material retained after that time.

12. ANIMAL WELFARE

MPI Research is committed to complying with all applicable regulations governing the care and use of laboratory animals. Animal welfare for this study will be in compliance with the U.S. Department of Agriculture's (USDA) Animal Welfare Act (9 CFR Parts 1, 2 and 3). The Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, National Academy Press, Washington, D.C., 1996, will be followed. This facility maintains an Animal Welfare Assurance statement with National Institutes of Health, Office of Laboratory Animal Welfare.

To ensure compliance:

- A. This protocol will be reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) before animal receipt or transfer.
- B. The Sponsor, by his or her approval, attests that the activities specified in this protocol do not unnecessarily duplicate any previous experiment.
- C. The Study Director has considered alternatives to procedures that may cause more than momentary or slight pain or distress to the animal and has signified that (select one):
 - X i.) The relevant supervisory government agency currently gives no alternatives.
- ___ ii.) The following literature searches have been performed to determine whether an alternative species could be used or another procedure to reduce any pain or distress was available and none was found.

Date: November 17, 2009 Literature Search Reference Number: 0001

Interval Searched: All years to Present

Search terms: general alternative testing methods; alternative testing methods, toxicology; general toxicology testing method alternatives

Databases searched: toxnet.nlm.nih.gov;pubmed.gov;medscape.com;caat.jhsph.edu

MPI Research Study Number: 125-141 Page 27 of 28

iii.) This study does not require any procedures that may cause more than slight or momentary pain or distress to the animal. Note, unknown test articles are presumed to have the potential to cause more than slight pain or distress.

13. **APPROVAL**

13.1. Date of Sponsor Approval

12-Jul-2010 Date

Study Director Approval/Study Initiation

Study Director

12 - Jul - 2010 Date

13.3. MPI Research Management Approval

David G. Serota, Ph.D., D.A.B.T.

Senior Vice President, Drug Safety Evaluation



	Duront – 18403-1238
DuPon	t Work Request/Study Code Number: DuPont-18405-1238
Title:	H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats
Protoco	ol Amendment No. 1 Page 1 of 1
Item	Revision or Clarification
1.	Section 6.4, Body Weights
	Change: Body weights will be measured and recorded within 3 days of arrival, at least once prior to randomization, weekly during the first 14 weeks starting on Day 1 (prior to dosing), and every other week thereafter in accordance with SOP TOX-4.
Item	Justification
1.	Updated to take body weights in week 14 due to food consumption measured in week 14.
Approv	ed by:
	24-Sep-2010 Date of Sponsor Approval
	Lisa Craig, B.S. Date Study Director



DuPont Work Request/Study Code Number: DuPont-18405-1238 Title: H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats Protocol Amendment No. 2 Page 1 of 1 Item Revision or Clarification 1. Section 9. Statistics Add: Food efficiency will be statistically analyzed using Rank Transformation with Dunnett's Test. Effective Date: November 10, 2010 Justification Item 1. The method of statistically analyzing food efficiency was added. Approved by: 12-NOV-2010 Date of Sponsor Approval Lisa Craig, B.S. Study Director James G. Laveglia, Ph.D. Executive Vice President Drug Safety **Evaluation**

MPI Research Study Number: 125-141



DuPont Work Request/Study Code Number: DuPont-18405-1238

Title: H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage

Study in Rats

Protocol Amendment No. 3

Page 1 of 2

Item Revision or Clarification

1. Section 2.3.4. Analysis

Change to:

Principal Investigator (Formulation Analysis): Jennifer Boughton, M.S.

Telephone: 814-272-1039 ext. **4248**

Telefax: 814-231-1580

E-mail: jennifer.boughton@mpiresearch.com

Effective Date: November 17, 2010

Item Justification

1. Principal Investigator updated due to change in personnel.

MPI Research Study Number: 125-141

Page 4022 of 4037



DuPont Work Request/Study Code Number: DuPont-18405-1238

Title: H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage

Study in Rats

Protocol Amendment No. 3

Page 2 of 2

Approved by:

/7 - Nov - 2010

Date of Sponsor

Approval

Study Director

James G. Laveglia, Ph.D.

Executive Vice President Drug Safety Evaluation

MPI Research Study Number: 125-141

Page 4023 of 4037



DuPont Work Request/Study Code Number: DuPont-18405-1238

Title: H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage

Study in Rats

Protocol Amendment No. 4

Page 1 of 2

Item Revision or Clarification

1. Section 2.4. Analyses and Amendment 3, Item 1.

Change to:

Principal Investigator (Formulation Analysis): Devon Kyle, B.S.

Telephone: 814-272-1039 ext. **4339**

Telefax: 814-231-1580

E-mail: **devon.kyle@mpiresearch.com**

Item Justification

1. Principal Investigator updated due to change in personnel.

MPI Research Study Number: 125-141

Page 4024 of 4037



DuPont Work Request/Study Code Number: DuPont-18405-1238

Title: H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage

Study in Rats

Protocol Amendment No. 4

Page 2 of 2

Approved by:

Date of Sponsor

Approval

Lisa Craig, B.S.

Study Director

James G. Laveglia, Ph.D.

Executive Vice President Drug Safety Evaluation

14-MW-2011

/16/

MPI Research Study Number: 125-141

Page 4025 of 4037



DuPont Work Request/Study Code Number: DuPont-18405-1238

Title: H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage

Study in Rats

Protocol Amendment No. 5

Page 1 of 2

Item Revision or Clarification

1. Section 2.3. Test Article Analysis – Analytical Sample Collection Table

Add:

Concentration samples will also be collected per protocol from the Weeks 47 and 48 preparations and analyzed.

Effective Date: June 9, 2011 and June 21, 2011

2. Section 2.4. Analyses

Add:

Acceptance criteria for solutions will be $\pm 10\%$ for recovery and $\leq 10\%$ RSD for precision.

Effective Date: June 29, 2011

3. **6.6.5. Peripheral Blood Smears**

Add:

Animals having blood samples collected for use in blood smear preparations only will not be fasted overnight prior to sample collection.

Effective Date: July 27, 2011

Item Justification

- 1. Additional intervals added due to previous preparations failing to meet recovery.
- 2. Acceptance criteria added per Sponsor request.
- 3. Clarification to protocol.

MPI Research Study Number: 125-141

Page 4026 of 4037



DuPont Work Request/Study Code Number: DuPont-18405-1238

Title:

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage

Study in Rats

Protocol Amendment No. 5

Page 2 of 2

Approved by:

36 Apr-2012
Date of Sponsor

Date of Sponsor Approval

Lisa Craig, B.S.

Study Director

30-Apr -2012

Date

Scott Boley, Ph.D., D.A.B.T.

Senior Director, General Toxicology and

Infusion

Date

MPI Research Study Number: 125-141

Page 4027 of 4037



Title: H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage

Study in Rats

Protocol Amendment No. 6

Page 1 of 3

Item Revision or Clarification

1. Section 4. Study Design

G R O U	Dose Level	Initial		Clinical Pathology ^a		lumber of Anima 12-Month Interim Necropsy ^{a, b}		als Terminal Necropsy ^d		Microscopic Pathology ^c	
Г	(mg/kg/day)	M	F	M	F	M	F	M	F	M	F
1	0	80	80	10	10	10	10	70	70	80	80
2	0.1	80	-	10	-	10	-	70	-	AR	-
3	1	80	80	10	10	10	10	70	70	AR	AR
4	50	80	80	10	10	10	10	70	70	80	AR
5	500	-	80	-	10	-	10	-	70	-	80
89*	-	25	25	-	-	-	-	-	-	-	-

a: Hematology, and clinical chemistry will be performed on 10 animals/sex/group at 3 months. Hematology, coagulation, clinical chemistry, and urinalysis evaluations will be conducted on 10 animals/sex/group at 6 and 12 months. Differential blood smear will be prepared on all animals designated for necropsy at 12 months, all survivors at 12, 18, and 24 months (termination), and all animals euthanized in extremis.

Effective Date: July 2, 2012

2. Peripheral Blood Smears

Section 6.6.5.2. Collection Intervals

12 and 18 months and **prior to termination** (24 months)

Peripheral blood smears will be prepared and held for possible future analysis from all surviving animals at 12, 18, and 24 months prior to study termination.

Effective Date: July 2, 2012

MPI Research Study Number: 125-141

Page 4028 of 4037

b: An interim necropsy will be conducted at 12 months on 10 animals/sex/group.

c: Animals from both the 12 month interim and terminal necropsies, and other animals as required..

d: The animals will be terminated early once survival for any group reaches 15 remaining animals.

AR = As Required: 1) Target tissues identified by high dose group evaluations, 2) Tissues in all animals found dead or euthanized in a moribund condition, and 3) gross lesions.

^{*}Sentinel animals



Title: H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage

Study in Rats

Protocol Amendment No. 6 Page 2 of 3

Item

Revision or Clarification

3. Section 8. Postmortem Evaluations

At the appropriate intervals (after 12 and 24 months or at early termination), all appropriate animals will be euthanized and examined.

Effective Date: July 2, 2012

Item Justification

1-3. Per discussions with the Sponsor, all surviving animals of a given sex will be termed once survival of that sex in any group reaches 15 remaining. This is to ensure at least 25% survival (13/50) so that the carcinogenicity endpoints can be accurately evaluated.

MPI Research Study Number: 125-141

Page 4029 of 4037



Title:	H-28548: Combined	Chronic	Toxicity/	Oncogenicity	Study 2-	Year (Oral	Gavage
--------	-------------------	---------	-----------	--------------	----------	--------	------	--------

Study in Rats

Protocol Amendment No. 6

Page 3 of 3

Approved by:

Swan amarkengre 7/11/12 Approval

Lisa Craig, B.S.

Study Director

Senior Director, General Toxicology and

Infusion

11- Jul-2012 Date

11 July 2012
Date



Title: H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage

Study in Rats

Protocol Amendment No. 7 Page 1 of 2

Item

Revision or Clarification

1. Section 8. Postmortem Study Evaluations

Add:

The liver (both sexes) and kidneys (females only) are potential target organs and will be examined on all animals on study at the interim necropsy.

The liver, pancreas, testes, and tongue are potential target organs and will be examined on all male animals in Groups 2 and 3 at the terminal necropsy.

The tongue, pancreas, stomach (non-glandular limiting ridge), adrenal glands, lung, and uterus with cervix are potential target organs and will be examined on all female animals in Groups 3 and 4 at the terminal necropsy.

Add:

A pathologist other than the study pathologist will perform a formal peer review of the histopathologic findings. This review will consist of an examination of all tissues determined to be target organs by the study pathologist, all neoplasms diagnosed in the study and all tissues from 10% of the animals selected randomly from control and high dose groups. Other selected tissues may be examined at the discretion of the reviewing pathologist. A signed statement by the reviewing pathologist will appear in the final report.

The slides for the 10% control and high dose animals and the livers and kidneys for all females will be shipped to the following for completion of the pathology peer review: Carolyn Lloyd, S320/525

1090 Elkton Road Newark, DE 19714-0050 Ph. 302-366-5401 Fax 302-451-4530 carolyn.w.lloyd@usa.dupont.com

Effective Date: October 17, 2012

MPI Research Study Number: 125-141

Page 4031 of 4037



DuPont Work Request/Study Code Number: DuPont-18405-1238 Title: H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats Protocol Amendment No. 7 Page 2 of 2 Item Justification 1. Potential target organs added and slide shipment information added. Approved by: 15-Nov-2012 Date of Sponsor Approval Lisa Craig, B.S. **Study Director** Scott Boley, Ph.D., D.A.B.T. Senior Director, General Toxicology and

Infusion



MPI Research Study Number: 125-141 DuPont Work Request/Study Code Number: DuPont-18405-1238 H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage Study in Rats Protocol Amendment No. 8 Page 1 of 1 Item Revision or Clarification 1. Section 9.5. Tumor Analysis Change to: **Evaluation Criteria for Common and Rare Tumors Test for Positive Trends** Control-High Pair-wise Comparisons Common and rare tumors will be tested Common and rare tumors will be tested at a 0.05 significance level at a 0.05 significance level Item Justification 1. Clarification of the significance level for tumor analysis. Approved by: 10 - Jan - 2013

Date of Sponsor Approval 31 - Jan - 2013 Date Lisa Craig, B.S. Study Director Scott Boley, Ph.D., D.A.B.T.

Senior Director, General Toxicology and

Infusion



MPI Research Study Number: 125-141 DuPont Study Number: DuPont-18405/1238

Title: H-28548; Co

H-28548: Combined Chronic Toxicity/Oncogenicity Study 2-Year Oral Gavage

Study in Rats

Protocol Amendment No. 9

Page 1 of 1

Item

Revision or Clarification

1. Section 11. Data and Specimen Retention

Update to:

All raw data, documentation, records, protocol, specimens, samples and the final report generated as a result of this study will be retained at MPI Research or an MPI Research contracted archive facility for a period of 1 year following the issuance of the draft report. The Sponsor will be contacted annually by MPI Research Archive staff regarding the retained material and will be responsible for the incurred costs for the return, disposal, or continued storage of any study generated material retained after that time. The tissue slides sent for pathology peer review to the Sponsor will be archived at that site.

Item Justification

1. Additional specimen retention instructions added.

Approved by:

25- May - 2013
Date of Sponsor
Approval

Lisa Craig, B.S.

Study Director

Date

Scott Boley, Ph.D., D.A.B.T.

Senior Director, General Toxicology and

Infusion

Date

Appendix N Deviations This study was conducted in accordance with the protocol except for the following deviations. Unplanned protocol deviations are listed below. The following event occurred as the result of an unintended deviation from the protocol.

On Days -14 and -13, two banks of animal cages were found to be disconnected from the automatic water line during the morning cageside observation on Day -13. The evening cageside observation on Day -14 was performed at 16:30 and the Day -13 morning cageside observation was performed at 07:10.

On Day -6, the humidity in the animal room was documented at 73.17%.

On Days -7, 78, and 456, the lot numbers for the basal laboratory diet were incorrectly entered; therefore, there is no documentation of the exact lot numbers in the study data.

On Day 140, the temperature in the animal room was documented at 62.98°F.

Between Days 174 to 357, blood smears were not collected for the following animals euthanized *in extremis*: three males at 0.1 mg/kg/day (1111, 1145, and 1155), three males at 1 mg/kg/day (animal numbers 1190, 1230, and 1237), one male at 50 mg/kg/day (animal number 1284), four females at 0 mg/kg/day (animal numbers 1341, 1371, 1373, and 1399), two females at 1 mg/kg/day (animal numbers 1421 and 1458), three females at 50 mg/kg/day (animal numbers 1513, 1518, and 1556), and two females at 500 mg/kg/day (animal numbers 1580 and 1610).

On Day 183, the animals designated for the 6 month urinalysis collections were not fasted for the entirety of the sample collection.

On Day 253, the first dose of the day began at 12:03, instead of occurring in the AM.

On Day 294 (Week 42), the Week 43 formulations were completed without taking the appropriate formulation samples. The samples were taken during Week 44 for this interval instead.

On Day 328, the first dose of the day began at 12:00, instead of occurring in the AM.

On Days 330 and 337, the lot numbers for the basal laboratory diet were incorrectly entered; therefore, there is no documentation of the exact lot numbers in the study data.

On Day 337, food was not available *ad libitum* for one male at 1 mg/kg/day (animal number 1217) and two males at 50 mg/kg/day (animal numbers 1283 and 1309) at the morning cageside observation.

On Day 341, food was not available *ad libitum* for one male at 0 mg/kg/day (animal number 1071) at the morning cageside observation.

On Day 344 (Week 50), the food consumption was incorrectly calculated for Group 1 males (last 10 cages), Group 1 females, all males in Groups 2, 3, and 4, and the last 20 cages in Group 5. The values for this week were excluded from the data.

On Day 357, the humidity in the animal room was documented at 74.67% and 72.77%.

On Day 369, the blood sample collected from one female at 50 mg/kg/day (animal number 1481) was collected via cardiac puncture after carbon dioxide inhalation.

On Day 374, the first dose of the day began at 13:22, instead of occurring in the AM.

On Day 378, the first dose of the day began at 12:03, instead of occurring in the AM.

From Days 429 to 449, food consumption was not calculated for one female at 50 mg/kg/day (animal number 1502).

On Day 462, the harderian gland was fixed in modified Davidson's fixative for one female at 0 mg/kg/day (animal number 1375), one male at 1 mg/kg/day (animal number 1189), one male at 50 mg/kg/day (animal number 1259), and one female at 500 mg/kg/day (animal number 1635) euthanized *in extremis*.

On Day 573, the first dose of the day began at 12:06, instead of occurring in the AM.

On Day 602, the blood smear for one male at 0 mg/kg/day (animal number 1055) euthanized *in extremis* was collected via the vena cava after carbon dioxide inhalation.

At terminal necropsy (Day 723, Week 104), the Mass A was not located at the time of tissue trimming for one male at 50 mg/kg/day (animal number 1289).

In the opinion of the Study Director, these deviations did not affect the quality or integrity of the study.